nct_id,antibody_name,antibody_category,indication,phase,enrollment,adverse_event_term,organ_system,serious,severity,assessed_participants,affected_participants,events,fraction_affected_%,is_failed_candidate,failure_reason,dose_mg_m2,duration_days,reversible,manageable,management_strategy,time_to_onset_days,resolution_days
NCT34070808,Rituximab,Anti-CD20,Breast Cancer,Phase 4,277,Anemia,Hepatobiliary disorders,Yes,Moderate,277,18,19,6.5,Yes,Safety concerns,5,72,Yes,No,Supportive care,19,14
NCT54643195,Rituximab,Anti-CD20,Breast Cancer,Phase 4,225,Diarrhea,Skin disorders,No,Moderate,225,19,20,8.44,No,,15,133,Yes,Yes,Dose reduction,24,51
NCT55829664,Rituximab,Anti-CD20,Multiple Myeloma,Phase 3,31,Diarrhea,Musculoskeletal disorders,No,Severe,31,4,8,12.9,No,,7,101,Yes,No,Dose reduction,9,70
NCT32052616,Rituximab,Anti-CD20,Rheumatoid Arthritis,Phase 3,50,Rash,Cardiac disorders,No,Mild,50,11,12,22.0,No,,8,56,No,Yes,Supportive care,28,5
NCT89290892,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,38,Pneumonitis,Skin disorders,Yes,Severe,38,3,4,7.89,Yes,Regulatory issues,3,235,Yes,No,Discontinuation,2,73
NCT80462634,Rituximab,Anti-CD20,Colorectal Cancer,Phase 3,46,Infusion-related reaction,Respiratory disorders,Yes,Mild,46,5,7,10.87,No,,12,77,No,Yes,Dose reduction,25,26
NCT10100570,Rituximab,Anti-CD20,Multiple Myeloma,Phase 4,194,Hyperthyroidism,Endocrine disorders,No,Severe,194,11,12,5.67,Yes,Safety concerns,8,362,Yes,Yes,Discontinuation,11,66
NCT72031846,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,458,Fatigue,Blood disorders,No,Moderate,458,95,96,20.74,Yes,Lack of efficacy,6,81,Yes,No,Discontinuation,7,15
NCT90184158,Rituximab,Anti-CD20,Lung Cancer,Phase 4,450,Fatigue,Respiratory disorders,No,Mild,450,7,11,1.56,Yes,Safety concerns,3,102,Yes,Yes,Discontinuation,11,65
NCT28812442,Rituximab,Anti-CD20,Melanoma,Phase 3,325,Anemia,Hepatobiliary disorders,No,Mild,325,54,58,16.62,No,,4,334,Yes,No,Dose reduction,18,2
NCT81691212,Rituximab,Anti-CD20,Breast Cancer,Phase 3,40,Thrombocytopenia,General disorders,No,Severe,40,12,12,30.0,Yes,Safety concerns,19,232,Yes,Yes,Treatment interruption,1,67
NCT95525437,Rituximab,Anti-CD20,Breast Cancer,Phase 2,454,Hypothyroidism,Endocrine disorders,No,Mild,454,97,97,21.37,No,,10,218,Yes,Yes,Supportive care,13,46
NCT77796362,Rituximab,Anti-CD20,Rheumatoid Arthritis,Phase 4,68,Cardiotoxicity,General disorders,No,Moderate,68,12,16,17.65,Yes,Regulatory issues,3,309,Yes,No,Discontinuation,9,80
NCT18883869,Rituximab,Anti-CD20,Lung Cancer,Phase 2,421,Arthralgia,General disorders,No,Severe,421,115,116,27.32,No,,17,256,Yes,No,Treatment interruption,26,54
NCT22653415,Rituximab,Anti-CD20,Melanoma,Phase 1,443,Hyperthyroidism,Blood disorders,Yes,Severe,443,129,130,29.12,Yes,Safety concerns,6,346,No,Yes,Dose reduction,22,4
NCT43464084,Rituximab,Anti-CD20,Melanoma,Phase 3,420,Hypothyroidism,Respiratory disorders,No,Severe,420,77,82,18.33,No,,1,255,No,No,Supportive care,19,29
NCT90007946,Rituximab,Anti-CD20,Breast Cancer,Phase 2,149,Anemia,Respiratory disorders,No,Moderate,149,28,30,18.79,No,,1,37,No,Yes,Supportive care,12,6
NCT78927629,Rituximab,Anti-CD20,Rheumatoid Arthritis,Phase 1,101,Arthralgia,Cardiac disorders,No,Mild,101,9,14,8.91,No,,20,76,No,No,Supportive care,17,80
NCT63073574,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,343,Rash,Skin disorders,No,Moderate,343,28,30,8.16,No,,5,233,Yes,Yes,Treatment interruption,16,81
NCT69408494,Rituximab,Anti-CD20,Melanoma,Phase 3,188,Thrombocytopenia,Blood disorders,Yes,Mild,188,52,52,27.66,No,,6,265,Yes,No,Discontinuation,16,7
NCT61073682,Rituximab,Anti-CD20,Melanoma,Phase 2,244,Rash,Blood disorders,No,Mild,244,20,24,8.2,No,,4,328,Yes,Yes,Treatment interruption,10,70
NCT74526527,Rituximab,Anti-CD20,Lung Cancer,Phase 1,356,Colitis,Blood disorders,No,Mild,356,72,77,20.22,No,,12,327,Yes,Yes,Supportive care,20,54
NCT62698991,Rituximab,Anti-CD20,Breast Cancer,Phase 1,442,Cardiotoxicity,Respiratory disorders,No,Mild,442,128,131,28.96,No,,9,38,No,Yes,Supportive care,2,25
NCT30448127,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,411,Nausea,Hepatobiliary disorders,No,Mild,411,70,72,17.03,No,,4,297,No,No,Supportive care,6,12
NCT27702894,Rituximab,Anti-CD20,Breast Cancer,Phase 4,95,Nausea,Skin disorders,No,Moderate,95,3,5,3.16,No,,13,87,No,Yes,Discontinuation,25,85
NCT81152410,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,498,Hyperthyroidism,Blood disorders,No,Mild,498,58,60,11.65,No,,17,177,No,Yes,Treatment interruption,1,16
NCT74057704,Rituximab,Anti-CD20,Multiple Myeloma,Phase 2,77,Anemia,Endocrine disorders,No,Moderate,77,20,23,25.97,No,,18,336,No,Yes,Discontinuation,21,47
NCT10516448,Rituximab,Anti-CD20,Multiple Myeloma,Phase 1,232,Hyperthyroidism,Respiratory disorders,Yes,Moderate,232,56,61,24.14,Yes,Lack of efficacy,11,53,Yes,No,Discontinuation,24,43
NCT69642321,Rituximab,Anti-CD20,Lung Cancer,Phase 4,169,Rash,Skin disorders,Yes,Severe,169,6,10,3.55,Yes,Competition,6,81,No,No,Supportive care,20,45
NCT81214834,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,355,Colitis,Skin disorders,No,Moderate,355,42,46,11.83,No,,3,104,No,Yes,Supportive care,17,47
NCT32381556,Rituximab,Anti-CD20,Multiple Myeloma,Phase 2,276,Pneumonitis,Gastrointestinal disorders,No,Mild,276,53,58,19.2,No,,13,284,No,No,Dose reduction,1,33
NCT88756077,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,204,Hepatotoxicity,Respiratory disorders,No,Moderate,204,30,34,14.71,No,,10,60,No,Yes,Discontinuation,22,66
NCT61568412,Rituximab,Anti-CD20,Lung Cancer,Phase 1,149,Pneumonitis,Respiratory disorders,No,Moderate,149,41,45,27.52,No,,13,74,Yes,No,Discontinuation,3,41
NCT56257719,Rituximab,Anti-CD20,Melanoma,Phase 4,73,Rash,Skin disorders,No,Moderate,73,4,8,5.48,No,,2,258,Yes,No,Discontinuation,12,14
NCT12612786,Rituximab,Anti-CD20,Colorectal Cancer,Phase 4,479,Hyperthyroidism,Endocrine disorders,No,Mild,479,94,95,19.62,No,,6,119,No,No,Treatment interruption,23,77
NCT65890467,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,192,Diarrhea,Respiratory disorders,No,Moderate,192,37,42,19.27,Yes,Safety concerns,4,86,Yes,Yes,Discontinuation,22,28
NCT95821730,Rituximab,Anti-CD20,Rheumatoid Arthritis,Phase 1,217,Infusion-related reaction,Cardiac disorders,No,Severe,217,38,43,17.51,Yes,Safety concerns,12,270,No,No,Dose reduction,4,42
NCT58445173,Rituximab,Anti-CD20,Colorectal Cancer,Phase 2,288,Hypothyroidism,Hepatobiliary disorders,Yes,Severe,288,79,79,27.43,No,,11,281,No,No,Discontinuation,11,86
NCT66001287,Rituximab,Anti-CD20,Colorectal Cancer,Phase 3,128,Rash,Hepatobiliary disorders,No,Moderate,128,7,7,5.47,No,,20,108,Yes,Yes,Dose reduction,7,3
NCT97051422,Rituximab,Anti-CD20,Melanoma,Phase 2,175,Rash,Respiratory disorders,No,Mild,175,19,19,10.86,No,,18,94,No,Yes,Dose reduction,25,24
NCT83168992,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,83,Diarrhea,Gastrointestinal disorders,No,Moderate,83,3,5,3.61,No,,10,212,No,No,Discontinuation,21,26
NCT42543181,Rituximab,Anti-CD20,Breast Cancer,Phase 2,39,Pneumonitis,Blood disorders,No,Mild,39,9,11,23.08,No,,18,62,No,No,Supportive care,12,53
NCT85239579,Rituximab,Anti-CD20,Lung Cancer,Phase 4,146,Hepatotoxicity,Endocrine disorders,No,Moderate,146,37,41,25.34,No,,2,155,Yes,Yes,Treatment interruption,1,50
NCT10414100,Rituximab,Anti-CD20,Lung Cancer,Phase 3,300,Anemia,Hepatobiliary disorders,No,Severe,300,78,81,26.0,No,,6,142,No,Yes,Treatment interruption,21,63
NCT88726017,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,151,Hepatotoxicity,Gastrointestinal disorders,No,Moderate,151,24,24,15.89,No,,15,256,No,Yes,Discontinuation,11,40
NCT15051915,Rituximab,Anti-CD20,Colorectal Cancer,Phase 4,145,Hepatotoxicity,Cardiac disorders,No,Mild,145,4,7,2.76,No,,5,75,No,Yes,Dose reduction,30,54
NCT83734863,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,317,Arthralgia,Endocrine disorders,Yes,Severe,317,86,86,27.13,Yes,Regulatory issues,4,353,No,No,Dose reduction,12,82
NCT51957625,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,475,Fatigue,Respiratory disorders,No,Severe,475,25,28,5.26,No,,14,160,Yes,No,Dose reduction,18,76
NCT96054027,Rituximab,Anti-CD20,Colorectal Cancer,Phase 3,150,Thrombocytopenia,Cardiac disorders,Yes,Severe,150,25,26,16.67,No,,5,332,No,Yes,Discontinuation,12,17
NCT34968081,Rituximab,Anti-CD20,Colorectal Cancer,Phase 1,458,Infusion-related reaction,Musculoskeletal disorders,No,Mild,458,63,63,13.76,No,,5,160,No,Yes,Treatment interruption,21,49
NCT99114422,Rituximab,Anti-CD20,Melanoma,Phase 2,492,Thrombocytopenia,Blood disorders,Yes,Mild,492,133,137,27.03,No,,4,80,No,Yes,Treatment interruption,28,55
NCT55309473,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 4,218,Infusion-related reaction,General disorders,No,Mild,218,37,40,16.97,No,,1,248,No,Yes,Treatment interruption,29,57
NCT54012184,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,106,Cardiotoxicity,Gastrointestinal disorders,No,Mild,106,18,19,16.98,No,,6,232,No,No,Supportive care,20,60
NCT23095801,Rituximab,Anti-CD20,Colorectal Cancer,Phase 3,328,Nausea,Cardiac disorders,Yes,Mild,328,93,98,28.35,No,,20,280,Yes,Yes,Supportive care,7,16
NCT47785010,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,360,Hypothyroidism,Skin disorders,No,Mild,360,64,68,17.78,No,,16,300,Yes,No,Treatment interruption,2,31
NCT15489221,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,303,Neutropenia,Respiratory disorders,No,Mild,303,36,41,11.88,No,,14,298,No,Yes,Discontinuation,12,17
NCT60721582,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,354,Diarrhea,Endocrine disorders,No,Moderate,354,86,88,24.29,No,,20,125,Yes,Yes,Discontinuation,19,25
NCT94826032,Rituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,225,Pneumonitis,Skin disorders,No,Moderate,225,14,17,6.22,No,,9,33,No,Yes,Dose reduction,10,69
NCT46442649,Rituximab,Anti-CD20,Melanoma,Phase 1,140,Anemia,Endocrine disorders,Yes,Moderate,140,25,26,17.86,Yes,Regulatory issues,7,360,Yes,No,Supportive care,20,8
NCT36136160,Rituximab,Anti-CD20,Multiple Myeloma,Phase 1,328,Cardiotoxicity,Blood disorders,Yes,Mild,328,19,20,5.79,Yes,Safety concerns,11,154,No,No,Supportive care,10,10
NCT76520512,Rituximab,Anti-CD20,Lung Cancer,Phase 1,253,Diarrhea,Gastrointestinal disorders,No,Severe,253,22,27,8.7,Yes,Regulatory issues,2,84,Yes,Yes,Dose reduction,24,60
NCT20573464,Rituximab,Anti-CD20,Melanoma,Phase 4,314,Nausea,Hepatobiliary disorders,No,Severe,314,29,33,9.24,No,,8,134,No,Yes,Discontinuation,11,31
NCT86142637,Rituximab,Anti-CD20,Colorectal Cancer,Phase 1,216,Pneumonitis,Skin disorders,No,Mild,216,51,52,23.61,No,,5,123,Yes,Yes,Supportive care,10,58
NCT92702209,Rituximab,Anti-CD20,Colorectal Cancer,Phase 3,397,Arthralgia,Skin disorders,No,Moderate,397,75,77,18.89,No,,3,115,Yes,Yes,Discontinuation,30,87
NCT31597256,Rituximab,Anti-CD20,Colorectal Cancer,Phase 1,86,Nausea,Skin disorders,No,Moderate,86,25,27,29.07,No,,3,161,Yes,Yes,Treatment interruption,11,44
NCT65287679,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 4,446,Cardiotoxicity,Skin disorders,No,Moderate,446,54,56,12.11,No,,3,283,Yes,No,Supportive care,2,6
NCT79785576,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,299,Thrombocytopenia,Respiratory disorders,No,Mild,299,73,73,24.41,No,,20,199,Yes,Yes,Discontinuation,15,8
NCT99020283,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 3,230,Colitis,Blood disorders,No,Mild,230,11,13,4.78,No,,17,226,Yes,No,Treatment interruption,24,85
NCT53343772,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 4,363,Colitis,General disorders,No,Moderate,363,90,95,24.79,No,,11,40,No,No,Discontinuation,11,88
NCT73981535,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,344,Hyperthyroidism,Endocrine disorders,Yes,Severe,344,81,86,23.55,Yes,Safety concerns,8,106,No,No,Treatment interruption,22,32
NCT72954010,Obinutuzumab,Anti-CD20,Melanoma,Phase 4,229,Rash,Musculoskeletal disorders,No,Mild,229,26,29,11.35,No,,2,356,Yes,No,Discontinuation,10,33
NCT68039709,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,401,Arthralgia,Blood disorders,No,Mild,401,77,79,19.2,No,,16,322,No,Yes,Dose reduction,13,72
NCT70319076,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,74,Arthralgia,Gastrointestinal disorders,No,Mild,74,10,12,13.51,No,,12,345,No,No,Treatment interruption,14,45
NCT27049990,Obinutuzumab,Anti-CD20,Lung Cancer,Phase 2,320,Diarrhea,Gastrointestinal disorders,No,Mild,320,6,7,1.88,No,,13,312,No,No,Discontinuation,24,19
NCT81683219,Obinutuzumab,Anti-CD20,Lung Cancer,Phase 1,41,Thrombocytopenia,Hepatobiliary disorders,Yes,Mild,41,4,8,9.76,No,,14,285,No,No,Supportive care,1,88
NCT88573104,Obinutuzumab,Anti-CD20,Lung Cancer,Phase 2,96,Infusion-related reaction,Skin disorders,No,Moderate,96,26,26,27.08,Yes,Safety concerns,18,243,No,Yes,Discontinuation,23,69
NCT22913708,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 1,486,Hepatotoxicity,General disorders,No,Severe,486,61,64,12.55,Yes,Regulatory issues,7,258,Yes,Yes,Dose reduction,29,44
NCT89989819,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 4,432,Fatigue,Respiratory disorders,No,Mild,432,25,30,5.79,No,,17,95,No,No,Supportive care,21,52
NCT34872554,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 1,426,Rash,Skin disorders,No,Mild,426,99,99,23.24,No,,11,115,Yes,No,Discontinuation,28,72
NCT71410139,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,141,Diarrhea,Hepatobiliary disorders,No,Moderate,141,28,30,19.86,No,,14,346,Yes,Yes,Supportive care,7,14
NCT46439322,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,361,Hepatotoxicity,Musculoskeletal disorders,Yes,Severe,361,15,19,4.16,No,,17,365,Yes,Yes,Supportive care,2,46
NCT99575695,Obinutuzumab,Anti-CD20,Lung Cancer,Phase 4,398,Anemia,Musculoskeletal disorders,No,Mild,398,110,110,27.64,No,,13,208,No,No,Dose reduction,22,71
NCT32768859,Obinutuzumab,Anti-CD20,Melanoma,Phase 3,274,Cardiotoxicity,General disorders,No,Moderate,274,30,32,10.95,Yes,Competition,1,251,No,No,Dose reduction,11,11
NCT80057787,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 1,399,Anemia,Musculoskeletal disorders,No,Mild,399,70,71,17.54,No,,15,131,No,Yes,Supportive care,11,1
NCT17804205,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 3,341,Neutropenia,Skin disorders,No,Mild,341,31,32,9.09,No,,10,248,Yes,No,Supportive care,20,59
NCT25329894,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 4,163,Rash,Hepatobiliary disorders,No,Mild,163,33,33,20.25,No,,5,47,Yes,Yes,Discontinuation,12,77
NCT42861397,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 2,85,Colitis,Gastrointestinal disorders,No,Severe,85,21,22,24.71,No,,6,120,Yes,Yes,Treatment interruption,2,15
NCT40031461,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,397,Hepatotoxicity,Musculoskeletal disorders,No,Severe,397,115,118,28.97,No,,6,192,Yes,No,Dose reduction,17,21
NCT27024957,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 3,112,Neutropenia,Gastrointestinal disorders,No,Severe,112,24,26,21.43,No,,14,108,Yes,No,Supportive care,14,53
NCT22728178,Obinutuzumab,Anti-CD20,Melanoma,Phase 2,68,Infusion-related reaction,Skin disorders,No,Mild,68,15,20,22.06,No,,7,270,No,No,Treatment interruption,1,3
NCT76325293,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 1,374,Anemia,Skin disorders,No,Severe,374,45,47,12.03,No,,8,188,Yes,No,Dose reduction,28,84
NCT26244780,Obinutuzumab,Anti-CD20,Melanoma,Phase 4,372,Hyperthyroidism,Respiratory disorders,No,Severe,372,86,89,23.12,Yes,Regulatory issues,3,278,No,Yes,Dose reduction,27,36
NCT67245988,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 4,319,Hypothyroidism,Endocrine disorders,Yes,Severe,319,26,29,8.15,No,,19,315,No,Yes,Dose reduction,5,29
NCT36661875,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 2,169,Colitis,Skin disorders,Yes,Mild,169,10,15,5.92,No,,1,170,Yes,No,Treatment interruption,6,53
NCT13892094,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 3,56,Hepatotoxicity,Musculoskeletal disorders,No,Mild,56,15,18,26.79,No,,10,301,No,No,Dose reduction,1,4
NCT19103992,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 4,295,Rash,Musculoskeletal disorders,No,Mild,295,31,34,10.51,No,,18,220,No,Yes,Dose reduction,19,43
NCT61202363,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,410,Anemia,General disorders,No,Mild,410,7,10,1.71,No,,5,324,No,No,Treatment interruption,27,69
NCT28894326,Obinutuzumab,Anti-CD20,Melanoma,Phase 4,422,Fatigue,Blood disorders,Yes,Severe,422,62,67,14.69,No,,5,345,No,Yes,Dose reduction,14,21
NCT41406446,Obinutuzumab,Anti-CD20,Melanoma,Phase 4,236,Infusion-related reaction,Blood disorders,Yes,Severe,236,33,33,13.98,Yes,Lack of efficacy,17,143,Yes,Yes,Discontinuation,3,85
NCT75129044,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 2,325,Diarrhea,Hepatobiliary disorders,No,Mild,325,26,30,8.0,No,,10,307,Yes,Yes,Supportive care,6,59
NCT28030885,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 2,233,Infusion-related reaction,Musculoskeletal disorders,No,Severe,233,24,29,10.3,Yes,Regulatory issues,11,135,No,Yes,Treatment interruption,30,59
NCT86685806,Obinutuzumab,Anti-CD20,Melanoma,Phase 3,171,Anemia,Endocrine disorders,No,Severe,171,2,5,1.17,Yes,Lack of efficacy,14,136,No,Yes,Treatment interruption,26,87
NCT26385094,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 3,306,Rash,Cardiac disorders,No,Mild,306,28,33,9.15,No,,20,220,Yes,No,Dose reduction,26,82
NCT23786007,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 4,369,Arthralgia,Skin disorders,No,Mild,369,57,60,15.45,Yes,Competition,4,349,Yes,No,Discontinuation,24,86
NCT53168780,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 1,42,Neutropenia,Blood disorders,No,Severe,42,9,12,21.43,No,,16,40,Yes,Yes,Treatment interruption,13,61
NCT50098373,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 4,252,Infusion-related reaction,Hepatobiliary disorders,No,Mild,252,21,26,8.33,No,,2,34,Yes,No,Supportive care,6,76
NCT83721814,Obinutuzumab,Anti-CD20,Melanoma,Phase 4,480,Hypothyroidism,Endocrine disorders,Yes,Severe,480,84,85,17.5,No,,11,295,No,No,Treatment interruption,6,68
NCT78372430,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,298,Diarrhea,Musculoskeletal disorders,No,Mild,298,60,65,20.13,No,,4,282,Yes,No,Dose reduction,24,52
NCT18605111,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 1,326,Rash,Blood disorders,No,Mild,326,77,79,23.62,No,,13,45,No,Yes,Dose reduction,29,16
NCT29417704,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,123,Anemia,Gastrointestinal disorders,No,Severe,123,33,33,26.83,Yes,Regulatory issues,12,178,Yes,No,Discontinuation,17,80
NCT35438658,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 4,434,Pneumonitis,Skin disorders,No,Severe,434,118,122,27.19,No,,9,156,Yes,Yes,Dose reduction,23,72
NCT28932188,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,239,Hypothyroidism,Skin disorders,No,Moderate,239,58,61,24.27,No,,3,356,No,Yes,Discontinuation,24,27
NCT60493289,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 2,308,Rash,Hepatobiliary disorders,No,Severe,308,11,15,3.57,No,,11,363,Yes,No,Discontinuation,22,65
NCT49694418,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,56,Anemia,Cardiac disorders,No,Mild,56,10,14,17.86,No,,16,210,No,Yes,Dose reduction,20,58
NCT50586477,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 2,359,Cardiotoxicity,Skin disorders,No,Moderate,359,69,69,19.22,No,,18,71,No,Yes,Treatment interruption,1,2
NCT17559063,Obinutuzumab,Anti-CD20,Melanoma,Phase 4,433,Thrombocytopenia,Skin disorders,No,Mild,433,10,10,2.31,No,,4,191,No,No,Discontinuation,14,23
NCT88010908,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,54,Nausea,Hepatobiliary disorders,No,Moderate,54,1,3,1.85,Yes,Safety concerns,4,342,Yes,No,Dose reduction,17,52
NCT58957056,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 2,100,Diarrhea,Respiratory disorders,Yes,Mild,100,22,25,22.0,No,,14,316,No,Yes,Dose reduction,2,87
NCT61810124,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 2,435,Cardiotoxicity,Gastrointestinal disorders,No,Moderate,435,128,131,29.43,No,,6,105,Yes,No,Treatment interruption,11,39
NCT81821019,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 3,132,Hepatotoxicity,Respiratory disorders,No,Moderate,132,18,20,13.64,No,,6,205,No,No,Discontinuation,10,21
NCT37541691,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 1,208,Hepatotoxicity,Hepatobiliary disorders,No,Moderate,208,12,13,5.77,No,,9,282,Yes,Yes,Discontinuation,28,66
NCT91319817,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 1,482,Pneumonitis,Cardiac disorders,Yes,Moderate,482,124,125,25.73,Yes,Lack of efficacy,20,359,No,No,Discontinuation,8,7
NCT77076917,Obinutuzumab,Anti-CD20,Rheumatoid Arthritis,Phase 4,197,Arthralgia,Respiratory disorders,No,Moderate,197,37,37,18.78,No,,4,34,No,No,Discontinuation,25,88
NCT73722965,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 2,118,Hyperthyroidism,Blood disorders,No,Severe,118,10,11,8.47,No,,17,317,Yes,Yes,Treatment interruption,19,10
NCT64947021,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,489,Fatigue,Blood disorders,No,Mild,489,74,75,15.13,No,,3,308,Yes,No,Dose reduction,2,1
NCT21563298,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 2,352,Diarrhea,Skin disorders,No,Mild,352,28,33,7.95,No,,1,250,No,Yes,Treatment interruption,6,90
NCT60686307,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 4,246,Fatigue,Cardiac disorders,No,Mild,246,27,32,10.98,No,,8,275,No,Yes,Supportive care,12,11
NCT26268184,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 1,140,Thrombocytopenia,Endocrine disorders,No,Mild,140,13,13,9.29,No,,17,101,No,Yes,Dose reduction,22,35
NCT43391088,Obinutuzumab,Anti-CD20,Melanoma,Phase 2,253,Arthralgia,Gastrointestinal disorders,Yes,Mild,253,72,76,28.46,No,,17,31,No,Yes,Discontinuation,6,81
NCT95233758,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 1,401,Colitis,Endocrine disorders,No,Moderate,401,67,70,16.71,Yes,Regulatory issues,16,150,Yes,No,Discontinuation,25,66
NCT49279009,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,223,Diarrhea,Skin disorders,No,Severe,223,63,66,28.25,Yes,Lack of efficacy,18,341,Yes,Yes,Dose reduction,25,36
NCT46209817,Obinutuzumab,Anti-CD20,Breast Cancer,Phase 4,334,Fatigue,Cardiac disorders,No,Severe,334,36,36,10.78,No,,15,243,No,Yes,Dose reduction,10,88
NCT28134594,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 1,329,Cardiotoxicity,Gastrointestinal disorders,No,Mild,329,3,6,0.91,No,,5,133,No,Yes,Treatment interruption,24,32
NCT33075580,Obinutuzumab,Anti-CD20,Lung Cancer,Phase 1,175,Neutropenia,Endocrine disorders,No,Mild,175,52,54,29.71,No,,3,353,No,No,Discontinuation,28,51
NCT78610284,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,147,Arthralgia,Skin disorders,No,Moderate,147,30,33,20.41,No,,12,191,No,Yes,Supportive care,1,79
NCT44191517,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 1,197,Cardiotoxicity,Endocrine disorders,No,Moderate,197,47,52,23.86,No,,14,181,Yes,Yes,Dose reduction,29,26
NCT38751841,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,372,Fatigue,Skin disorders,Yes,Severe,372,7,8,1.88,Yes,Lack of efficacy,17,297,Yes,Yes,Supportive care,11,58
NCT48836650,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,41,Arthralgia,Musculoskeletal disorders,No,Mild,41,2,5,4.88,No,,3,119,Yes,No,Dose reduction,13,33
NCT39453601,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 1,201,Colitis,Gastrointestinal disorders,No,Mild,201,2,6,1.0,No,,12,30,No,Yes,Dose reduction,25,28
NCT48335158,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,69,Cardiotoxicity,Cardiac disorders,No,Moderate,69,1,3,1.45,Yes,Competition,14,164,Yes,No,Treatment interruption,16,6
NCT24624600,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 3,426,Nausea,Respiratory disorders,Yes,Mild,426,76,76,17.84,No,,19,266,Yes,No,Discontinuation,17,34
NCT90086463,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,85,Rash,Respiratory disorders,No,Mild,85,20,20,23.53,No,,16,80,Yes,No,Supportive care,19,87
NCT64295520,Obinutuzumab,Anti-CD20,Colorectal Cancer,Phase 3,150,Fatigue,Musculoskeletal disorders,No,Severe,150,11,12,7.33,No,,17,60,No,Yes,Dose reduction,4,72
NCT71088583,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 4,104,Neutropenia,Skin disorders,Yes,Severe,104,26,28,25.0,No,,15,261,Yes,Yes,Supportive care,15,63
NCT31381391,Obinutuzumab,Anti-CD20,Melanoma,Phase 2,101,Diarrhea,Cardiac disorders,No,Moderate,101,9,10,8.91,No,,11,286,No,Yes,Treatment interruption,22,5
NCT52154252,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 3,288,Rash,Cardiac disorders,No,Mild,288,8,11,2.78,No,,11,330,Yes,No,Discontinuation,27,86
NCT38706462,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 3,52,Nausea,Blood disorders,Yes,Severe,52,1,5,1.92,Yes,Safety concerns,5,187,No,Yes,Discontinuation,9,83
NCT13719135,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,164,Thrombocytopenia,Skin disorders,No,Mild,164,40,43,24.39,No,,2,335,No,Yes,Dose reduction,23,21
NCT45276367,Obinutuzumab,Anti-CD20,Multiple Myeloma,Phase 2,342,Nausea,Respiratory disorders,No,Moderate,342,81,86,23.68,Yes,Competition,3,68,No,Yes,Supportive care,13,8
NCT79666857,Obinutuzumab,Anti-CD20,Lung Cancer,Phase 4,98,Fatigue,Cardiac disorders,No,Severe,98,26,29,26.53,No,,17,77,No,Yes,Dose reduction,11,62
NCT26927586,Obinutuzumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,496,Neutropenia,Blood disorders,No,Moderate,496,88,93,17.74,Yes,Regulatory issues,12,216,No,Yes,Dose reduction,10,8
NCT73855958,Ofatumumab,Anti-CD20,Breast Cancer,Phase 1,225,Rash,Gastrointestinal disorders,Yes,Moderate,225,31,34,13.78,Yes,Safety concerns,13,55,Yes,Yes,Supportive care,21,68
NCT63031537,Ofatumumab,Anti-CD20,Multiple Myeloma,Phase 4,377,Rash,General disorders,No,Moderate,377,45,46,11.94,No,,15,324,No,No,Treatment interruption,30,58
NCT75033899,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,77,Pneumonitis,Respiratory disorders,No,Mild,77,5,8,6.49,No,,4,293,No,No,Discontinuation,7,5
NCT56956264,Ofatumumab,Anti-CD20,Lung Cancer,Phase 1,243,Hypothyroidism,General disorders,No,Moderate,243,53,53,21.81,No,,3,130,Yes,No,Discontinuation,9,28
NCT69321487,Ofatumumab,Anti-CD20,Lung Cancer,Phase 1,61,Nausea,Skin disorders,No,Mild,61,8,9,13.11,No,,5,100,No,Yes,Dose reduction,26,82
NCT55022619,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,289,Infusion-related reaction,Musculoskeletal disorders,No,Moderate,289,20,21,6.92,No,,10,146,Yes,Yes,Dose reduction,18,45
NCT49474437,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 1,293,Nausea,General disorders,No,Mild,293,23,26,7.85,No,,4,290,No,Yes,Discontinuation,21,39
NCT68629724,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 3,309,Neutropenia,Endocrine disorders,No,Mild,309,74,75,23.95,No,,20,86,Yes,Yes,Discontinuation,6,23
NCT52873055,Ofatumumab,Anti-CD20,Rheumatoid Arthritis,Phase 1,283,Pneumonitis,Endocrine disorders,No,Moderate,283,3,5,1.06,No,,20,155,Yes,Yes,Dose reduction,16,27
NCT29828367,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,247,Infusion-related reaction,Hepatobiliary disorders,No,Mild,247,52,56,21.05,No,,3,362,No,No,Supportive care,21,65
NCT63756985,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,237,Hepatotoxicity,Hepatobiliary disorders,No,Mild,237,66,66,27.85,No,,13,32,Yes,Yes,Supportive care,15,32
NCT35668692,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,264,Thrombocytopenia,Respiratory disorders,No,Mild,264,14,16,5.3,No,,18,134,No,No,Treatment interruption,17,90
NCT61147669,Ofatumumab,Anti-CD20,Melanoma,Phase 4,400,Thrombocytopenia,Gastrointestinal disorders,No,Moderate,400,31,35,7.75,No,,7,75,Yes,No,Dose reduction,14,88
NCT95269128,Ofatumumab,Anti-CD20,Melanoma,Phase 4,418,Rash,Gastrointestinal disorders,Yes,Severe,418,100,105,23.92,No,,9,112,Yes,Yes,Discontinuation,27,68
NCT68942849,Ofatumumab,Anti-CD20,Lung Cancer,Phase 2,385,Hyperthyroidism,Cardiac disorders,No,Moderate,385,71,76,18.44,No,,15,40,No,Yes,Treatment interruption,17,60
NCT36812377,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,222,Hyperthyroidism,Endocrine disorders,No,Mild,222,31,34,13.96,No,,6,122,Yes,No,Supportive care,24,55
NCT61786911,Ofatumumab,Anti-CD20,Lung Cancer,Phase 4,317,Fatigue,Blood disorders,No,Severe,317,55,59,17.35,No,,6,128,Yes,No,Dose reduction,4,70
NCT13287860,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,21,Rash,Musculoskeletal disorders,Yes,Severe,21,4,7,19.05,Yes,Safety concerns,4,226,Yes,Yes,Treatment interruption,14,52
NCT10240174,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,137,Hepatotoxicity,Blood disorders,No,Mild,137,3,7,2.19,No,,3,165,Yes,No,Treatment interruption,20,41
NCT32367600,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,269,Fatigue,Endocrine disorders,No,Mild,269,13,16,4.83,No,,19,109,Yes,No,Discontinuation,28,68
NCT43770298,Ofatumumab,Anti-CD20,Multiple Myeloma,Phase 2,70,Anemia,Skin disorders,No,Severe,70,14,14,20.0,No,,16,116,No,Yes,Treatment interruption,4,27
NCT80676377,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,445,Cardiotoxicity,General disorders,No,Mild,445,106,111,23.82,No,,2,96,Yes,No,Dose reduction,7,6
NCT84067523,Ofatumumab,Anti-CD20,Rheumatoid Arthritis,Phase 2,57,Hypothyroidism,Endocrine disorders,Yes,Severe,57,17,20,29.82,No,,6,92,Yes,Yes,Discontinuation,25,43
NCT76870621,Ofatumumab,Anti-CD20,Lung Cancer,Phase 4,419,Hypothyroidism,Hepatobiliary disorders,No,Severe,419,114,115,27.21,No,,6,131,Yes,Yes,Treatment interruption,23,13
NCT46611758,Ofatumumab,Anti-CD20,Multiple Myeloma,Phase 4,39,Arthralgia,Skin disorders,No,Mild,39,5,5,12.82,No,,4,290,Yes,Yes,Treatment interruption,23,85
NCT77607653,Ofatumumab,Anti-CD20,Lung Cancer,Phase 1,213,Hepatotoxicity,Cardiac disorders,No,Severe,213,11,13,5.16,No,,5,206,No,No,Discontinuation,3,24
NCT25621915,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,218,Hyperthyroidism,Endocrine disorders,No,Severe,218,56,57,25.69,No,,8,122,Yes,No,Dose reduction,28,28
NCT63818819,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 3,395,Arthralgia,Musculoskeletal disorders,Yes,Moderate,395,61,61,15.44,Yes,Lack of efficacy,11,358,Yes,No,Supportive care,27,6
NCT20114896,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,478,Hypothyroidism,General disorders,Yes,Severe,478,109,112,22.8,Yes,Regulatory issues,4,246,Yes,No,Treatment interruption,22,76
NCT74887722,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 4,353,Neutropenia,Endocrine disorders,No,Mild,353,94,96,26.63,No,,4,285,No,Yes,Dose reduction,14,36
NCT33098505,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,369,Hypothyroidism,Skin disorders,No,Mild,369,33,38,8.94,No,,2,277,No,No,Treatment interruption,26,10
NCT33172980,Ofatumumab,Anti-CD20,Lung Cancer,Phase 3,29,Hypothyroidism,Cardiac disorders,No,Severe,29,5,5,17.24,Yes,Regulatory issues,18,231,No,No,Treatment interruption,15,68
NCT60855152,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 2,490,Fatigue,General disorders,Yes,Severe,490,23,27,4.69,Yes,Safety concerns,5,60,Yes,Yes,Treatment interruption,22,87
NCT36588741,Ofatumumab,Anti-CD20,Lung Cancer,Phase 4,62,Colitis,Blood disorders,Yes,Mild,62,17,21,27.42,No,,10,199,No,Yes,Supportive care,21,13
NCT10049793,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,418,Infusion-related reaction,Hepatobiliary disorders,No,Mild,418,56,57,13.4,No,,16,89,No,No,Dose reduction,8,19
NCT48944801,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,445,Diarrhea,Blood disorders,No,Moderate,445,44,44,9.89,Yes,Regulatory issues,6,152,Yes,Yes,Supportive care,22,25
NCT48595881,Ofatumumab,Anti-CD20,Rheumatoid Arthritis,Phase 1,80,Anemia,Skin disorders,No,Mild,80,20,21,25.0,No,,14,200,No,No,Supportive care,6,62
NCT58046251,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 3,96,Cardiotoxicity,Hepatobiliary disorders,No,Mild,96,1,5,1.04,No,,1,332,No,Yes,Supportive care,10,64
NCT23507180,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,391,Arthralgia,Musculoskeletal disorders,No,Mild,391,72,75,18.41,No,,8,187,Yes,Yes,Discontinuation,1,47
NCT46079876,Ofatumumab,Anti-CD20,Multiple Myeloma,Phase 2,167,Pneumonitis,Endocrine disorders,No,Severe,167,7,9,4.19,No,,7,126,No,Yes,Treatment interruption,12,65
NCT12551194,Ofatumumab,Anti-CD20,Rheumatoid Arthritis,Phase 1,87,Cardiotoxicity,Respiratory disorders,No,Mild,87,13,17,14.94,No,,10,193,No,No,Dose reduction,19,75
NCT60099201,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 1,488,Neutropenia,Hepatobiliary disorders,No,Mild,488,15,19,3.07,No,,15,52,No,No,Discontinuation,7,41
NCT36830061,Ofatumumab,Anti-CD20,Breast Cancer,Phase 3,371,Diarrhea,Endocrine disorders,No,Moderate,371,55,59,14.82,Yes,Regulatory issues,17,146,Yes,No,Supportive care,21,61
NCT11925116,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 4,75,Pneumonitis,Hepatobiliary disorders,No,Moderate,75,9,10,12.0,No,,17,182,No,No,Supportive care,22,17
NCT26002759,Ofatumumab,Anti-CD20,Lung Cancer,Phase 4,480,Anemia,Respiratory disorders,No,Mild,480,66,66,13.75,No,,14,293,Yes,Yes,Dose reduction,4,25
NCT52680635,Ofatumumab,Anti-CD20,Lung Cancer,Phase 2,60,Pneumonitis,Blood disorders,No,Mild,60,13,17,21.67,No,,8,260,Yes,No,Supportive care,2,58
NCT64417788,Ofatumumab,Anti-CD20,Rheumatoid Arthritis,Phase 2,178,Neutropenia,Cardiac disorders,No,Severe,178,23,27,12.92,Yes,Safety concerns,5,341,No,Yes,Dose reduction,29,64
NCT35924189,Ofatumumab,Anti-CD20,Lung Cancer,Phase 4,288,Hepatotoxicity,Musculoskeletal disorders,No,Mild,288,86,91,29.86,No,,5,259,No,Yes,Discontinuation,23,56
NCT49267199,Ofatumumab,Anti-CD20,Melanoma,Phase 1,135,Neutropenia,Endocrine disorders,No,Severe,135,33,36,24.44,No,,18,239,Yes,No,Supportive care,19,67
NCT30359676,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 4,123,Arthralgia,Musculoskeletal disorders,No,Severe,123,8,10,6.5,No,,20,193,No,Yes,Dose reduction,28,52
NCT11074440,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 4,460,Hypothyroidism,Musculoskeletal disorders,No,Moderate,460,75,76,16.3,No,,17,35,Yes,Yes,Supportive care,12,76
NCT22240588,Ofatumumab,Anti-CD20,Breast Cancer,Phase 4,376,Fatigue,Hepatobiliary disorders,Yes,Mild,376,22,24,5.85,No,,17,340,No,No,Discontinuation,30,14
NCT90711045,Ofatumumab,Anti-CD20,Colorectal Cancer,Phase 1,456,Arthralgia,Blood disorders,No,Severe,456,124,127,27.19,No,,12,321,No,Yes,Supportive care,21,35
NCT79131135,Ofatumumab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,424,Rash,General disorders,Yes,Mild,424,24,26,5.66,No,,19,137,Yes,No,Discontinuation,6,28
NCT20733217,Ofatumumab,Anti-CD20,Rheumatoid Arthritis,Phase 2,124,Rash,Blood disorders,No,Mild,124,25,25,20.16,No,,19,342,No,Yes,Dose reduction,12,27
NCT49338841,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,225,Infusion-related reaction,Respiratory disorders,Yes,Severe,225,56,57,24.89,Yes,Lack of efficacy,4,34,No,No,Dose reduction,10,8
NCT83398249,Ofatumumab,Anti-CD20,Lung Cancer,Phase 2,238,Pneumonitis,General disorders,No,Mild,238,64,67,26.89,No,,8,263,Yes,No,Discontinuation,16,71
NCT76925130,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 1,207,Nausea,Respiratory disorders,No,Moderate,207,30,30,14.49,No,,19,251,No,Yes,Treatment interruption,2,59
NCT79713834,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,392,Nausea,Skin disorders,No,Mild,392,78,80,19.9,No,,13,203,Yes,No,Dose reduction,16,84
NCT25543673,Ublituximab,Anti-CD20,Breast Cancer,Phase 2,445,Hypothyroidism,Blood disorders,Yes,Moderate,445,130,131,29.21,No,,16,123,Yes,No,Dose reduction,16,76
NCT59184536,Ublituximab,Anti-CD20,Breast Cancer,Phase 1,278,Colitis,Musculoskeletal disorders,No,Moderate,278,34,35,12.23,No,,1,275,Yes,Yes,Discontinuation,27,3
NCT30693579,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 1,368,Fatigue,Musculoskeletal disorders,Yes,Moderate,368,4,8,1.09,No,,11,198,Yes,Yes,Discontinuation,5,77
NCT62065765,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 4,68,Anemia,Hepatobiliary disorders,Yes,Mild,68,11,13,16.18,Yes,Competition,17,201,No,No,Dose reduction,11,23
NCT24989008,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 1,89,Pneumonitis,Gastrointestinal disorders,No,Moderate,89,8,12,8.99,No,,1,102,Yes,Yes,Discontinuation,27,52
NCT13806268,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,102,Pneumonitis,Gastrointestinal disorders,No,Moderate,102,5,10,4.9,Yes,Competition,9,170,No,Yes,Dose reduction,25,27
NCT51495893,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 4,81,Arthralgia,Respiratory disorders,Yes,Severe,81,23,28,28.4,Yes,Lack of efficacy,5,249,No,No,Supportive care,12,81
NCT56258236,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 4,457,Diarrhea,Skin disorders,No,Mild,457,121,126,26.48,No,,9,88,No,Yes,Treatment interruption,13,25
NCT76345956,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,81,Hyperthyroidism,Blood disorders,No,Mild,81,19,22,23.46,No,,4,364,No,Yes,Treatment interruption,25,77
NCT15810677,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 3,377,Rash,Respiratory disorders,No,Mild,377,25,28,6.63,No,,10,230,No,No,Dose reduction,4,72
NCT33425164,Ublituximab,Anti-CD20,Breast Cancer,Phase 1,167,Anemia,Cardiac disorders,No,Mild,167,48,49,28.74,No,,13,153,No,No,Supportive care,25,30
NCT96938753,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,78,Infusion-related reaction,Gastrointestinal disorders,No,Mild,78,18,19,23.08,No,,19,364,No,No,Supportive care,16,18
NCT22212176,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 3,102,Fatigue,Gastrointestinal disorders,No,Mild,102,14,14,13.73,No,,20,273,No,Yes,Dose reduction,15,74
NCT29395523,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,78,Arthralgia,Hepatobiliary disorders,No,Mild,78,5,6,6.41,No,,14,306,No,No,Treatment interruption,7,74
NCT69520185,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,278,Cardiotoxicity,Skin disorders,No,Mild,278,30,34,10.79,No,,8,304,Yes,No,Discontinuation,19,75
NCT54680905,Ublituximab,Anti-CD20,Lung Cancer,Phase 1,235,Hypothyroidism,Endocrine disorders,No,Mild,235,60,62,25.53,No,,12,279,Yes,No,Dose reduction,11,37
NCT60984828,Ublituximab,Anti-CD20,Lung Cancer,Phase 4,107,Diarrhea,Skin disorders,No,Moderate,107,1,1,0.93,No,,10,310,No,Yes,Treatment interruption,19,83
NCT81847947,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 3,266,Nausea,General disorders,No,Mild,266,74,79,27.82,No,,14,122,Yes,No,Discontinuation,3,84
NCT79533741,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 2,88,Infusion-related reaction,Endocrine disorders,No,Severe,88,24,27,27.27,No,,8,332,No,Yes,Supportive care,14,69
NCT55385097,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 3,360,Rash,Cardiac disorders,Yes,Moderate,360,50,52,13.89,No,,12,277,No,No,Supportive care,10,9
NCT92822684,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,158,Cardiotoxicity,Gastrointestinal disorders,No,Mild,158,11,15,6.96,No,,18,181,Yes,No,Supportive care,1,90
NCT30583463,Ublituximab,Anti-CD20,Lung Cancer,Phase 1,378,Cardiotoxicity,Skin disorders,Yes,Moderate,378,99,100,26.19,No,,2,190,Yes,Yes,Supportive care,7,6
NCT66303156,Ublituximab,Anti-CD20,Breast Cancer,Phase 2,218,Hyperthyroidism,Blood disorders,No,Mild,218,45,48,20.64,No,,6,263,No,No,Treatment interruption,23,22
NCT74717190,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 4,131,Arthralgia,Endocrine disorders,No,Mild,131,4,5,3.05,No,,7,100,No,No,Dose reduction,4,58
NCT91974221,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 3,235,Hyperthyroidism,Gastrointestinal disorders,No,Mild,235,42,43,17.87,No,,18,48,No,No,Supportive care,1,89
NCT76969929,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 3,418,Hepatotoxicity,Endocrine disorders,No,Severe,418,35,36,8.37,Yes,Regulatory issues,11,148,No,No,Supportive care,29,33
NCT27630390,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 3,274,Anemia,Hepatobiliary disorders,No,Moderate,274,74,74,27.01,No,,4,135,Yes,Yes,Treatment interruption,13,54
NCT41251833,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 1,299,Infusion-related reaction,General disorders,No,Mild,299,1,3,0.33,No,,1,348,Yes,No,Supportive care,15,73
NCT40514481,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,365,Thrombocytopenia,Respiratory disorders,No,Severe,365,105,109,28.77,Yes,Safety concerns,18,302,Yes,No,Dose reduction,16,87
NCT95519630,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 2,471,Rash,Respiratory disorders,Yes,Mild,471,34,38,7.22,No,,13,36,Yes,No,Discontinuation,27,76
NCT95872109,Ublituximab,Anti-CD20,Melanoma,Phase 1,191,Hepatotoxicity,Cardiac disorders,Yes,Moderate,191,57,58,29.84,No,,7,65,Yes,Yes,Discontinuation,8,31
NCT38605763,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 4,499,Hypothyroidism,Endocrine disorders,No,Mild,499,43,44,8.62,No,,20,189,No,No,Dose reduction,11,63
NCT86461462,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 4,435,Fatigue,Skin disorders,No,Mild,435,3,3,0.69,No,,10,363,No,No,Treatment interruption,2,30
NCT17563622,Ublituximab,Anti-CD20,Breast Cancer,Phase 4,36,Nausea,General disorders,No,Moderate,36,9,13,25.0,Yes,Regulatory issues,12,30,No,Yes,Discontinuation,23,80
NCT63759269,Ublituximab,Anti-CD20,Breast Cancer,Phase 1,255,Cardiotoxicity,Skin disorders,No,Moderate,255,36,41,14.12,No,,10,347,Yes,Yes,Discontinuation,9,85
NCT20943295,Ublituximab,Anti-CD20,Lung Cancer,Phase 2,42,Nausea,Respiratory disorders,No,Severe,42,9,10,21.43,No,,11,125,Yes,No,Supportive care,1,54
NCT51736082,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 4,487,Hepatotoxicity,Skin disorders,No,Mild,487,31,34,6.37,No,,17,193,No,Yes,Discontinuation,3,38
NCT81458936,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 1,454,Arthralgia,Hepatobiliary disorders,No,Moderate,454,112,117,24.67,No,,14,258,Yes,No,Supportive care,2,41
NCT62039969,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 2,157,Arthralgia,Endocrine disorders,No,Severe,157,8,10,5.1,No,,14,358,Yes,Yes,Discontinuation,28,89
NCT19253720,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 4,467,Diarrhea,Blood disorders,No,Mild,467,90,91,19.27,No,,5,275,No,Yes,Dose reduction,5,16
NCT86142521,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 3,112,Pneumonitis,Musculoskeletal disorders,No,Mild,112,27,30,24.11,No,,9,146,Yes,No,Treatment interruption,4,46
NCT66304633,Ublituximab,Anti-CD20,Breast Cancer,Phase 2,320,Arthralgia,Musculoskeletal disorders,No,Severe,320,75,77,23.44,Yes,Lack of efficacy,13,36,Yes,No,Dose reduction,7,17
NCT88621234,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,456,Rash,Skin disorders,No,Mild,456,6,9,1.32,No,,1,214,No,No,Dose reduction,23,24
NCT79782864,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 1,49,Pneumonitis,Blood disorders,No,Mild,49,14,19,28.57,Yes,Safety concerns,3,344,Yes,Yes,Supportive care,24,51
NCT52578897,Ublituximab,Anti-CD20,Breast Cancer,Phase 1,253,Colitis,Cardiac disorders,No,Mild,253,30,33,11.86,No,,6,110,Yes,No,Supportive care,3,59
NCT72439179,Ublituximab,Anti-CD20,Lung Cancer,Phase 1,317,Colitis,Musculoskeletal disorders,No,Moderate,317,8,12,2.52,No,,15,156,No,Yes,Supportive care,1,90
NCT87917907,Ublituximab,Anti-CD20,Breast Cancer,Phase 1,53,Cardiotoxicity,Endocrine disorders,Yes,Severe,53,1,5,1.89,Yes,Regulatory issues,18,309,No,No,Dose reduction,24,74
NCT44790392,Ublituximab,Anti-CD20,Lung Cancer,Phase 4,128,Cardiotoxicity,Respiratory disorders,No,Severe,128,30,35,23.44,No,,4,124,Yes,Yes,Treatment interruption,24,80
NCT90107470,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 4,402,Diarrhea,Musculoskeletal disorders,No,Moderate,402,119,122,29.6,No,,3,310,Yes,No,Treatment interruption,20,84
NCT21665206,Ublituximab,Anti-CD20,Lung Cancer,Phase 3,34,Infusion-related reaction,Hepatobiliary disorders,No,Mild,34,4,9,11.76,No,,6,324,Yes,Yes,Treatment interruption,10,69
NCT47447677,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 3,196,Arthralgia,Musculoskeletal disorders,Yes,Mild,196,40,40,20.41,Yes,Competition,19,128,No,Yes,Discontinuation,22,69
NCT57439332,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 2,413,Thrombocytopenia,General disorders,No,Severe,413,46,47,11.14,No,,4,50,Yes,Yes,Discontinuation,6,35
NCT21300876,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 2,102,Diarrhea,Skin disorders,No,Mild,102,15,15,14.71,No,,10,50,No,Yes,Supportive care,27,70
NCT52763216,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 4,413,Colitis,Hepatobiliary disorders,No,Mild,413,101,101,24.46,No,,18,355,Yes,Yes,Treatment interruption,18,82
NCT97061962,Ublituximab,Anti-CD20,Multiple Myeloma,Phase 1,270,Cardiotoxicity,Hepatobiliary disorders,No,Mild,270,43,47,15.93,No,,13,127,Yes,No,Discontinuation,29,80
NCT48590361,Ublituximab,Anti-CD20,Breast Cancer,Phase 1,38,Rash,Endocrine disorders,No,Mild,38,4,9,10.53,No,,19,324,Yes,Yes,Supportive care,18,37
NCT72805117,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 4,109,Hypothyroidism,Respiratory disorders,No,Mild,109,13,18,11.93,No,,16,263,Yes,Yes,Treatment interruption,2,24
NCT65681000,Ublituximab,Anti-CD20,Melanoma,Phase 2,116,Thrombocytopenia,Blood disorders,No,Mild,116,32,34,27.59,No,,4,156,Yes,Yes,Supportive care,22,76
NCT40274552,Ublituximab,Anti-CD20,Lung Cancer,Phase 2,299,Rash,Cardiac disorders,No,Mild,299,68,69,22.74,No,,13,275,No,No,Supportive care,8,67
NCT42373289,Ublituximab,Anti-CD20,Lung Cancer,Phase 3,299,Cardiotoxicity,Skin disorders,No,Moderate,299,50,55,16.72,No,,14,341,Yes,Yes,Treatment interruption,11,36
NCT48921578,Ublituximab,Anti-CD20,Rheumatoid Arthritis,Phase 2,276,Cardiotoxicity,General disorders,No,Mild,276,12,12,4.35,No,,6,165,No,Yes,Dose reduction,28,47
NCT77271447,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 2,344,Cardiotoxicity,Cardiac disorders,No,Mild,344,61,66,17.73,No,,13,80,Yes,Yes,Dose reduction,25,22
NCT44999061,Ublituximab,Anti-CD20,Lung Cancer,Phase 4,67,Cardiotoxicity,Blood disorders,Yes,Severe,67,14,16,20.9,No,,9,308,No,Yes,Supportive care,21,46
NCT27665996,Ublituximab,Anti-CD20,Melanoma,Phase 4,68,Neutropenia,General disorders,No,Severe,68,20,20,29.41,Yes,Safety concerns,18,94,Yes,No,Treatment interruption,6,37
NCT91728884,Ublituximab,Anti-CD20,Melanoma,Phase 2,364,Nausea,Blood disorders,Yes,Moderate,364,70,73,19.23,No,,13,148,No,Yes,Supportive care,7,57
NCT89987104,Ublituximab,Anti-CD20,Lung Cancer,Phase 3,227,Colitis,Skin disorders,No,Severe,227,15,16,6.61,No,,4,211,No,No,Discontinuation,26,57
NCT26590096,Ublituximab,Anti-CD20,Non-Hodgkin Lymphoma,Phase 2,121,Fatigue,Endocrine disorders,Yes,Mild,121,21,26,17.36,No,,2,63,No,Yes,Discontinuation,30,68
NCT97914938,Ublituximab,Anti-CD20,Colorectal Cancer,Phase 3,249,Infusion-related reaction,General disorders,No,Moderate,249,34,38,13.65,No,,4,275,No,No,Supportive care,29,35
NCT13479226,Ublituximab,Anti-CD20,Multiple Sclerosis,Phase 2,225,Diarrhea,Cardiac disorders,No,Mild,225,62,67,27.56,No,,4,299,Yes,Yes,Supportive care,21,78
NCT12948114,Ublituximab,Anti-CD20,Lung Cancer,Phase 3,486,Thrombocytopenia,Gastrointestinal disorders,No,Mild,486,94,95,19.34,No,,2,349,No,Yes,Discontinuation,4,52
NCT56319582,Trastuzumab,Anti-HER2,Lung Cancer,Phase 3,400,Hepatotoxicity,Cardiac disorders,No,Mild,400,1,5,0.25,No,,6,145,No,No,Dose reduction,27,38
NCT31198891,Trastuzumab,Anti-HER2,Melanoma,Phase 1,37,Hypothyroidism,General disorders,No,Mild,37,5,10,13.51,No,,5,350,Yes,No,Supportive care,26,18
NCT63536494,Trastuzumab,Anti-HER2,Lung Cancer,Phase 4,48,Pneumonitis,Respiratory disorders,No,Mild,48,5,5,10.42,No,,17,335,No,No,Discontinuation,7,25
NCT34527545,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 4,215,Hepatotoxicity,Gastrointestinal disorders,No,Mild,215,45,47,20.93,No,,16,347,Yes,No,Supportive care,8,29
NCT35271827,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,417,Infusion-related reaction,Hepatobiliary disorders,No,Severe,417,91,91,21.82,No,,15,264,Yes,Yes,Discontinuation,11,4
NCT48162439,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,185,Fatigue,Cardiac disorders,Yes,Mild,185,11,11,5.95,No,,8,316,No,Yes,Discontinuation,25,53
NCT32488043,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,43,Hypothyroidism,General disorders,No,Severe,43,7,9,16.28,No,,8,246,Yes,Yes,Treatment interruption,23,43
NCT91051184,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 1,270,Colitis,Endocrine disorders,No,Mild,270,49,53,18.15,No,,20,239,No,No,Dose reduction,1,25
NCT72877298,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 2,467,Diarrhea,Hepatobiliary disorders,No,Moderate,467,27,31,5.78,No,,9,67,Yes,Yes,Discontinuation,8,55
NCT69322483,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 4,307,Hyperthyroidism,Blood disorders,No,Moderate,307,24,26,7.82,No,,18,237,Yes,Yes,Dose reduction,12,65
NCT62004283,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 4,155,Cardiotoxicity,Gastrointestinal disorders,No,Moderate,155,20,23,12.9,No,,5,283,Yes,No,Treatment interruption,14,70
NCT19504794,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 2,333,Hyperthyroidism,Endocrine disorders,No,Mild,333,74,78,22.22,No,,2,31,Yes,Yes,Dose reduction,4,26
NCT16415447,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 4,284,Infusion-related reaction,Endocrine disorders,No,Moderate,284,32,37,11.27,No,,2,146,Yes,No,Dose reduction,6,35
NCT78195887,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,230,Nausea,Skin disorders,No,Moderate,230,52,53,22.61,Yes,Lack of efficacy,4,72,Yes,Yes,Supportive care,25,19
NCT82609444,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 1,130,Pneumonitis,Skin disorders,No,Mild,130,35,40,26.92,No,,15,96,Yes,No,Dose reduction,4,56
NCT10472369,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,271,Arthralgia,Cardiac disorders,No,Mild,271,56,59,20.66,No,,13,227,Yes,Yes,Treatment interruption,27,29
NCT89336363,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,336,Rash,Musculoskeletal disorders,Yes,Moderate,336,70,73,20.83,Yes,Competition,11,208,No,No,Dose reduction,30,51
NCT59309411,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 2,194,Thrombocytopenia,Gastrointestinal disorders,No,Moderate,194,22,23,11.34,No,,18,32,Yes,Yes,Dose reduction,4,33
NCT73252080,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,211,Nausea,Musculoskeletal disorders,No,Mild,211,2,6,0.95,No,,3,314,No,Yes,Dose reduction,10,22
NCT68346210,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 4,406,Cardiotoxicity,Skin disorders,No,Moderate,406,15,16,3.69,No,,19,84,No,Yes,Supportive care,16,75
NCT69427412,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 4,395,Colitis,Musculoskeletal disorders,Yes,Moderate,395,13,14,3.29,Yes,Competition,8,194,Yes,Yes,Treatment interruption,20,37
NCT90140496,Trastuzumab,Anti-HER2,Lung Cancer,Phase 2,268,Arthralgia,General disorders,No,Mild,268,18,19,6.72,No,,18,296,Yes,Yes,Treatment interruption,7,82
NCT87271592,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 3,445,Arthralgia,Cardiac disorders,No,Mild,445,129,134,28.99,No,,19,310,Yes,Yes,Dose reduction,16,34
NCT10311431,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,391,Nausea,Hepatobiliary disorders,No,Mild,391,66,70,16.88,No,,7,238,No,No,Treatment interruption,2,1
NCT25348752,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,115,Diarrhea,Respiratory disorders,No,Mild,115,8,13,6.96,No,,16,39,Yes,Yes,Discontinuation,11,69
NCT14877758,Trastuzumab,Anti-HER2,Lung Cancer,Phase 3,190,Pneumonitis,Cardiac disorders,Yes,Severe,190,23,27,12.11,No,,19,342,No,No,Dose reduction,11,90
NCT50306867,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,76,Neutropenia,Blood disorders,No,Severe,76,5,6,6.58,No,,18,216,Yes,No,Dose reduction,25,17
NCT77686416,Trastuzumab,Anti-HER2,Melanoma,Phase 3,161,Diarrhea,Blood disorders,No,Severe,161,35,35,21.74,No,,5,353,No,Yes,Dose reduction,28,24
NCT86886957,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 3,453,Pneumonitis,Cardiac disorders,No,Moderate,453,33,37,7.28,Yes,Competition,18,211,No,Yes,Dose reduction,6,89
NCT19353098,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 2,420,Infusion-related reaction,Cardiac disorders,No,Mild,420,98,98,23.33,No,,1,38,No,Yes,Dose reduction,24,18
NCT92808637,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,382,Hepatotoxicity,Gastrointestinal disorders,No,Moderate,382,55,60,14.4,Yes,Competition,18,311,Yes,Yes,Supportive care,25,8
NCT22071084,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,351,Colitis,Skin disorders,Yes,Moderate,351,56,57,15.95,No,,1,86,No,No,Supportive care,14,10
NCT16119199,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 1,158,Arthralgia,General disorders,Yes,Severe,158,36,39,22.78,Yes,Safety concerns,7,210,Yes,No,Discontinuation,19,43
NCT68571440,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,250,Diarrhea,Endocrine disorders,No,Severe,250,25,30,10.0,No,,6,216,No,No,Supportive care,13,26
NCT39047986,Trastuzumab,Anti-HER2,Lung Cancer,Phase 1,310,Pneumonitis,General disorders,No,Mild,310,38,38,12.26,No,,17,318,Yes,Yes,Dose reduction,1,19
NCT10578878,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 2,341,Colitis,Gastrointestinal disorders,No,Severe,341,78,83,22.87,Yes,Competition,12,49,No,Yes,Supportive care,19,8
NCT97251856,Trastuzumab,Anti-HER2,Melanoma,Phase 1,237,Thrombocytopenia,Blood disorders,No,Moderate,237,47,47,19.83,Yes,Safety concerns,19,241,No,Yes,Dose reduction,24,75
NCT55254270,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,398,Hepatotoxicity,Cardiac disorders,No,Mild,398,4,6,1.01,No,,18,151,Yes,Yes,Discontinuation,4,55
NCT92402918,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,283,Hepatotoxicity,Musculoskeletal disorders,No,Moderate,283,51,55,18.02,No,,9,315,No,Yes,Dose reduction,27,24
NCT61202112,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 4,324,Diarrhea,General disorders,No,Mild,324,37,41,11.42,No,,16,305,Yes,No,Discontinuation,17,56
NCT62603015,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,352,Rash,Blood disorders,Yes,Moderate,352,69,69,19.6,Yes,Competition,1,333,No,No,Supportive care,16,70
NCT24304838,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 1,271,Colitis,Gastrointestinal disorders,No,Severe,271,34,38,12.55,Yes,Regulatory issues,4,165,Yes,Yes,Supportive care,16,24
NCT88789255,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,269,Pneumonitis,Skin disorders,No,Mild,269,39,43,14.5,No,,1,137,Yes,No,Discontinuation,3,29
NCT29290182,Trastuzumab,Anti-HER2,Melanoma,Phase 2,339,Neutropenia,Gastrointestinal disorders,No,Moderate,339,49,53,14.45,No,,19,59,No,No,Dose reduction,23,6
NCT47248425,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,439,Pneumonitis,Cardiac disorders,Yes,Mild,439,114,119,25.97,No,,13,118,No,Yes,Treatment interruption,1,79
NCT94517616,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,388,Pneumonitis,Cardiac disorders,Yes,Severe,388,4,4,1.03,Yes,Regulatory issues,18,128,Yes,No,Supportive care,20,68
NCT46968297,Trastuzumab,Anti-HER2,Melanoma,Phase 1,274,Neutropenia,Endocrine disorders,Yes,Severe,274,13,17,4.74,Yes,Regulatory issues,11,365,No,Yes,Treatment interruption,10,63
NCT34282228,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,184,Hypothyroidism,Cardiac disorders,No,Mild,184,5,6,2.72,No,,13,324,No,Yes,Dose reduction,13,14
NCT88411201,Trastuzumab,Anti-HER2,Melanoma,Phase 3,67,Hepatotoxicity,Musculoskeletal disorders,No,Severe,67,5,5,7.46,Yes,Regulatory issues,18,80,Yes,No,Treatment interruption,2,77
NCT87034827,Trastuzumab,Anti-HER2,Melanoma,Phase 1,162,Hypothyroidism,Gastrointestinal disorders,No,Mild,162,27,30,16.67,No,,10,349,No,No,Treatment interruption,2,78
NCT97767467,Trastuzumab,Anti-HER2,Melanoma,Phase 3,399,Arthralgia,Skin disorders,No,Mild,399,113,114,28.32,No,,13,82,No,No,Supportive care,7,49
NCT56855067,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,113,Hyperthyroidism,Blood disorders,Yes,Severe,113,32,34,28.32,Yes,Competition,16,179,No,Yes,Supportive care,2,78
NCT44513298,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,418,Hepatotoxicity,Respiratory disorders,No,Mild,418,34,37,8.13,No,,4,363,No,Yes,Treatment interruption,21,71
NCT64808798,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 3,412,Rash,Skin disorders,No,Severe,412,62,65,15.05,No,,13,199,Yes,No,Discontinuation,25,83
NCT19211808,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,385,Rash,Cardiac disorders,No,Severe,385,86,88,22.34,Yes,Regulatory issues,5,239,No,Yes,Dose reduction,16,28
NCT84301501,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,301,Cardiotoxicity,Hepatobiliary disorders,No,Moderate,301,50,50,16.61,No,,8,99,Yes,Yes,Discontinuation,11,66
NCT11059367,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,424,Diarrhea,Cardiac disorders,No,Moderate,424,82,83,19.34,No,,1,354,Yes,No,Treatment interruption,11,77
NCT26319128,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 4,127,Arthralgia,Cardiac disorders,No,Mild,127,3,5,2.36,No,,2,185,Yes,No,Dose reduction,25,76
NCT33783593,Trastuzumab,Anti-HER2,Melanoma,Phase 2,343,Hypothyroidism,Skin disorders,No,Mild,343,37,41,10.79,No,,13,221,Yes,Yes,Dose reduction,15,45
NCT39217142,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 1,211,Hepatotoxicity,General disorders,Yes,Severe,211,30,31,14.22,Yes,Lack of efficacy,20,130,Yes,Yes,Supportive care,2,83
NCT50650749,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,106,Nausea,Endocrine disorders,No,Mild,106,15,18,14.15,No,,2,210,Yes,No,Supportive care,23,21
NCT99514286,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 2,322,Cardiotoxicity,Gastrointestinal disorders,No,Severe,322,51,55,15.84,Yes,Competition,8,310,Yes,Yes,Treatment interruption,13,25
NCT91968347,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 2,77,Colitis,Endocrine disorders,No,Moderate,77,11,11,14.29,No,,11,183,No,Yes,Supportive care,21,77
NCT27811411,Trastuzumab,Anti-HER2,Lung Cancer,Phase 1,31,Anemia,Respiratory disorders,No,Mild,31,4,7,12.9,No,,2,44,Yes,No,Treatment interruption,27,26
NCT39181952,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 1,202,Neutropenia,Blood disorders,No,Mild,202,14,17,6.93,No,,2,131,No,Yes,Supportive care,10,78
NCT33857194,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,176,Pneumonitis,Hepatobiliary disorders,No,Mild,176,10,11,5.68,No,,16,247,No,Yes,Dose reduction,2,77
NCT94141611,Trastuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 3,342,Anemia,Skin disorders,No,Severe,342,5,5,1.46,No,,7,255,Yes,No,Dose reduction,29,22
NCT19102296,Trastuzumab,Anti-HER2,Lung Cancer,Phase 2,175,Nausea,Gastrointestinal disorders,No,Mild,175,16,20,9.14,No,,4,255,Yes,No,Supportive care,27,68
NCT96876553,Trastuzumab,Anti-HER2,Lung Cancer,Phase 1,350,Anemia,Respiratory disorders,Yes,Severe,350,95,96,27.14,No,,18,144,No,No,Supportive care,8,4
NCT16037073,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,187,Cardiotoxicity,Gastrointestinal disorders,No,Severe,187,12,14,6.42,No,,12,51,Yes,Yes,Discontinuation,25,20
NCT78426719,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 4,246,Hypothyroidism,Respiratory disorders,No,Mild,246,7,10,2.85,No,,18,193,Yes,No,Discontinuation,15,49
NCT40378437,Trastuzumab,Anti-HER2,Lung Cancer,Phase 3,490,Hepatotoxicity,Endocrine disorders,Yes,Severe,490,49,51,10.0,Yes,Safety concerns,13,43,Yes,No,Supportive care,1,33
NCT82349809,Trastuzumab,Anti-HER2,Melanoma,Phase 3,367,Infusion-related reaction,Endocrine disorders,Yes,Mild,367,36,41,9.81,No,,8,269,Yes,Yes,Treatment interruption,3,40
NCT52341339,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,71,Anemia,Musculoskeletal disorders,No,Mild,71,9,9,12.68,No,,13,357,No,Yes,Supportive care,16,53
NCT69658912,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,461,Arthralgia,Musculoskeletal disorders,No,Mild,461,130,134,28.2,No,,4,37,No,Yes,Supportive care,3,9
NCT54089721,Trastuzumab,Anti-HER2,Melanoma,Phase 1,256,Rash,Hepatobiliary disorders,No,Moderate,256,43,48,16.8,No,,19,37,No,Yes,Discontinuation,11,11
NCT59633763,Trastuzumab,Anti-HER2,Lung Cancer,Phase 4,131,Cardiotoxicity,Musculoskeletal disorders,No,Mild,131,14,14,10.69,No,,15,241,Yes,Yes,Supportive care,7,77
NCT89449443,Trastuzumab,Anti-HER2,Lung Cancer,Phase 2,417,Arthralgia,Skin disorders,Yes,Mild,417,38,40,9.11,No,,15,314,Yes,Yes,Discontinuation,25,63
NCT10643293,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,282,Neutropenia,Musculoskeletal disorders,Yes,Moderate,282,64,67,22.7,Yes,Lack of efficacy,13,344,Yes,No,Dose reduction,8,63
NCT21783905,Trastuzumab,Anti-HER2,Colorectal Cancer,Phase 1,164,Hypothyroidism,Skin disorders,No,Mild,164,29,30,17.68,No,,13,220,Yes,Yes,Treatment interruption,17,48
NCT92054397,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,91,Fatigue,Respiratory disorders,No,Severe,91,18,23,19.78,No,,19,257,Yes,No,Treatment interruption,9,65
NCT19511220,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 1,443,Colitis,Cardiac disorders,No,Moderate,443,13,17,2.93,No,,18,197,Yes,No,Dose reduction,28,65
NCT24459215,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,258,Diarrhea,General disorders,No,Mild,258,76,79,29.46,No,,1,316,Yes,Yes,Dose reduction,20,2
NCT91270566,Trastuzumab,Anti-HER2,Lung Cancer,Phase 1,473,Rash,Skin disorders,No,Severe,473,44,48,9.3,No,,17,230,Yes,Yes,Discontinuation,4,30
NCT13356065,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,103,Arthralgia,Hepatobiliary disorders,No,Moderate,103,30,30,29.13,No,,7,38,Yes,No,Treatment interruption,14,17
NCT18957468,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,70,Diarrhea,Skin disorders,No,Severe,70,15,20,21.43,No,,8,112,No,No,Treatment interruption,8,71
NCT23182194,Trastuzumab,Anti-HER2,Multiple Sclerosis,Phase 2,167,Hepatotoxicity,Blood disorders,Yes,Moderate,167,3,3,1.8,Yes,Lack of efficacy,10,182,No,No,Discontinuation,2,68
NCT94486419,Trastuzumab,Anti-HER2,Multiple Myeloma,Phase 3,87,Diarrhea,Gastrointestinal disorders,No,Moderate,87,5,8,5.75,No,,6,306,No,Yes,Discontinuation,20,11
NCT78714973,Trastuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 4,34,Anemia,Gastrointestinal disorders,No,Mild,34,10,12,29.41,No,,13,300,No,Yes,Dose reduction,4,16
NCT55679314,Trastuzumab,Anti-HER2,Lung Cancer,Phase 3,367,Fatigue,Musculoskeletal disorders,Yes,Severe,367,80,83,21.8,Yes,Safety concerns,3,67,Yes,No,Discontinuation,27,69
NCT76940352,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 1,396,Arthralgia,Gastrointestinal disorders,No,Mild,396,51,53,12.88,No,,2,242,No,Yes,Supportive care,7,29
NCT15933957,Pertuzumab,Anti-HER2,Melanoma,Phase 4,448,Cardiotoxicity,Endocrine disorders,No,Mild,448,1,5,0.22,No,,19,117,No,Yes,Supportive care,14,86
NCT16608348,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 3,240,Infusion-related reaction,Gastrointestinal disorders,No,Mild,240,1,3,0.42,No,,15,173,Yes,Yes,Discontinuation,22,23
NCT40106225,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 3,171,Thrombocytopenia,General disorders,No,Mild,171,42,45,24.56,No,,10,338,Yes,No,Treatment interruption,11,29
NCT46200342,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,123,Arthralgia,Blood disorders,No,Severe,123,13,13,10.57,No,,5,133,No,Yes,Discontinuation,28,14
NCT22869051,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 2,41,Anemia,Musculoskeletal disorders,No,Moderate,41,10,15,24.39,No,,9,336,Yes,Yes,Supportive care,29,68
NCT53611988,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 4,298,Pneumonitis,Gastrointestinal disorders,No,Mild,298,30,34,10.07,No,,9,138,No,Yes,Supportive care,22,40
NCT62773382,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,178,Cardiotoxicity,Hepatobiliary disorders,No,Severe,178,29,29,16.29,Yes,Lack of efficacy,14,293,No,No,Supportive care,9,64
NCT77765138,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 4,26,Infusion-related reaction,Skin disorders,No,Moderate,26,4,8,15.38,No,,19,324,Yes,Yes,Dose reduction,20,83
NCT61040050,Pertuzumab,Anti-HER2,Lung Cancer,Phase 4,28,Fatigue,General disorders,No,Moderate,28,2,6,7.14,No,,2,335,No,No,Treatment interruption,4,34
NCT26030315,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 1,290,Nausea,General disorders,No,Severe,290,45,48,15.52,No,,18,84,Yes,No,Dose reduction,27,23
NCT13272749,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 1,184,Diarrhea,Musculoskeletal disorders,No,Mild,184,30,32,16.3,No,,13,87,No,No,Discontinuation,16,10
NCT90915365,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 2,303,Neutropenia,Gastrointestinal disorders,Yes,Severe,303,80,80,26.4,Yes,Safety concerns,4,351,No,Yes,Discontinuation,6,85
NCT94764338,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,212,Neutropenia,Cardiac disorders,No,Severe,212,43,43,20.28,No,,20,145,No,Yes,Treatment interruption,1,77
NCT64027776,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,203,Hyperthyroidism,Blood disorders,Yes,Mild,203,37,39,18.23,No,,15,240,No,Yes,Dose reduction,25,64
NCT76068108,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 1,95,Hyperthyroidism,Cardiac disorders,No,Severe,95,15,20,15.79,No,,11,63,Yes,Yes,Supportive care,22,41
NCT85710771,Pertuzumab,Anti-HER2,Lung Cancer,Phase 3,222,Colitis,Endocrine disorders,No,Moderate,222,46,48,20.72,Yes,Competition,16,190,Yes,No,Dose reduction,2,16
NCT69016823,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,444,Arthralgia,Hepatobiliary disorders,No,Moderate,444,44,46,9.91,No,,8,149,Yes,No,Supportive care,16,11
NCT22973904,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,148,Nausea,Hepatobiliary disorders,No,Moderate,148,19,23,12.84,Yes,Lack of efficacy,11,232,Yes,No,Treatment interruption,23,54
NCT31888544,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 2,305,Infusion-related reaction,Hepatobiliary disorders,No,Moderate,305,54,55,17.7,No,,1,99,No,Yes,Discontinuation,18,24
NCT22321563,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 4,160,Hypothyroidism,Gastrointestinal disorders,No,Mild,160,12,17,7.5,No,,10,347,Yes,Yes,Dose reduction,21,77
NCT56321476,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,439,Thrombocytopenia,Cardiac disorders,Yes,Mild,439,80,83,18.22,No,,1,76,No,No,Dose reduction,2,79
NCT91119979,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 1,200,Nausea,Respiratory disorders,No,Mild,200,56,56,28.0,No,,1,296,No,Yes,Treatment interruption,6,40
NCT96351943,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,338,Infusion-related reaction,General disorders,Yes,Moderate,338,2,5,0.59,Yes,Competition,5,124,Yes,Yes,Dose reduction,1,40
NCT33403588,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 1,332,Colitis,Skin disorders,No,Moderate,332,19,22,5.72,No,,2,337,Yes,Yes,Treatment interruption,4,56
NCT31833829,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,456,Cardiotoxicity,Blood disorders,No,Moderate,456,65,69,14.25,No,,8,98,No,Yes,Treatment interruption,25,59
NCT59884268,Pertuzumab,Anti-HER2,Melanoma,Phase 1,63,Infusion-related reaction,Musculoskeletal disorders,No,Severe,63,17,17,26.98,Yes,Safety concerns,10,263,Yes,No,Treatment interruption,23,6
NCT68549292,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 2,283,Arthralgia,Respiratory disorders,No,Mild,283,59,64,20.85,No,,12,277,Yes,No,Discontinuation,26,17
NCT16585655,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,335,Neutropenia,Endocrine disorders,No,Severe,335,24,28,7.16,Yes,Competition,1,172,Yes,Yes,Dose reduction,14,78
NCT13786211,Pertuzumab,Anti-HER2,Melanoma,Phase 1,319,Hepatotoxicity,Skin disorders,No,Mild,319,13,14,4.08,No,,15,154,Yes,No,Discontinuation,21,69
NCT80402633,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,343,Nausea,Cardiac disorders,No,Mild,343,66,71,19.24,No,,11,163,Yes,Yes,Treatment interruption,16,23
NCT90198796,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,245,Rash,Blood disorders,No,Moderate,245,18,23,7.35,No,,19,97,No,No,Treatment interruption,12,19
NCT45154171,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,307,Arthralgia,Hepatobiliary disorders,Yes,Mild,307,24,28,7.82,No,,4,93,No,No,Treatment interruption,17,2
NCT99113663,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 4,391,Hepatotoxicity,Blood disorders,No,Moderate,391,47,52,12.02,No,,14,38,No,No,Treatment interruption,7,44
NCT37484083,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 3,357,Cardiotoxicity,Hepatobiliary disorders,No,Mild,357,43,44,12.04,No,,12,238,Yes,Yes,Supportive care,7,28
NCT32973774,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 4,446,Anemia,Musculoskeletal disorders,No,Mild,446,98,101,21.97,No,,20,35,No,Yes,Dose reduction,23,41
NCT49834994,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 1,456,Cardiotoxicity,Musculoskeletal disorders,No,Moderate,456,115,120,25.22,No,,8,348,Yes,No,Dose reduction,18,83
NCT62419614,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,261,Diarrhea,Blood disorders,No,Mild,261,76,79,29.12,No,,1,227,No,Yes,Dose reduction,25,7
NCT33146205,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 2,33,Nausea,Cardiac disorders,No,Moderate,33,7,12,21.21,No,,18,344,Yes,Yes,Treatment interruption,8,79
NCT82922219,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,498,Hyperthyroidism,Blood disorders,No,Severe,498,138,140,27.71,No,,12,231,Yes,Yes,Dose reduction,4,18
NCT95712353,Pertuzumab,Anti-HER2,Lung Cancer,Phase 2,209,Infusion-related reaction,Hepatobiliary disorders,Yes,Mild,209,38,43,18.18,No,,6,349,Yes,Yes,Dose reduction,7,31
NCT80215120,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,369,Hypothyroidism,Skin disorders,No,Moderate,369,20,24,5.42,Yes,Competition,16,285,No,No,Dose reduction,8,16
NCT93109518,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 2,326,Nausea,Respiratory disorders,Yes,Severe,326,64,65,19.63,No,,11,239,No,No,Supportive care,26,17
NCT55072151,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 2,119,Pneumonitis,Hepatobiliary disorders,No,Moderate,119,32,34,26.89,No,,14,255,No,Yes,Supportive care,2,86
NCT16618165,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 2,397,Arthralgia,Blood disorders,No,Severe,397,46,49,11.59,No,,2,49,No,No,Treatment interruption,22,8
NCT67323350,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,335,Hepatotoxicity,Hepatobiliary disorders,No,Mild,335,44,49,13.13,No,,1,207,No,Yes,Discontinuation,14,90
NCT70622171,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,100,Cardiotoxicity,Endocrine disorders,No,Severe,100,29,32,29.0,No,,7,244,Yes,No,Treatment interruption,25,43
NCT63569758,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,361,Arthralgia,Gastrointestinal disorders,No,Mild,361,69,69,19.11,No,,13,233,No,No,Dose reduction,19,84
NCT23247700,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,35,Colitis,Endocrine disorders,No,Mild,35,10,15,28.57,No,,14,149,Yes,No,Dose reduction,26,20
NCT90754576,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 3,231,Anemia,Endocrine disorders,No,Severe,231,12,14,5.19,No,,16,100,No,Yes,Dose reduction,21,23
NCT44994270,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,110,Infusion-related reaction,Gastrointestinal disorders,No,Moderate,110,29,31,26.36,No,,5,173,Yes,No,Discontinuation,16,22
NCT32813534,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,346,Nausea,Musculoskeletal disorders,No,Severe,346,39,44,11.27,No,,13,86,Yes,Yes,Supportive care,25,66
NCT46179643,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,62,Pneumonitis,Endocrine disorders,No,Severe,62,14,14,22.58,Yes,Competition,18,47,No,Yes,Supportive care,15,58
NCT75852352,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 3,474,Neutropenia,Respiratory disorders,Yes,Moderate,474,110,113,23.21,No,,20,334,Yes,Yes,Supportive care,14,6
NCT68072118,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,290,Hyperthyroidism,Skin disorders,No,Moderate,290,87,91,30.0,No,,11,251,No,Yes,Supportive care,8,13
NCT56496152,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,316,Colitis,Cardiac disorders,No,Moderate,316,67,72,21.2,No,,16,181,No,No,Supportive care,21,37
NCT62968034,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 4,375,Infusion-related reaction,Skin disorders,No,Mild,375,6,10,1.6,No,,17,79,No,Yes,Discontinuation,6,13
NCT91653186,Pertuzumab,Anti-HER2,Lung Cancer,Phase 1,428,Arthralgia,Hepatobiliary disorders,Yes,Severe,428,26,30,6.07,Yes,Competition,8,119,Yes,Yes,Treatment interruption,15,57
NCT10726930,Pertuzumab,Anti-HER2,Melanoma,Phase 4,26,Cardiotoxicity,Skin disorders,No,Mild,26,3,6,11.54,No,,18,43,No,Yes,Dose reduction,17,2
NCT42702187,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,312,Anemia,Respiratory disorders,No,Severe,312,46,50,14.74,No,,13,116,Yes,Yes,Discontinuation,8,60
NCT87604159,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 2,332,Pneumonitis,General disorders,Yes,Moderate,332,16,21,4.82,Yes,Safety concerns,10,149,Yes,No,Discontinuation,1,14
NCT10127845,Pertuzumab,Anti-HER2,Melanoma,Phase 3,441,Hypothyroidism,Skin disorders,No,Mild,441,89,91,20.18,No,,10,112,No,No,Supportive care,6,60
NCT69389973,Pertuzumab,Anti-HER2,Breast Cancer,Phase 4,365,Colitis,Blood disorders,Yes,Mild,365,68,70,18.63,No,,2,281,No,No,Treatment interruption,3,76
NCT59881292,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,297,Anemia,Respiratory disorders,Yes,Moderate,297,76,77,25.59,Yes,Lack of efficacy,10,233,No,Yes,Treatment interruption,30,53
NCT80145602,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 2,442,Hypothyroidism,Gastrointestinal disorders,No,Severe,442,132,135,29.86,Yes,Regulatory issues,2,86,No,No,Treatment interruption,15,19
NCT16132627,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 3,99,Hypothyroidism,Cardiac disorders,No,Severe,99,12,12,12.12,No,,15,345,No,No,Treatment interruption,8,32
NCT65620637,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 4,238,Neutropenia,Hepatobiliary disorders,No,Mild,238,44,46,18.49,No,,10,97,Yes,No,Dose reduction,1,34
NCT44419293,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,443,Arthralgia,Blood disorders,No,Mild,443,28,28,6.32,No,,10,178,No,Yes,Discontinuation,10,39
NCT34081421,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,33,Arthralgia,Cardiac disorders,No,Severe,33,5,8,15.15,Yes,Competition,14,207,Yes,No,Dose reduction,27,88
NCT32476649,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 2,426,Infusion-related reaction,General disorders,No,Mild,426,88,88,20.66,No,,13,58,No,No,Dose reduction,1,42
NCT41815418,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,448,Anemia,Musculoskeletal disorders,No,Mild,448,93,93,20.76,No,,15,42,No,No,Supportive care,29,21
NCT30474936,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,62,Arthralgia,Blood disorders,No,Mild,62,8,10,12.9,No,,12,307,No,No,Dose reduction,10,2
NCT85147069,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,350,Nausea,Cardiac disorders,Yes,Mild,350,80,84,22.86,No,,15,238,No,Yes,Treatment interruption,11,12
NCT31307805,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,143,Diarrhea,Hepatobiliary disorders,No,Mild,143,30,31,20.98,No,,5,147,No,No,Supportive care,22,76
NCT17791378,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,430,Anemia,Hepatobiliary disorders,Yes,Severe,430,100,103,23.26,Yes,Lack of efficacy,10,291,No,Yes,Treatment interruption,14,68
NCT31312268,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,481,Nausea,Respiratory disorders,No,Mild,481,27,29,5.61,No,,5,280,No,Yes,Treatment interruption,6,64
NCT56667881,Pertuzumab,Anti-HER2,Melanoma,Phase 1,312,Cardiotoxicity,Gastrointestinal disorders,No,Mild,312,40,41,12.82,No,,14,73,Yes,Yes,Discontinuation,29,30
NCT35779804,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,241,Nausea,Gastrointestinal disorders,Yes,Moderate,241,6,6,2.49,No,,19,301,No,No,Discontinuation,25,81
NCT42310721,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 2,149,Cardiotoxicity,Cardiac disorders,No,Moderate,149,16,17,10.74,No,,11,279,Yes,No,Discontinuation,22,31
NCT75088297,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,348,Colitis,Endocrine disorders,Yes,Moderate,348,87,87,25.0,Yes,Competition,4,226,Yes,Yes,Supportive care,16,63
NCT39034637,Pertuzumab,Anti-HER2,Rheumatoid Arthritis,Phase 2,138,Colitis,Endocrine disorders,No,Severe,138,11,16,7.97,No,,20,144,Yes,No,Dose reduction,28,11
NCT64288935,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,500,Pneumonitis,Blood disorders,No,Severe,500,13,14,2.6,Yes,Lack of efficacy,3,306,Yes,Yes,Discontinuation,25,57
NCT55630803,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 4,362,Rash,Cardiac disorders,No,Moderate,362,60,63,16.57,No,,11,354,Yes,Yes,Discontinuation,18,17
NCT35719211,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,100,Hepatotoxicity,Endocrine disorders,No,Severe,100,29,34,29.0,No,,12,307,No,No,Supportive care,22,85
NCT25269863,Pertuzumab,Anti-HER2,Melanoma,Phase 1,371,Diarrhea,Respiratory disorders,Yes,Severe,371,90,93,24.26,Yes,Competition,7,223,No,No,Supportive care,4,13
NCT51941873,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,252,Colitis,Hepatobiliary disorders,No,Mild,252,49,53,19.44,No,,20,110,No,No,Discontinuation,26,15
NCT70740088,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 2,200,Rash,Gastrointestinal disorders,Yes,Mild,200,15,15,7.5,No,,3,104,No,Yes,Discontinuation,8,60
NCT28467886,Pertuzumab,Anti-HER2,Colorectal Cancer,Phase 1,349,Pneumonitis,Skin disorders,No,Mild,349,5,8,1.43,No,,7,232,Yes,Yes,Supportive care,27,1
NCT15909095,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 3,350,Pneumonitis,Musculoskeletal disorders,Yes,Severe,350,57,58,16.29,No,,13,171,Yes,No,Supportive care,21,4
NCT32130329,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 4,131,Neutropenia,Gastrointestinal disorders,No,Moderate,131,21,23,16.03,No,,8,107,Yes,No,Discontinuation,8,51
NCT63414079,Pertuzumab,Anti-HER2,Multiple Myeloma,Phase 1,355,Anemia,General disorders,Yes,Moderate,355,53,53,14.93,Yes,Regulatory issues,6,332,Yes,No,Supportive care,13,73
NCT71488367,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,419,Neutropenia,Hepatobiliary disorders,No,Mild,419,118,118,28.16,No,,15,186,No,No,Discontinuation,28,78
NCT78068230,Pertuzumab,Anti-HER2,Multiple Sclerosis,Phase 1,298,Colitis,Musculoskeletal disorders,No,Moderate,298,16,20,5.37,No,,6,80,No,Yes,Discontinuation,18,18
NCT82451610,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,184,Hyperthyroidism,Skin disorders,No,Mild,184,16,18,8.7,No,,16,219,Yes,No,Discontinuation,26,89
NCT45855024,Pertuzumab,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,210,Pneumonitis,Gastrointestinal disorders,No,Mild,210,57,58,27.14,No,,18,170,Yes,No,Dose reduction,15,1
NCT87924316,Pertuzumab,Anti-HER2,Melanoma,Phase 1,74,Pneumonitis,Musculoskeletal disorders,No,Severe,74,2,3,2.7,No,,8,227,No,Yes,Dose reduction,29,54
NCT10464316,Pertuzumab,Anti-HER2,Melanoma,Phase 3,306,Hypothyroidism,Blood disorders,No,Mild,306,48,52,15.69,No,,12,97,Yes,No,Treatment interruption,19,70
NCT65538636,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 2,26,Pneumonitis,Endocrine disorders,No,Moderate,26,2,2,7.69,No,,1,320,Yes,No,Dose reduction,7,65
NCT14569851,Ado-trastuzumab emtansine,Anti-HER2,Multiple Sclerosis,Phase 4,67,Pneumonitis,Hepatobiliary disorders,No,Mild,67,10,15,14.93,No,,17,150,Yes,No,Supportive care,24,43
NCT43984830,Ado-trastuzumab emtansine,Anti-HER2,Lung Cancer,Phase 2,343,Nausea,Cardiac disorders,No,Moderate,343,52,55,15.16,No,,17,262,Yes,No,Dose reduction,15,21
NCT67500193,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 2,28,Neutropenia,Musculoskeletal disorders,No,Moderate,28,1,2,3.57,No,,15,288,Yes,No,Discontinuation,17,74
NCT97895426,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 4,376,Colitis,Endocrine disorders,No,Mild,376,63,63,16.76,No,,4,317,Yes,No,Treatment interruption,13,65
NCT33143213,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 1,180,Neutropenia,General disorders,No,Moderate,180,36,41,20.0,No,,8,347,No,Yes,Discontinuation,6,77
NCT76019327,Ado-trastuzumab emtansine,Anti-HER2,Multiple Sclerosis,Phase 4,132,Colitis,Musculoskeletal disorders,Yes,Severe,132,25,28,18.94,No,,14,236,Yes,No,Treatment interruption,23,3
NCT81591391,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 2,183,Fatigue,Respiratory disorders,No,Mild,183,26,29,14.21,No,,8,149,No,No,Treatment interruption,19,38
NCT24334634,Ado-trastuzumab emtansine,Anti-HER2,Multiple Sclerosis,Phase 4,139,Fatigue,Skin disorders,No,Mild,139,36,36,25.9,No,,3,202,Yes,No,Supportive care,12,26
NCT13075361,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 2,428,Infusion-related reaction,Skin disorders,Yes,Severe,428,102,103,23.83,Yes,Regulatory issues,17,224,Yes,Yes,Discontinuation,9,7
NCT38101800,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 4,220,Nausea,Respiratory disorders,No,Moderate,220,12,16,5.45,No,,9,102,No,No,Supportive care,22,9
NCT24333981,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 3,147,Colitis,Cardiac disorders,No,Mild,147,12,17,8.16,No,,3,147,No,Yes,Supportive care,14,46
NCT23370587,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 3,265,Pneumonitis,Skin disorders,Yes,Mild,265,71,76,26.79,No,,15,243,Yes,No,Dose reduction,19,60
NCT37671205,Ado-trastuzumab emtansine,Anti-HER2,Lung Cancer,Phase 2,168,Cardiotoxicity,Endocrine disorders,No,Mild,168,2,2,1.19,No,,6,223,Yes,Yes,Dose reduction,23,38
NCT93349102,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 1,220,Neutropenia,Respiratory disorders,No,Mild,220,57,62,25.91,No,,16,281,No,No,Treatment interruption,16,79
NCT53677994,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 3,270,Fatigue,Musculoskeletal disorders,No,Mild,270,11,16,4.07,No,,7,121,No,No,Treatment interruption,25,90
NCT80089930,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 2,225,Nausea,Cardiac disorders,Yes,Moderate,225,36,41,16.0,No,,9,346,No,Yes,Treatment interruption,8,38
NCT36227539,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 1,120,Arthralgia,Gastrointestinal disorders,Yes,Severe,120,24,26,20.0,Yes,Safety concerns,20,264,Yes,Yes,Dose reduction,21,59
NCT63666810,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,139,Diarrhea,Respiratory disorders,No,Moderate,139,20,23,14.39,Yes,Lack of efficacy,3,343,No,Yes,Treatment interruption,19,16
NCT63632439,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,345,Pneumonitis,Cardiac disorders,No,Mild,345,25,26,7.25,No,,8,59,No,Yes,Discontinuation,17,38
NCT38864226,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,43,Rash,General disorders,No,Moderate,43,11,15,25.58,No,,6,274,No,No,Dose reduction,1,82
NCT24052907,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 4,130,Colitis,Gastrointestinal disorders,No,Mild,130,10,12,7.69,No,,17,138,Yes,Yes,Discontinuation,30,31
NCT31880050,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 4,495,Cardiotoxicity,Skin disorders,No,Mild,495,83,87,16.77,No,,16,68,Yes,Yes,Discontinuation,18,1
NCT49317178,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 1,362,Hypothyroidism,Cardiac disorders,Yes,Mild,362,72,77,19.89,No,,7,235,Yes,No,Treatment interruption,9,21
NCT91092049,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,358,Arthralgia,Musculoskeletal disorders,Yes,Moderate,358,9,13,2.51,Yes,Safety concerns,17,364,No,No,Dose reduction,22,19
NCT21070038,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,289,Infusion-related reaction,Blood disorders,No,Mild,289,8,11,2.77,No,,12,265,Yes,No,Dose reduction,22,77
NCT76304008,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,293,Hypothyroidism,Endocrine disorders,Yes,Moderate,293,87,91,29.69,Yes,Lack of efficacy,7,362,Yes,Yes,Discontinuation,5,19
NCT83216064,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 3,390,Rash,General disorders,Yes,Severe,390,99,102,25.38,No,,10,351,Yes,Yes,Treatment interruption,9,46
NCT76609479,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 3,354,Fatigue,Respiratory disorders,No,Severe,354,42,46,11.86,No,,8,333,No,No,Supportive care,24,53
NCT20647998,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 3,380,Pneumonitis,Gastrointestinal disorders,No,Mild,380,17,19,4.47,No,,12,97,Yes,No,Dose reduction,30,42
NCT57697567,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 2,157,Arthralgia,General disorders,No,Moderate,157,26,27,16.56,No,,2,140,Yes,No,Supportive care,15,10
NCT56745695,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 1,497,Neutropenia,Endocrine disorders,No,Severe,497,137,140,27.57,Yes,Safety concerns,8,258,No,No,Supportive care,15,82
NCT50280415,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 3,494,Infusion-related reaction,Respiratory disorders,No,Moderate,494,31,31,6.28,No,,13,108,Yes,Yes,Supportive care,17,89
NCT92331219,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 1,114,Thrombocytopenia,General disorders,No,Mild,114,5,6,4.39,No,,3,78,No,Yes,Dose reduction,24,76
NCT80457922,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 4,244,Nausea,Endocrine disorders,No,Mild,244,53,57,21.72,No,,18,161,No,Yes,Discontinuation,9,40
NCT32576022,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 3,385,Diarrhea,Blood disorders,Yes,Mild,385,13,15,3.38,No,,20,238,No,Yes,Dose reduction,1,71
NCT45798896,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 4,320,Neutropenia,General disorders,No,Severe,320,69,70,21.56,No,,5,66,Yes,Yes,Discontinuation,29,63
NCT92661951,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 2,208,Neutropenia,Hepatobiliary disorders,No,Severe,208,58,62,27.88,No,,17,244,No,Yes,Treatment interruption,25,20
NCT72382595,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 3,156,Neutropenia,Blood disorders,Yes,Mild,156,44,45,28.21,No,,20,279,No,No,Dose reduction,6,78
NCT83116387,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 2,194,Neutropenia,Musculoskeletal disorders,No,Severe,194,4,6,2.06,No,,10,88,No,Yes,Discontinuation,7,61
NCT67013188,Ado-trastuzumab emtansine,Anti-HER2,Lung Cancer,Phase 4,203,Infusion-related reaction,Musculoskeletal disorders,Yes,Severe,203,24,27,11.82,Yes,Safety concerns,11,77,No,Yes,Dose reduction,26,52
NCT23264578,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,252,Diarrhea,General disorders,No,Severe,252,51,53,20.24,No,,10,197,No,Yes,Treatment interruption,9,79
NCT40302058,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,309,Diarrhea,General disorders,Yes,Moderate,309,51,52,16.5,No,,3,82,Yes,No,Discontinuation,28,61
NCT11141610,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 1,101,Hyperthyroidism,Cardiac disorders,No,Moderate,101,13,17,12.87,No,,19,93,Yes,No,Treatment interruption,23,51
NCT34059894,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 4,115,Colitis,Skin disorders,No,Mild,115,25,28,21.74,No,,11,80,No,No,Treatment interruption,9,42
NCT26729171,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 1,415,Fatigue,Endocrine disorders,No,Mild,415,8,9,1.93,No,,15,152,Yes,Yes,Supportive care,24,49
NCT93304551,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 4,290,Anemia,Endocrine disorders,No,Severe,290,24,24,8.28,Yes,Safety concerns,2,158,Yes,Yes,Discontinuation,15,40
NCT88730017,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 2,151,Hypothyroidism,Gastrointestinal disorders,No,Moderate,151,26,29,17.22,No,,11,62,No,Yes,Treatment interruption,30,65
NCT43124872,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,425,Arthralgia,Respiratory disorders,No,Mild,425,35,38,8.24,No,,7,107,Yes,No,Treatment interruption,13,38
NCT62022011,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 3,482,Cardiotoxicity,Cardiac disorders,Yes,Severe,482,127,131,26.35,Yes,Lack of efficacy,15,129,No,Yes,Treatment interruption,15,46
NCT32919714,Ado-trastuzumab emtansine,Anti-HER2,Multiple Sclerosis,Phase 4,79,Rash,Skin disorders,No,Mild,79,9,11,11.39,No,,10,355,No,No,Dose reduction,25,64
NCT10732825,Ado-trastuzumab emtansine,Anti-HER2,Lung Cancer,Phase 4,61,Diarrhea,Hepatobiliary disorders,No,Severe,61,13,13,21.31,Yes,Competition,16,302,Yes,No,Supportive care,6,43
NCT70050618,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,78,Infusion-related reaction,Cardiac disorders,No,Moderate,78,21,24,26.92,Yes,Lack of efficacy,2,98,Yes,No,Dose reduction,2,49
NCT61586628,Ado-trastuzumab emtansine,Anti-HER2,Colorectal Cancer,Phase 3,45,Arthralgia,Musculoskeletal disorders,No,Severe,45,10,15,22.22,Yes,Regulatory issues,8,116,No,Yes,Treatment interruption,27,71
NCT73024348,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,345,Pneumonitis,Blood disorders,No,Severe,345,31,31,8.99,No,,12,221,Yes,No,Treatment interruption,8,44
NCT16686262,Ado-trastuzumab emtansine,Anti-HER2,Rheumatoid Arthritis,Phase 3,467,Pneumonitis,Skin disorders,No,Mild,467,126,130,26.98,No,,3,207,Yes,No,Treatment interruption,21,74
NCT91140489,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 2,227,Hyperthyroidism,Endocrine disorders,No,Mild,227,22,23,9.69,No,,3,112,No,No,Dose reduction,14,11
NCT85566041,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,167,Cardiotoxicity,Musculoskeletal disorders,No,Mild,167,37,41,22.16,Yes,Competition,19,36,No,Yes,Supportive care,4,31
NCT79991176,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,63,Hepatotoxicity,Gastrointestinal disorders,No,Mild,63,16,19,25.4,No,,2,188,Yes,Yes,Supportive care,3,41
NCT93072342,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,240,Fatigue,Hepatobiliary disorders,Yes,Severe,240,19,22,7.92,No,,7,62,Yes,Yes,Discontinuation,16,27
NCT95493286,Ado-trastuzumab emtansine,Anti-HER2,Melanoma,Phase 2,33,Fatigue,Cardiac disorders,Yes,Mild,33,3,4,9.09,No,,5,39,Yes,Yes,Discontinuation,5,59
NCT23251205,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,459,Nausea,Blood disorders,No,Mild,459,108,112,23.53,No,,7,136,No,No,Dose reduction,16,84
NCT61273927,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 3,151,Rash,General disorders,Yes,Severe,151,20,23,13.25,No,,9,171,Yes,No,Treatment interruption,25,18
NCT88575835,Ado-trastuzumab emtansine,Anti-HER2,Multiple Sclerosis,Phase 1,209,Rash,Musculoskeletal disorders,Yes,Severe,209,44,45,21.05,Yes,Competition,17,357,No,No,Supportive care,14,18
NCT68311433,Ado-trastuzumab emtansine,Anti-HER2,Multiple Myeloma,Phase 2,111,Neutropenia,Hepatobiliary disorders,No,Mild,111,1,3,0.9,No,,13,146,Yes,No,Treatment interruption,25,14
NCT62156607,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,349,Nausea,Gastrointestinal disorders,No,Mild,349,37,37,10.6,No,,2,179,Yes,No,Treatment interruption,14,7
NCT88338596,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,299,Fatigue,Hepatobiliary disorders,No,Mild,299,69,71,23.08,No,,15,91,No,Yes,Supportive care,12,40
NCT31993878,Ado-trastuzumab emtansine,Anti-HER2,Non-Hodgkin Lymphoma,Phase 4,134,Arthralgia,General disorders,No,Mild,134,9,13,6.72,No,,5,244,No,Yes,Discontinuation,19,8
NCT89601550,Ado-trastuzumab emtansine,Anti-HER2,Multiple Sclerosis,Phase 3,485,Colitis,Respiratory disorders,No,Mild,485,75,77,15.46,No,,19,191,No,No,Supportive care,5,34
NCT36440977,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,152,Rash,Blood disorders,No,Severe,152,29,29,19.08,No,,5,96,No,No,Dose reduction,15,63
NCT27090965,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 3,78,Infusion-related reaction,Hepatobiliary disorders,No,Severe,78,17,20,21.79,No,,1,226,No,Yes,Dose reduction,21,48
NCT86237704,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,315,Infusion-related reaction,Hepatobiliary disorders,No,Mild,315,76,76,24.13,No,,11,174,Yes,No,Dose reduction,5,72
NCT25465280,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 4,486,Neutropenia,Endocrine disorders,No,Mild,486,111,116,22.84,No,,20,75,Yes,No,Supportive care,14,64
NCT66051877,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 1,69,Rash,Blood disorders,No,Mild,69,7,11,10.14,No,,6,84,Yes,No,Dose reduction,20,74
NCT89464074,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,486,Hepatotoxicity,Skin disorders,No,Severe,486,39,42,8.02,No,,4,105,No,Yes,Treatment interruption,12,79
NCT86871013,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 1,470,Infusion-related reaction,Gastrointestinal disorders,No,Mild,470,96,100,20.43,No,,16,290,No,Yes,Supportive care,16,19
NCT81659550,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,119,Arthralgia,General disorders,Yes,Severe,119,26,27,21.85,No,,7,39,No,No,Dose reduction,7,72
NCT99161570,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 4,480,Pneumonitis,Skin disorders,No,Mild,480,68,72,14.17,No,,1,166,No,No,Supportive care,28,35
NCT80457614,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,30,Anemia,General disorders,Yes,Mild,30,2,5,6.67,No,,13,280,No,No,Treatment interruption,28,52
NCT50745819,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 2,193,Colitis,Musculoskeletal disorders,No,Moderate,193,17,19,8.81,No,,16,123,No,No,Treatment interruption,4,23
NCT50271337,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 1,327,Fatigue,General disorders,No,Moderate,327,74,76,22.63,No,,18,112,Yes,No,Treatment interruption,17,48
NCT36284306,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 4,301,Neutropenia,Respiratory disorders,No,Moderate,301,74,77,24.58,No,,17,225,Yes,Yes,Dose reduction,15,26
NCT28821735,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 4,396,Cardiotoxicity,Endocrine disorders,No,Mild,396,27,28,6.82,No,,11,95,No,No,Dose reduction,15,43
NCT79398013,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,38,Anemia,Skin disorders,No,Moderate,38,4,8,10.53,No,,5,65,Yes,No,Supportive care,17,80
NCT23565374,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 1,151,Nausea,General disorders,No,Moderate,151,44,48,29.14,No,,11,297,No,Yes,Treatment interruption,23,69
NCT98892114,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,63,Diarrhea,General disorders,No,Mild,63,15,17,23.81,No,,7,80,No,Yes,Discontinuation,14,10
NCT70564854,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 1,491,Hyperthyroidism,Hepatobiliary disorders,No,Severe,491,45,50,9.16,Yes,Safety concerns,6,116,No,Yes,Dose reduction,24,29
NCT25048944,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 3,337,Fatigue,Musculoskeletal disorders,No,Moderate,337,34,36,10.09,No,,10,237,No,Yes,Discontinuation,8,86
NCT85430249,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 3,165,Anemia,Respiratory disorders,No,Severe,165,21,21,12.73,Yes,Regulatory issues,18,107,Yes,No,Discontinuation,1,86
NCT97805553,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,314,Arthralgia,Respiratory disorders,No,Mild,314,53,55,16.88,No,,13,257,No,Yes,Discontinuation,9,4
NCT49118569,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,104,Colitis,Respiratory disorders,No,Severe,104,2,3,1.92,Yes,Competition,16,291,Yes,No,Treatment interruption,17,33
NCT74923634,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,131,Pneumonitis,Cardiac disorders,No,Mild,131,1,2,0.76,No,,5,225,Yes,No,Supportive care,14,71
NCT26358559,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,43,Infusion-related reaction,Skin disorders,Yes,Moderate,43,9,14,20.93,No,,19,135,No,No,Discontinuation,24,90
NCT68613234,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 1,450,Diarrhea,Respiratory disorders,No,Mild,450,129,132,28.67,No,,10,180,Yes,Yes,Supportive care,24,84
NCT15268827,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 1,26,Hyperthyroidism,Endocrine disorders,No,Mild,26,6,9,23.08,No,,4,104,No,No,Supportive care,4,3
NCT24585096,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,412,Hyperthyroidism,Musculoskeletal disorders,No,Mild,412,41,42,9.95,No,,9,83,No,No,Discontinuation,12,27
NCT16833500,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 3,474,Arthralgia,Musculoskeletal disorders,No,Moderate,474,15,20,3.16,No,,7,80,No,Yes,Discontinuation,23,79
NCT10186078,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,300,Diarrhea,Musculoskeletal disorders,Yes,Mild,300,78,79,26.0,No,,10,355,No,Yes,Dose reduction,27,75
NCT34799376,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 4,409,Nausea,Hepatobiliary disorders,No,Moderate,409,55,60,13.45,No,,13,70,No,No,Dose reduction,6,68
NCT82478166,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,347,Colitis,Blood disorders,Yes,Severe,347,27,28,7.78,No,,6,349,Yes,No,Treatment interruption,26,35
NCT97740228,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 2,137,Neutropenia,Cardiac disorders,Yes,Severe,137,37,38,27.01,Yes,Safety concerns,1,155,No,Yes,Treatment interruption,13,60
NCT21156424,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 1,241,Hyperthyroidism,Hepatobiliary disorders,No,Mild,241,65,66,26.97,No,,17,278,Yes,Yes,Dose reduction,29,37
NCT96100742,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,66,Rash,Hepatobiliary disorders,No,Severe,66,2,6,3.03,Yes,Safety concerns,1,164,No,Yes,Supportive care,5,89
NCT34190508,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 3,325,Fatigue,Cardiac disorders,Yes,Mild,325,5,9,1.54,No,,7,41,No,Yes,Dose reduction,17,37
NCT73980913,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 3,435,Arthralgia,Skin disorders,Yes,Mild,435,98,100,22.53,No,,9,276,No,No,Discontinuation,19,85
NCT27374050,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 3,249,Arthralgia,Gastrointestinal disorders,Yes,Moderate,249,34,34,13.65,Yes,Competition,18,189,No,No,Supportive care,9,61
NCT58234029,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 2,104,Cardiotoxicity,Blood disorders,No,Mild,104,18,21,17.31,No,,14,176,Yes,Yes,Discontinuation,14,5
NCT90475015,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 2,430,Diarrhea,Skin disorders,No,Moderate,430,111,116,25.81,No,,3,214,Yes,Yes,Discontinuation,27,64
NCT99867446,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 4,253,Fatigue,Musculoskeletal disorders,No,Moderate,253,31,33,12.25,Yes,Competition,8,286,No,Yes,Treatment interruption,26,33
NCT44235002,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 2,249,Rash,Cardiac disorders,Yes,Moderate,249,42,45,16.87,No,,3,345,Yes,No,Dose reduction,29,11
NCT30606606,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,115,Cardiotoxicity,Skin disorders,No,Moderate,115,15,19,13.04,No,,14,128,No,Yes,Supportive care,4,14
NCT41192389,Pembrolizumab,Anti-PD-1,Multiple Myeloma,Phase 2,47,Arthralgia,Hepatobiliary disorders,No,Moderate,47,7,8,14.89,No,,19,70,Yes,No,Treatment interruption,27,17
NCT56569410,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 2,51,Nausea,General disorders,No,Severe,51,2,7,3.92,Yes,Lack of efficacy,8,91,Yes,No,Treatment interruption,30,76
NCT37596292,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,184,Colitis,Gastrointestinal disorders,No,Mild,184,38,40,20.65,No,,7,272,Yes,No,Treatment interruption,3,84
NCT87121719,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 2,212,Hyperthyroidism,Skin disorders,No,Moderate,212,45,47,21.23,No,,8,81,Yes,No,Supportive care,23,1
NCT50423111,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 1,307,Anemia,Hepatobiliary disorders,No,Moderate,307,38,39,12.38,No,,1,216,Yes,No,Dose reduction,11,50
NCT97933123,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 3,254,Nausea,Gastrointestinal disorders,No,Mild,254,51,53,20.08,No,,4,97,No,Yes,Treatment interruption,25,74
NCT14794201,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,427,Pneumonitis,Skin disorders,Yes,Severe,427,18,18,4.22,No,,1,313,Yes,Yes,Dose reduction,17,44
NCT52030667,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,190,Pneumonitis,Skin disorders,No,Moderate,190,24,29,12.63,No,,19,32,No,No,Dose reduction,16,34
NCT74239131,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 4,244,Pneumonitis,Hepatobiliary disorders,No,Mild,244,51,53,20.9,No,,2,151,Yes,No,Dose reduction,10,79
NCT62351758,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 1,122,Neutropenia,General disorders,No,Mild,122,26,29,21.31,No,,7,39,Yes,Yes,Dose reduction,9,34
NCT92335518,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,375,Anemia,Endocrine disorders,No,Mild,375,12,14,3.2,No,,19,88,No,No,Discontinuation,18,47
NCT74312416,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 4,362,Fatigue,Musculoskeletal disorders,No,Mild,362,63,66,17.4,No,,15,236,No,Yes,Supportive care,17,25
NCT55132820,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 1,408,Infusion-related reaction,Endocrine disorders,No,Moderate,408,36,41,8.82,No,,5,274,No,No,Supportive care,4,14
NCT85157142,Pembrolizumab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,492,Anemia,General disorders,Yes,Severe,492,89,90,18.09,Yes,Safety concerns,1,88,Yes,No,Supportive care,28,18
NCT58310186,Pembrolizumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,117,Hepatotoxicity,Endocrine disorders,No,Severe,117,22,24,18.8,No,,13,62,No,No,Discontinuation,2,11
NCT15424779,Pembrolizumab,Anti-PD-1,Multiple Sclerosis,Phase 2,231,Infusion-related reaction,Musculoskeletal disorders,No,Severe,231,52,54,22.51,No,,2,108,No,Yes,Dose reduction,9,66
NCT61053333,Pembrolizumab,Anti-PD-1,Breast Cancer,Phase 3,396,Arthralgia,Cardiac disorders,No,Moderate,396,110,112,27.78,No,,1,153,No,No,Supportive care,7,51
NCT19132895,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,131,Anemia,Musculoskeletal disorders,No,Moderate,131,4,7,3.05,Yes,Safety concerns,9,277,Yes,No,Treatment interruption,16,55
NCT42158876,Pembrolizumab,Anti-PD-1,Colorectal Cancer,Phase 1,127,Hypothyroidism,Respiratory disorders,No,Moderate,127,30,33,23.62,No,,17,324,Yes,Yes,Discontinuation,19,1
NCT24546828,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 2,274,Colitis,Cardiac disorders,Yes,Mild,274,49,53,17.88,No,,12,205,No,No,Dose reduction,20,63
NCT46147278,Nivolumab,Anti-PD-1,Breast Cancer,Phase 1,46,Hepatotoxicity,Cardiac disorders,No,Severe,46,7,8,15.22,No,,3,83,No,Yes,Treatment interruption,3,2
NCT50099854,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,27,Colitis,Cardiac disorders,No,Mild,27,4,5,14.81,No,,9,363,Yes,No,Discontinuation,20,33
NCT99613799,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,36,Neutropenia,Gastrointestinal disorders,Yes,Severe,36,1,5,2.78,No,,15,254,Yes,Yes,Discontinuation,21,57
NCT10745994,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 3,159,Hyperthyroidism,Respiratory disorders,No,Mild,159,11,16,6.92,No,,12,320,Yes,No,Dose reduction,22,14
NCT18366991,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,211,Rash,Gastrointestinal disorders,No,Moderate,211,62,64,29.38,No,,5,262,No,No,Treatment interruption,26,86
NCT66412570,Nivolumab,Anti-PD-1,Breast Cancer,Phase 3,138,Infusion-related reaction,Gastrointestinal disorders,No,Moderate,138,39,39,28.26,No,,12,67,Yes,No,Discontinuation,20,28
NCT50568649,Nivolumab,Anti-PD-1,Melanoma,Phase 1,370,Anemia,Musculoskeletal disorders,No,Mild,370,44,45,11.89,No,,3,86,No,No,Discontinuation,12,58
NCT16259995,Nivolumab,Anti-PD-1,Multiple Myeloma,Phase 2,442,Infusion-related reaction,Musculoskeletal disorders,No,Mild,442,129,134,29.19,No,,1,33,Yes,Yes,Discontinuation,6,74
NCT66695499,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 1,268,Colitis,Hepatobiliary disorders,No,Severe,268,75,80,27.99,No,,16,226,Yes,Yes,Supportive care,24,32
NCT63480113,Nivolumab,Anti-PD-1,Melanoma,Phase 2,262,Rash,Respiratory disorders,No,Severe,262,72,73,27.48,No,,14,211,No,Yes,Treatment interruption,18,78
NCT19087815,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 4,466,Pneumonitis,Gastrointestinal disorders,No,Moderate,466,117,119,25.11,No,,12,327,Yes,Yes,Supportive care,12,58
NCT62631842,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 1,321,Pneumonitis,Cardiac disorders,Yes,Severe,321,96,96,29.91,Yes,Competition,5,271,Yes,Yes,Treatment interruption,28,70
NCT37921494,Nivolumab,Anti-PD-1,Breast Cancer,Phase 3,178,Anemia,Endocrine disorders,No,Moderate,178,7,8,3.93,No,,6,249,Yes,No,Discontinuation,21,17
NCT56474351,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,170,Fatigue,Gastrointestinal disorders,No,Mild,170,33,33,19.41,No,,15,48,No,Yes,Discontinuation,9,23
NCT32763731,Nivolumab,Anti-PD-1,Multiple Myeloma,Phase 1,449,Rash,Gastrointestinal disorders,No,Moderate,449,125,129,27.84,No,,2,309,No,Yes,Dose reduction,8,3
NCT89252883,Nivolumab,Anti-PD-1,Breast Cancer,Phase 4,448,Anemia,General disorders,No,Severe,448,93,93,20.76,Yes,Lack of efficacy,13,183,Yes,Yes,Dose reduction,26,23
NCT52832144,Nivolumab,Anti-PD-1,Melanoma,Phase 4,41,Pneumonitis,Respiratory disorders,No,Moderate,41,11,16,26.83,No,,2,237,No,Yes,Dose reduction,26,43
NCT47658965,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 2,146,Pneumonitis,Respiratory disorders,No,Moderate,146,38,42,26.03,No,,3,148,Yes,No,Treatment interruption,4,61
NCT46711346,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311,Anemia,Skin disorders,Yes,Severe,311,85,88,27.33,Yes,Competition,4,42,No,No,Treatment interruption,11,39
NCT80497102,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,60,Hepatotoxicity,Hepatobiliary disorders,Yes,Moderate,60,5,5,8.33,Yes,Lack of efficacy,8,262,Yes,Yes,Discontinuation,6,9
NCT27542751,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 3,415,Rash,Gastrointestinal disorders,Yes,Severe,415,101,104,24.34,No,,17,159,Yes,No,Supportive care,16,6
NCT38205283,Nivolumab,Anti-PD-1,Melanoma,Phase 3,93,Colitis,General disorders,No,Severe,93,7,10,7.53,No,,18,178,No,Yes,Dose reduction,23,15
NCT28774100,Nivolumab,Anti-PD-1,Rheumatoid Arthritis,Phase 2,403,Cardiotoxicity,Endocrine disorders,No,Mild,403,19,20,4.71,No,,5,271,No,Yes,Discontinuation,23,29
NCT96841776,Nivolumab,Anti-PD-1,Breast Cancer,Phase 2,311,Neutropenia,General disorders,No,Mild,311,13,18,4.18,No,,3,291,No,No,Treatment interruption,27,37
NCT30943855,Nivolumab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,459,Hypothyroidism,Hepatobiliary disorders,No,Mild,459,44,49,9.59,No,,12,338,No,No,Discontinuation,13,1
NCT25619198,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,467,Colitis,Gastrointestinal disorders,No,Mild,467,16,17,3.43,No,,6,286,Yes,Yes,Supportive care,3,22
NCT86539260,Nivolumab,Anti-PD-1,Breast Cancer,Phase 2,196,Hyperthyroidism,Skin disorders,No,Mild,196,18,21,9.18,No,,11,203,Yes,No,Treatment interruption,2,69
NCT58278058,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,417,Thrombocytopenia,Blood disorders,No,Severe,417,91,96,21.82,No,,15,145,Yes,Yes,Treatment interruption,12,61
NCT69673016,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,454,Colitis,General disorders,No,Mild,454,31,34,6.83,No,,7,193,Yes,No,Treatment interruption,10,75
NCT21911260,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,452,Pneumonitis,Musculoskeletal disorders,Yes,Moderate,452,50,55,11.06,No,,15,164,Yes,Yes,Supportive care,25,10
NCT33713694,Nivolumab,Anti-PD-1,Melanoma,Phase 1,462,Hypothyroidism,Gastrointestinal disorders,No,Severe,462,90,93,19.48,No,,2,218,No,Yes,Dose reduction,7,23
NCT32809939,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 3,73,Thrombocytopenia,Cardiac disorders,No,Severe,73,2,4,2.74,No,,17,203,No,No,Dose reduction,2,82
NCT79343541,Nivolumab,Anti-PD-1,Melanoma,Phase 1,83,Hyperthyroidism,Blood disorders,No,Mild,83,17,20,20.48,No,,8,337,No,No,Treatment interruption,9,20
NCT21703661,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 4,135,Pneumonitis,Gastrointestinal disorders,No,Mild,135,30,31,22.22,No,,3,236,No,Yes,Discontinuation,22,82
NCT12070460,Nivolumab,Anti-PD-1,Breast Cancer,Phase 4,381,Hyperthyroidism,Blood disorders,No,Mild,381,67,67,17.59,No,,7,157,No,Yes,Treatment interruption,10,40
NCT60158133,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,290,Infusion-related reaction,Musculoskeletal disorders,Yes,Mild,290,81,84,27.93,No,,15,84,No,No,Supportive care,18,76
NCT47447597,Nivolumab,Anti-PD-1,Melanoma,Phase 4,82,Cardiotoxicity,Gastrointestinal disorders,No,Mild,82,5,10,6.1,No,,7,187,Yes,Yes,Dose reduction,7,53
NCT61304279,Nivolumab,Anti-PD-1,Breast Cancer,Phase 2,471,Anemia,Gastrointestinal disorders,No,Mild,471,30,30,6.37,No,,3,174,No,Yes,Supportive care,9,48
NCT41632649,Nivolumab,Anti-PD-1,Melanoma,Phase 4,436,Colitis,Cardiac disorders,No,Moderate,436,117,120,26.83,No,,9,78,Yes,Yes,Dose reduction,28,52
NCT23080545,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,127,Diarrhea,Skin disorders,No,Severe,127,23,24,18.11,No,,15,167,Yes,Yes,Discontinuation,19,19
NCT84896261,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 2,382,Pneumonitis,Respiratory disorders,No,Moderate,382,69,74,18.06,Yes,Competition,5,37,Yes,No,Treatment interruption,29,14
NCT65526339,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 1,163,Cardiotoxicity,Skin disorders,No,Mild,163,28,30,17.18,No,,19,145,Yes,No,Supportive care,6,47
NCT87695573,Nivolumab,Anti-PD-1,Melanoma,Phase 3,392,Pneumonitis,General disorders,Yes,Moderate,392,98,98,25.0,No,,8,344,Yes,Yes,Supportive care,1,61
NCT32314714,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 1,407,Rash,Hepatobiliary disorders,No,Mild,407,94,97,23.1,No,,19,263,Yes,Yes,Dose reduction,25,82
NCT60021795,Nivolumab,Anti-PD-1,Colorectal Cancer,Phase 3,55,Anemia,Musculoskeletal disorders,No,Mild,55,9,11,16.36,No,,5,230,Yes,No,Treatment interruption,6,29
NCT89441871,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 3,302,Hyperthyroidism,Skin disorders,No,Mild,302,37,42,12.25,No,,10,315,Yes,Yes,Treatment interruption,18,41
NCT56904306,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 1,448,Hepatotoxicity,General disorders,No,Mild,448,128,133,28.57,No,,8,134,Yes,No,Dose reduction,29,6
NCT20722130,Nivolumab,Anti-PD-1,Melanoma,Phase 3,311,Pneumonitis,Hepatobiliary disorders,No,Severe,311,68,70,21.86,Yes,Lack of efficacy,20,290,No,Yes,Supportive care,8,54
NCT27323755,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,86,Neutropenia,Skin disorders,No,Mild,86,12,13,13.95,No,,14,263,No,No,Supportive care,28,88
NCT60614899,Nivolumab,Anti-PD-1,Rheumatoid Arthritis,Phase 4,249,Hypothyroidism,Hepatobiliary disorders,No,Mild,249,62,66,24.9,No,,16,280,No,No,Supportive care,7,56
NCT93218781,Nivolumab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,33,Hyperthyroidism,Gastrointestinal disorders,Yes,Moderate,33,3,3,9.09,Yes,Lack of efficacy,11,197,No,Yes,Supportive care,28,85
NCT11766521,Nivolumab,Anti-PD-1,Multiple Myeloma,Phase 3,44,Diarrhea,Blood disorders,No,Mild,44,5,10,11.36,No,,7,118,Yes,No,Dose reduction,19,15
NCT80947598,Nivolumab,Anti-PD-1,Multiple Myeloma,Phase 3,290,Arthralgia,Skin disorders,Yes,Moderate,290,12,14,4.14,No,,6,266,Yes,Yes,Dose reduction,29,7
NCT89107880,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,309,Neutropenia,Respiratory disorders,No,Mild,309,50,52,16.18,No,,14,140,Yes,No,Discontinuation,15,27
NCT49261477,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,435,Rash,Blood disorders,Yes,Mild,435,44,45,10.11,No,,18,185,No,No,Treatment interruption,4,51
NCT90912674,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,213,Rash,Skin disorders,No,Mild,213,49,53,23.0,No,,16,261,Yes,Yes,Supportive care,27,37
NCT54585574,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 4,43,Neutropenia,Hepatobiliary disorders,No,Mild,43,11,13,25.58,No,,11,138,Yes,No,Treatment interruption,27,27
NCT13028629,Nivolumab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,230,Cardiotoxicity,Musculoskeletal disorders,No,Severe,230,8,12,3.48,Yes,Lack of efficacy,9,109,No,Yes,Dose reduction,12,16
NCT59240918,Nivolumab,Anti-PD-1,Multiple Sclerosis,Phase 2,89,Pneumonitis,Blood disorders,No,Mild,89,26,28,29.21,No,,2,46,Yes,No,Supportive care,28,90
NCT87437012,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,161,Fatigue,Hepatobiliary disorders,No,Severe,161,34,34,21.12,No,,14,309,No,Yes,Treatment interruption,11,43
NCT53841845,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,230,Anemia,Hepatobiliary disorders,No,Mild,230,5,8,2.17,No,,13,320,Yes,Yes,Discontinuation,18,22
NCT56988979,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 2,152,Infusion-related reaction,Blood disorders,No,Mild,152,7,10,4.61,No,,18,254,No,Yes,Discontinuation,15,25
NCT27632678,Cemiplimab,Anti-PD-1,Multiple Myeloma,Phase 2,204,Diarrhea,Hepatobiliary disorders,No,Mild,204,44,44,21.57,No,,14,277,No,No,Dose reduction,18,57
NCT65436958,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,310,Hypothyroidism,Respiratory disorders,No,Severe,310,50,54,16.13,Yes,Competition,14,239,Yes,No,Treatment interruption,22,62
NCT23897488,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,381,Hypothyroidism,Endocrine disorders,No,Mild,381,70,71,18.37,No,,8,116,Yes,No,Treatment interruption,10,19
NCT10320650,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,191,Fatigue,Respiratory disorders,No,Severe,191,5,10,2.62,No,,8,309,Yes,Yes,Treatment interruption,29,44
NCT94516879,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,466,Hepatotoxicity,Endocrine disorders,No,Mild,466,3,6,0.64,No,,6,177,No,No,Treatment interruption,27,65
NCT53020846,Cemiplimab,Anti-PD-1,Multiple Sclerosis,Phase 1,53,Diarrhea,General disorders,No,Mild,53,1,1,1.89,No,,4,240,No,No,Supportive care,29,67
NCT65699254,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,441,Colitis,Musculoskeletal disorders,No,Mild,441,74,74,16.78,No,,13,233,Yes,Yes,Supportive care,1,86
NCT15479249,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 4,313,Hepatotoxicity,Skin disorders,Yes,Severe,313,57,59,18.21,Yes,Regulatory issues,1,72,No,Yes,Discontinuation,11,38
NCT34876284,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 1,424,Hepatotoxicity,General disorders,Yes,Mild,424,81,83,19.1,Yes,Safety concerns,15,92,Yes,No,Supportive care,28,81
NCT42561392,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 2,349,Cardiotoxicity,Hepatobiliary disorders,Yes,Mild,349,84,86,24.07,No,,17,243,No,No,Supportive care,26,58
NCT60683680,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 2,238,Anemia,Skin disorders,No,Severe,238,46,50,19.33,No,,8,263,Yes,Yes,Discontinuation,6,31
NCT52258986,Cemiplimab,Anti-PD-1,Multiple Myeloma,Phase 2,109,Arthralgia,Endocrine disorders,No,Moderate,109,20,24,18.35,Yes,Safety concerns,9,243,No,No,Supportive care,5,73
NCT39121466,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,154,Diarrhea,Respiratory disorders,No,Severe,154,35,35,22.73,No,,13,52,Yes,No,Dose reduction,11,87
NCT77504273,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 4,477,Neutropenia,Respiratory disorders,Yes,Mild,477,138,138,28.93,No,,6,241,Yes,Yes,Dose reduction,22,41
NCT56552458,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,60,Fatigue,Respiratory disorders,No,Moderate,60,12,13,20.0,No,,3,219,No,No,Dose reduction,13,82
NCT69852096,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,90,Anemia,Skin disorders,No,Mild,90,12,16,13.33,No,,4,258,Yes,No,Dose reduction,27,70
NCT43989123,Cemiplimab,Anti-PD-1,Colorectal Cancer,Phase 1,111,Hypothyroidism,Endocrine disorders,No,Severe,111,20,23,18.02,Yes,Lack of efficacy,15,276,Yes,No,Supportive care,15,39
NCT39227266,Cemiplimab,Anti-PD-1,Breast Cancer,Phase 3,349,Arthralgia,Gastrointestinal disorders,Yes,Moderate,349,90,92,25.79,Yes,Regulatory issues,9,287,No,Yes,Dose reduction,1,81
NCT25743672,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,70,Diarrhea,Blood disorders,No,Moderate,70,14,17,20.0,No,,14,121,Yes,No,Supportive care,11,8
NCT18854019,Cemiplimab,Anti-PD-1,Breast Cancer,Phase 4,368,Anemia,Cardiac disorders,Yes,Severe,368,108,112,29.35,No,,14,120,Yes,Yes,Dose reduction,7,82
NCT46852458,Cemiplimab,Anti-PD-1,Colorectal Cancer,Phase 1,55,Cardiotoxicity,Skin disorders,No,Severe,55,15,16,27.27,No,,10,190,Yes,No,Supportive care,28,31
NCT55717117,Cemiplimab,Anti-PD-1,Breast Cancer,Phase 3,363,Hyperthyroidism,Hepatobiliary disorders,No,Mild,363,68,69,18.73,No,,7,67,No,No,Discontinuation,10,88
NCT38782691,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,267,Diarrhea,Cardiac disorders,No,Mild,267,49,49,18.35,No,,9,182,Yes,No,Discontinuation,29,13
NCT95918139,Cemiplimab,Anti-PD-1,Colorectal Cancer,Phase 4,279,Fatigue,Endocrine disorders,No,Mild,279,48,53,17.2,No,,13,248,No,Yes,Dose reduction,30,10
NCT12119286,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,178,Hepatotoxicity,Cardiac disorders,No,Moderate,178,41,44,23.03,No,,11,90,No,No,Discontinuation,3,3
NCT95841188,Cemiplimab,Anti-PD-1,Multiple Sclerosis,Phase 4,168,Rash,Cardiac disorders,Yes,Severe,168,13,13,7.74,Yes,Regulatory issues,17,241,Yes,No,Supportive care,28,89
NCT25691715,Cemiplimab,Anti-PD-1,Multiple Myeloma,Phase 4,365,Fatigue,Musculoskeletal disorders,No,Moderate,365,50,55,13.7,No,,2,95,Yes,No,Supportive care,16,57
NCT79657695,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,172,Arthralgia,Hepatobiliary disorders,No,Mild,172,48,50,27.91,No,,4,351,No,No,Dose reduction,23,83
NCT47548319,Cemiplimab,Anti-PD-1,Multiple Sclerosis,Phase 3,95,Diarrhea,Cardiac disorders,No,Severe,95,19,21,20.0,Yes,Safety concerns,14,348,Yes,Yes,Dose reduction,25,65
NCT46627799,Cemiplimab,Anti-PD-1,Breast Cancer,Phase 1,318,Nausea,Cardiac disorders,No,Mild,318,52,56,16.35,No,,5,289,Yes,Yes,Treatment interruption,13,40
NCT50863927,Cemiplimab,Anti-PD-1,Multiple Sclerosis,Phase 4,340,Thrombocytopenia,Skin disorders,No,Mild,340,14,18,4.12,No,,4,318,Yes,Yes,Discontinuation,19,34
NCT32643621,Cemiplimab,Anti-PD-1,Multiple Sclerosis,Phase 4,207,Anemia,General disorders,No,Moderate,207,53,58,25.6,Yes,Lack of efficacy,12,251,No,No,Discontinuation,17,77
NCT64605687,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 3,153,Nausea,Musculoskeletal disorders,No,Mild,153,18,19,11.76,No,,8,256,Yes,No,Supportive care,20,63
NCT64947158,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 4,369,Arthralgia,Cardiac disorders,No,Mild,369,7,8,1.9,No,,3,286,No,No,Discontinuation,19,57
NCT27589510,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,167,Pneumonitis,Gastrointestinal disorders,Yes,Moderate,167,18,23,10.78,No,,13,43,Yes,Yes,Treatment interruption,3,87
NCT71212843,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,273,Colitis,Gastrointestinal disorders,No,Moderate,273,77,82,28.21,Yes,Safety concerns,10,166,No,Yes,Supportive care,24,60
NCT13433261,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,468,Rash,Endocrine disorders,Yes,Severe,468,135,137,28.85,Yes,Competition,6,222,No,No,Treatment interruption,1,23
NCT36131561,Cemiplimab,Anti-PD-1,Colorectal Cancer,Phase 3,303,Neutropenia,General disorders,Yes,Mild,303,72,72,23.76,No,,3,135,Yes,No,Supportive care,12,76
NCT52229236,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,126,Cardiotoxicity,General disorders,No,Mild,126,13,18,10.32,No,,6,79,No,Yes,Discontinuation,23,41
NCT49924641,Cemiplimab,Anti-PD-1,Multiple Myeloma,Phase 4,477,Pneumonitis,Skin disorders,No,Mild,477,83,84,17.4,No,,12,115,No,Yes,Treatment interruption,3,5
NCT20179677,Cemiplimab,Anti-PD-1,Multiple Myeloma,Phase 3,162,Rash,Hepatobiliary disorders,No,Mild,162,5,5,3.09,No,,4,70,No,Yes,Dose reduction,20,82
NCT93191520,Cemiplimab,Anti-PD-1,Rheumatoid Arthritis,Phase 2,373,Anemia,General disorders,Yes,Moderate,373,33,37,8.85,No,,17,247,Yes,Yes,Treatment interruption,23,42
NCT27136422,Cemiplimab,Anti-PD-1,Colorectal Cancer,Phase 2,430,Nausea,Hepatobiliary disorders,No,Mild,430,89,91,20.7,No,,9,338,Yes,Yes,Discontinuation,30,62
NCT29879277,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,150,Infusion-related reaction,Skin disorders,Yes,Severe,150,28,30,18.67,Yes,Competition,10,60,Yes,No,Dose reduction,17,66
NCT10269956,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 2,66,Rash,General disorders,No,Mild,66,12,15,18.18,Yes,Safety concerns,1,48,No,Yes,Dose reduction,18,84
NCT46376371,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,493,Hyperthyroidism,Endocrine disorders,No,Mild,493,99,103,20.08,No,,5,215,Yes,No,Discontinuation,25,48
NCT31590428,Cemiplimab,Anti-PD-1,Colorectal Cancer,Phase 2,267,Diarrhea,Gastrointestinal disorders,Yes,Moderate,267,74,77,27.72,No,,16,41,No,No,Supportive care,21,75
NCT20152764,Cemiplimab,Anti-PD-1,Non-Hodgkin Lymphoma,Phase 1,429,Diarrhea,Respiratory disorders,No,Severe,429,57,60,13.29,No,,9,140,Yes,Yes,Dose reduction,8,67
NCT50160717,Cemiplimab,Anti-PD-1,Multiple Myeloma,Phase 2,178,Cardiotoxicity,Blood disorders,No,Mild,178,16,19,8.99,No,,18,105,No,Yes,Discontinuation,5,51
NCT28137045,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,403,Fatigue,General disorders,No,Moderate,403,55,59,13.65,No,,1,52,Yes,No,Treatment interruption,9,66
NCT94764318,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,492,Hypothyroidism,Cardiac disorders,Yes,Mild,492,71,75,14.43,No,,17,322,No,Yes,Dose reduction,8,75
NCT83225624,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 2,491,Hypothyroidism,Blood disorders,No,Mild,491,62,62,12.63,No,,8,131,Yes,Yes,Dose reduction,14,89
NCT86394977,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,259,Nausea,Skin disorders,No,Moderate,259,33,34,12.74,Yes,Competition,1,171,Yes,Yes,Discontinuation,13,85
NCT21018646,Atezolizumab,Anti-PD-L1,Melanoma,Phase 2,405,Neutropenia,Blood disorders,No,Mild,405,16,18,3.95,No,,4,316,No,No,Treatment interruption,9,44
NCT10254847,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 1,475,Diarrhea,Cardiac disorders,No,Mild,475,106,107,22.32,No,,19,137,No,No,Dose reduction,14,44
NCT35106135,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 4,454,Diarrhea,Blood disorders,No,Severe,454,59,64,13.0,No,,19,64,No,No,Dose reduction,23,32
NCT74454514,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 3,389,Fatigue,General disorders,Yes,Mild,389,82,82,21.08,No,,17,128,No,Yes,Treatment interruption,26,10
NCT21121210,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,163,Rash,Cardiac disorders,No,Mild,163,3,4,1.84,No,,8,282,Yes,Yes,Dose reduction,1,16
NCT25856179,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 4,321,Neutropenia,Skin disorders,No,Moderate,321,95,97,29.6,No,,6,343,Yes,No,Discontinuation,17,13
NCT83205774,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,360,Neutropenia,Blood disorders,No,Severe,360,108,110,30.0,Yes,Lack of efficacy,2,341,Yes,Yes,Treatment interruption,26,17
NCT78304781,Atezolizumab,Anti-PD-L1,Melanoma,Phase 2,458,Hyperthyroidism,Cardiac disorders,No,Mild,458,90,94,19.65,No,,1,74,No,No,Dose reduction,17,4
NCT47845853,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,455,Hepatotoxicity,Gastrointestinal disorders,Yes,Moderate,455,88,93,19.34,No,,3,48,Yes,Yes,Dose reduction,25,11
NCT90039841,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 2,200,Fatigue,Cardiac disorders,No,Moderate,200,10,15,5.0,Yes,Regulatory issues,6,262,Yes,Yes,Dose reduction,22,78
NCT11078864,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,342,Nausea,Cardiac disorders,No,Mild,342,53,58,15.5,No,,9,184,Yes,No,Treatment interruption,21,64
NCT34751153,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 2,482,Fatigue,Blood disorders,No,Mild,482,5,6,1.04,No,,5,38,Yes,No,Treatment interruption,10,55
NCT44329395,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,263,Fatigue,General disorders,No,Moderate,263,7,10,2.66,No,,5,205,No,Yes,Supportive care,14,15
NCT62145875,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 3,369,Thrombocytopenia,Endocrine disorders,No,Moderate,369,85,85,23.04,Yes,Lack of efficacy,6,261,Yes,Yes,Treatment interruption,4,5
NCT14344551,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,131,Diarrhea,Respiratory disorders,No,Mild,131,11,11,8.4,No,,8,252,No,No,Discontinuation,23,11
NCT13169613,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,206,Hypothyroidism,Blood disorders,No,Moderate,206,46,51,22.33,No,,16,288,Yes,Yes,Discontinuation,25,73
NCT38186277,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,413,Rash,Musculoskeletal disorders,No,Moderate,413,50,54,12.11,Yes,Safety concerns,13,203,Yes,No,Treatment interruption,21,63
NCT61549352,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 4,42,Pneumonitis,Blood disorders,No,Severe,42,1,2,2.38,Yes,Regulatory issues,5,321,No,No,Supportive care,28,11
NCT51768356,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,300,Fatigue,Endocrine disorders,No,Moderate,300,31,34,10.33,No,,7,243,Yes,Yes,Dose reduction,8,69
NCT42016223,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 4,495,Nausea,Skin disorders,No,Mild,495,92,96,18.59,No,,8,327,Yes,No,Dose reduction,6,48
NCT83613212,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,172,Pneumonitis,Blood disorders,No,Moderate,172,25,30,14.53,No,,20,183,Yes,No,Treatment interruption,28,25
NCT40246618,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,262,Thrombocytopenia,General disorders,No,Mild,262,56,59,21.37,No,,9,161,No,No,Treatment interruption,22,82
NCT50796412,Atezolizumab,Anti-PD-L1,Melanoma,Phase 3,151,Hyperthyroidism,Blood disorders,No,Moderate,151,18,23,11.92,No,,9,175,Yes,No,Supportive care,16,13
NCT86468854,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,289,Diarrhea,Skin disorders,No,Mild,289,74,76,25.61,No,,9,285,No,Yes,Dose reduction,6,23
NCT42171684,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,341,Thrombocytopenia,Musculoskeletal disorders,Yes,Severe,341,97,102,28.45,No,,9,74,Yes,No,Supportive care,20,73
NCT26190774,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,228,Hepatotoxicity,Hepatobiliary disorders,No,Moderate,228,16,20,7.02,No,,12,61,Yes,No,Treatment interruption,3,75
NCT25442538,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,449,Pneumonitis,Cardiac disorders,No,Moderate,449,58,58,12.92,No,,8,167,No,Yes,Treatment interruption,15,19
NCT53163684,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 2,90,Infusion-related reaction,Endocrine disorders,No,Mild,90,5,10,5.56,No,,2,326,No,No,Discontinuation,14,46
NCT11842474,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,26,Diarrhea,Cardiac disorders,Yes,Severe,26,2,6,7.69,Yes,Regulatory issues,11,153,Yes,No,Treatment interruption,1,21
NCT17045924,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,68,Infusion-related reaction,Gastrointestinal disorders,No,Moderate,68,18,21,26.47,No,,18,239,Yes,Yes,Discontinuation,3,82
NCT71824585,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,256,Cardiotoxicity,Blood disorders,Yes,Moderate,256,46,47,17.97,Yes,Safety concerns,11,34,No,Yes,Treatment interruption,29,79
NCT85888687,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,238,Colitis,Skin disorders,No,Moderate,238,31,33,13.03,No,,15,213,No,Yes,Discontinuation,2,1
NCT33987125,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 2,224,Hyperthyroidism,Cardiac disorders,No,Mild,224,46,47,20.54,No,,17,176,No,No,Dose reduction,6,51
NCT57056681,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,149,Colitis,Blood disorders,No,Moderate,149,16,16,10.74,No,,13,212,No,No,Discontinuation,17,42
NCT75283643,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,232,Rash,Hepatobiliary disorders,No,Mild,232,15,19,6.47,No,,15,240,No,Yes,Discontinuation,6,89
NCT98386509,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,149,Rash,Skin disorders,No,Moderate,149,5,9,3.36,No,,11,169,Yes,Yes,Dose reduction,28,61
NCT38267526,Atezolizumab,Anti-PD-L1,Melanoma,Phase 1,376,Hepatotoxicity,Cardiac disorders,No,Moderate,376,99,99,26.33,No,,14,152,Yes,Yes,Treatment interruption,17,2
NCT94193013,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,84,Anemia,Cardiac disorders,No,Severe,84,20,20,23.81,No,,12,268,No,No,Supportive care,28,48
NCT69603695,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,248,Cardiotoxicity,Blood disorders,No,Severe,248,68,71,27.42,No,,17,298,Yes,No,Dose reduction,30,31
NCT59104307,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,196,Colitis,Respiratory disorders,No,Severe,196,38,39,19.39,No,,17,286,Yes,Yes,Dose reduction,9,5
NCT57453914,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 1,361,Rash,Gastrointestinal disorders,No,Mild,361,71,71,19.67,No,,6,131,Yes,No,Supportive care,18,52
NCT36200275,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,310,Fatigue,Hepatobiliary disorders,No,Severe,310,29,31,9.35,No,,9,148,No,No,Discontinuation,24,48
NCT86671187,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,325,Hypothyroidism,Hepatobiliary disorders,No,Moderate,325,94,97,28.92,No,,8,215,Yes,Yes,Discontinuation,22,36
NCT96361468,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,254,Arthralgia,Blood disorders,No,Severe,254,53,56,20.87,No,,12,357,No,No,Discontinuation,24,33
NCT66239274,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 4,342,Pneumonitis,Hepatobiliary disorders,No,Mild,342,7,9,2.05,No,,10,129,Yes,No,Dose reduction,5,39
NCT37920929,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,119,Anemia,Musculoskeletal disorders,No,Moderate,119,7,11,5.88,No,,4,222,No,No,Supportive care,10,56
NCT84725528,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,356,Infusion-related reaction,Gastrointestinal disorders,No,Moderate,356,70,73,19.66,Yes,Safety concerns,14,128,Yes,No,Dose reduction,3,23
NCT28014485,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,87,Pneumonitis,Respiratory disorders,No,Severe,87,4,8,4.6,No,,5,340,Yes,Yes,Treatment interruption,23,66
NCT95463242,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,371,Hypothyroidism,Hepatobiliary disorders,No,Moderate,371,6,9,1.62,No,,3,204,No,Yes,Supportive care,18,9
NCT96944150,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,291,Hepatotoxicity,General disorders,Yes,Moderate,291,71,75,24.4,No,,13,362,Yes,Yes,Treatment interruption,11,90
NCT75553444,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 3,177,Colitis,Cardiac disorders,No,Mild,177,23,25,12.99,No,,11,232,No,Yes,Treatment interruption,15,11
NCT39678175,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,148,Hypothyroidism,Blood disorders,Yes,Severe,148,41,41,27.7,Yes,Lack of efficacy,19,235,No,No,Discontinuation,2,64
NCT24274905,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 4,494,Diarrhea,General disorders,No,Severe,494,105,106,21.26,No,,17,54,Yes,No,Supportive care,21,88
NCT46551376,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,195,Rash,Gastrointestinal disorders,No,Moderate,195,33,33,16.92,No,,20,172,Yes,Yes,Treatment interruption,24,39
NCT60012816,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,464,Nausea,Endocrine disorders,No,Mild,464,43,45,9.27,Yes,Competition,6,98,Yes,Yes,Treatment interruption,17,87
NCT55781379,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 1,379,Infusion-related reaction,Respiratory disorders,No,Moderate,379,32,34,8.44,No,,5,219,Yes,Yes,Dose reduction,3,23
NCT11806552,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 1,426,Fatigue,Hepatobiliary disorders,No,Severe,426,37,38,8.69,No,,7,253,Yes,Yes,Dose reduction,20,28
NCT70767231,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,30,Anemia,General disorders,No,Mild,30,2,4,6.67,No,,9,348,Yes,No,Supportive care,22,35
NCT73411684,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,33,Arthralgia,Blood disorders,No,Moderate,33,7,9,21.21,No,,2,142,Yes,No,Supportive care,15,90
NCT44390074,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,123,Hypothyroidism,Respiratory disorders,Yes,Mild,123,30,31,24.39,No,,5,234,No,Yes,Supportive care,6,58
NCT17996721,Atezolizumab,Anti-PD-L1,Melanoma,Phase 3,342,Cardiotoxicity,Endocrine disorders,No,Mild,342,72,74,21.05,No,,6,47,Yes,Yes,Treatment interruption,13,5
NCT16681379,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 2,34,Anemia,Skin disorders,No,Moderate,34,5,8,14.71,No,,17,271,No,Yes,Treatment interruption,24,14
NCT31893097,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 1,174,Colitis,Respiratory disorders,No,Severe,174,46,50,26.44,No,,13,206,Yes,No,Dose reduction,14,48
NCT83854429,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 1,62,Diarrhea,Cardiac disorders,No,Mild,62,7,10,11.29,No,,18,339,No,No,Dose reduction,30,34
NCT48857109,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,171,Neutropenia,General disorders,No,Mild,171,9,9,5.26,No,,10,64,Yes,Yes,Treatment interruption,11,26
NCT68303790,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,292,Hyperthyroidism,Blood disorders,Yes,Severe,292,86,90,29.45,No,,7,83,No,Yes,Dose reduction,13,61
NCT14841758,Atezolizumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 1,187,Diarrhea,Hepatobiliary disorders,Yes,Moderate,187,19,22,10.16,Yes,Lack of efficacy,5,143,Yes,No,Treatment interruption,11,53
NCT31815172,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,47,Fatigue,Musculoskeletal disorders,No,Moderate,47,5,6,10.64,Yes,Lack of efficacy,13,300,Yes,Yes,Treatment interruption,10,16
NCT56929681,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 4,474,Cardiotoxicity,Cardiac disorders,No,Mild,474,48,48,10.13,No,,17,37,No,Yes,Discontinuation,25,67
NCT40069041,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 4,90,Hypothyroidism,Hepatobiliary disorders,No,Mild,90,2,7,2.22,No,,15,38,No,Yes,Supportive care,16,60
NCT88785774,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,97,Fatigue,Hepatobiliary disorders,No,Moderate,97,8,13,8.25,Yes,Safety concerns,16,44,No,No,Discontinuation,15,7
NCT93494051,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,300,Hepatotoxicity,Respiratory disorders,No,Severe,300,43,43,14.33,No,,6,165,No,No,Discontinuation,9,39
NCT83946601,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,131,Diarrhea,Skin disorders,Yes,Severe,131,37,38,28.24,No,,5,165,No,No,Discontinuation,30,52
NCT78855302,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 4,25,Rash,Endocrine disorders,No,Mild,25,4,9,16.0,No,,3,333,No,No,Supportive care,16,40
NCT11019397,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,338,Colitis,Blood disorders,No,Moderate,338,30,33,8.88,No,,20,127,No,No,Supportive care,5,56
NCT69994377,Atezolizumab,Anti-PD-L1,Melanoma,Phase 4,38,Hypothyroidism,Gastrointestinal disorders,No,Moderate,38,4,5,10.53,No,,11,336,No,No,Treatment interruption,16,17
NCT88238928,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,176,Hyperthyroidism,Musculoskeletal disorders,No,Severe,176,47,51,26.7,No,,9,240,Yes,Yes,Discontinuation,22,23
NCT63654074,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,424,Infusion-related reaction,Musculoskeletal disorders,No,Moderate,424,33,34,7.78,No,,5,285,No,No,Discontinuation,21,87
NCT54844759,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,170,Fatigue,Skin disorders,No,Moderate,170,19,20,11.18,Yes,Lack of efficacy,13,293,No,Yes,Discontinuation,3,15
NCT66684052,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 3,166,Hepatotoxicity,General disorders,No,Mild,166,13,16,7.83,No,,17,47,Yes,Yes,Treatment interruption,17,31
NCT84609583,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,200,Neutropenia,Respiratory disorders,No,Mild,200,50,55,25.0,No,,6,320,Yes,No,Supportive care,8,42
NCT29111590,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 4,88,Anemia,Skin disorders,No,Moderate,88,6,8,6.82,No,,2,275,Yes,Yes,Treatment interruption,24,28
NCT83427199,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,37,Infusion-related reaction,Skin disorders,Yes,Severe,37,1,5,2.7,Yes,Competition,3,352,Yes,Yes,Treatment interruption,11,31
NCT65753219,Atezolizumab,Anti-PD-L1,Melanoma,Phase 2,52,Diarrhea,Cardiac disorders,No,Mild,52,10,14,19.23,No,,19,181,Yes,Yes,Treatment interruption,24,16
NCT82714181,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,329,Hepatotoxicity,General disorders,No,Mild,329,76,78,23.1,No,,19,173,Yes,Yes,Dose reduction,23,75
NCT83176319,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 1,93,Rash,Skin disorders,No,Mild,93,6,11,6.45,No,,4,304,No,No,Treatment interruption,8,11
NCT16869213,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 3,265,Pneumonitis,Hepatobiliary disorders,No,Severe,265,50,52,18.87,Yes,Lack of efficacy,12,150,Yes,Yes,Supportive care,25,51
NCT74403057,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 2,68,Infusion-related reaction,Endocrine disorders,Yes,Moderate,68,2,7,2.94,No,,12,208,Yes,Yes,Treatment interruption,14,37
NCT70768081,Atezolizumab,Anti-PD-L1,Multiple Myeloma,Phase 3,72,Fatigue,Skin disorders,No,Mild,72,7,11,9.72,No,,18,224,Yes,No,Treatment interruption,20,9
NCT68500194,Atezolizumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,198,Diarrhea,Musculoskeletal disorders,Yes,Moderate,198,15,18,7.58,Yes,Competition,10,214,Yes,Yes,Treatment interruption,12,20
NCT80464681,Atezolizumab,Anti-PD-L1,Colorectal Cancer,Phase 4,116,Diarrhea,Cardiac disorders,Yes,Severe,116,19,24,16.38,Yes,Lack of efficacy,10,226,Yes,Yes,Discontinuation,3,60
NCT59042013,Atezolizumab,Anti-PD-L1,Melanoma,Phase 1,273,Pneumonitis,Skin disorders,No,Severe,273,17,19,6.23,Yes,Regulatory issues,1,228,Yes,No,Treatment interruption,16,61
NCT74937737,Atezolizumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,429,Infusion-related reaction,Gastrointestinal disorders,Yes,Moderate,429,94,98,21.91,No,,7,352,Yes,No,Supportive care,3,70
NCT33533906,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 2,384,Thrombocytopenia,Musculoskeletal disorders,No,Mild,384,12,12,3.12,No,,16,196,Yes,Yes,Dose reduction,3,44
NCT16330350,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,269,Fatigue,Endocrine disorders,Yes,Severe,269,3,3,1.12,No,,12,355,No,Yes,Dose reduction,6,48
NCT92082882,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,64,Hepatotoxicity,Blood disorders,No,Mild,64,8,8,12.5,No,,9,153,No,No,Treatment interruption,24,13
NCT87900749,Durvalumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,157,Infusion-related reaction,General disorders,No,Moderate,157,43,45,27.39,No,,4,161,Yes,No,Discontinuation,15,15
NCT47366233,Durvalumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,215,Diarrhea,Cardiac disorders,Yes,Severe,215,29,30,13.49,Yes,Lack of efficacy,2,166,Yes,Yes,Dose reduction,9,10
NCT20380572,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,192,Thrombocytopenia,Gastrointestinal disorders,Yes,Severe,192,31,32,16.15,No,,14,236,No,No,Supportive care,19,60
NCT43749454,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 3,360,Neutropenia,Gastrointestinal disorders,No,Mild,360,92,92,25.56,No,,18,89,No,Yes,Dose reduction,25,90
NCT90642230,Durvalumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,394,Colitis,Endocrine disorders,Yes,Severe,394,21,24,5.33,Yes,Regulatory issues,18,151,No,Yes,Dose reduction,27,70
NCT47996917,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 2,238,Cardiotoxicity,Blood disorders,No,Moderate,238,12,13,5.04,No,,19,267,No,No,Discontinuation,2,49
NCT21948034,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,45,Anemia,Cardiac disorders,No,Moderate,45,4,5,8.89,No,,4,173,Yes,Yes,Dose reduction,25,66
NCT52590651,Durvalumab,Anti-PD-L1,Melanoma,Phase 3,138,Cardiotoxicity,Gastrointestinal disorders,No,Mild,138,2,3,1.45,No,,16,114,No,Yes,Treatment interruption,30,76
NCT75570217,Durvalumab,Anti-PD-L1,Melanoma,Phase 3,359,Pneumonitis,Hepatobiliary disorders,Yes,Severe,359,42,42,11.7,Yes,Lack of efficacy,12,347,No,No,Discontinuation,19,48
NCT42501038,Durvalumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,430,Hypothyroidism,Musculoskeletal disorders,No,Moderate,430,72,72,16.74,No,,2,253,No,No,Dose reduction,29,25
NCT71042338,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 3,200,Anemia,Gastrointestinal disorders,No,Mild,200,19,22,9.5,No,,1,62,Yes,Yes,Discontinuation,2,90
NCT41034634,Durvalumab,Anti-PD-L1,Melanoma,Phase 3,423,Hypothyroidism,Respiratory disorders,No,Moderate,423,30,33,7.09,Yes,Lack of efficacy,19,325,No,Yes,Dose reduction,10,46
NCT14974278,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 4,490,Infusion-related reaction,General disorders,No,Moderate,490,76,78,15.51,No,,12,106,Yes,No,Treatment interruption,11,63
NCT51220347,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 2,462,Neutropenia,Cardiac disorders,No,Severe,462,133,137,28.79,No,,2,139,Yes,Yes,Treatment interruption,9,61
NCT67474269,Durvalumab,Anti-PD-L1,Melanoma,Phase 4,454,Hyperthyroidism,Skin disorders,Yes,Severe,454,29,33,6.39,No,,6,230,No,No,Supportive care,5,8
NCT97738828,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,69,Rash,Cardiac disorders,No,Moderate,69,5,9,7.25,No,,14,259,No,No,Discontinuation,2,59
NCT94774470,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 4,324,Rash,Cardiac disorders,No,Mild,324,23,24,7.1,No,,2,240,No,Yes,Supportive care,8,64
NCT68716084,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 2,313,Hypothyroidism,Hepatobiliary disorders,Yes,Mild,313,53,57,16.93,No,,18,128,No,No,Discontinuation,9,64
NCT39781160,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 4,155,Pneumonitis,Blood disorders,Yes,Severe,155,1,5,0.65,Yes,Regulatory issues,17,345,No,No,Dose reduction,26,5
NCT48473390,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 4,332,Hepatotoxicity,Gastrointestinal disorders,No,Mild,332,54,54,16.27,No,,10,352,Yes,Yes,Discontinuation,14,51
NCT55760602,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,482,Fatigue,General disorders,No,Severe,482,30,30,6.22,Yes,Safety concerns,11,231,No,No,Dose reduction,3,48
NCT78555678,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 1,293,Neutropenia,Hepatobiliary disorders,No,Mild,293,64,69,21.84,No,,8,229,No,Yes,Treatment interruption,23,90
NCT10820857,Durvalumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,359,Neutropenia,Endocrine disorders,No,Moderate,359,83,88,23.12,No,,13,115,Yes,Yes,Treatment interruption,10,35
NCT29856874,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,286,Diarrhea,General disorders,No,Moderate,286,3,4,1.05,No,,16,254,No,No,Treatment interruption,8,79
NCT21509644,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,267,Neutropenia,Musculoskeletal disorders,No,Mild,267,39,44,14.61,No,,8,169,Yes,No,Dose reduction,13,56
NCT43301586,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,222,Pneumonitis,Musculoskeletal disorders,No,Mild,222,10,15,4.5,No,,8,293,No,Yes,Treatment interruption,6,20
NCT61790996,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 3,141,Hepatotoxicity,Cardiac disorders,No,Moderate,141,27,30,19.15,No,,20,60,Yes,No,Discontinuation,18,35
NCT54199841,Durvalumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,432,Hepatotoxicity,Blood disorders,No,Moderate,432,55,55,12.73,No,,14,191,Yes,No,Supportive care,9,67
NCT46241776,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 3,32,Thrombocytopenia,Blood disorders,No,Mild,32,9,11,28.12,No,,16,78,Yes,Yes,Dose reduction,20,20
NCT44656135,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,223,Fatigue,Cardiac disorders,No,Mild,223,42,45,18.83,No,,13,296,Yes,No,Treatment interruption,1,80
NCT50936139,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,45,Hypothyroidism,Musculoskeletal disorders,No,Mild,45,10,15,22.22,No,,8,166,Yes,Yes,Treatment interruption,5,33
NCT55372211,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 4,414,Fatigue,Cardiac disorders,No,Severe,414,101,101,24.4,No,,16,341,Yes,No,Treatment interruption,23,29
NCT37847622,Durvalumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,440,Fatigue,Hepatobiliary disorders,No,Mild,440,74,79,16.82,No,,12,99,No,Yes,Treatment interruption,18,27
NCT41136442,Durvalumab,Anti-PD-L1,Melanoma,Phase 3,81,Arthralgia,Hepatobiliary disorders,Yes,Mild,81,20,22,24.69,No,,10,107,No,No,Supportive care,17,46
NCT55032339,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 2,323,Rash,Respiratory disorders,No,Moderate,323,85,90,26.32,No,,8,92,No,No,Treatment interruption,16,4
NCT51954584,Durvalumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 4,99,Anemia,Hepatobiliary disorders,No,Mild,99,3,7,3.03,No,,5,273,No,No,Dose reduction,1,56
NCT27950698,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,100,Nausea,Skin disorders,No,Severe,100,1,2,1.0,No,,14,57,Yes,No,Discontinuation,2,72
NCT31697613,Durvalumab,Anti-PD-L1,Melanoma,Phase 4,113,Anemia,Musculoskeletal disorders,Yes,Moderate,113,32,36,28.32,Yes,Regulatory issues,18,349,No,Yes,Treatment interruption,26,4
NCT69383135,Durvalumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,174,Fatigue,Hepatobiliary disorders,Yes,Moderate,174,47,52,27.01,Yes,Competition,5,211,Yes,No,Treatment interruption,30,23
NCT88168322,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 3,139,Rash,Cardiac disorders,No,Mild,139,39,40,28.06,No,,18,283,No,No,Treatment interruption,13,33
NCT87545676,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 4,55,Hepatotoxicity,Skin disorders,No,Severe,55,15,17,27.27,Yes,Competition,4,260,Yes,Yes,Discontinuation,5,77
NCT41660776,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 1,45,Neutropenia,Musculoskeletal disorders,No,Moderate,45,12,12,26.67,No,,14,95,No,Yes,Discontinuation,21,3
NCT21549273,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,318,Pneumonitis,Blood disorders,No,Moderate,318,40,42,12.58,Yes,Lack of efficacy,18,255,Yes,Yes,Discontinuation,15,24
NCT33862571,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,126,Neutropenia,Hepatobiliary disorders,No,Mild,126,7,9,5.56,No,,4,330,No,No,Supportive care,25,84
NCT81208956,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 4,65,Hyperthyroidism,General disorders,No,Mild,65,2,7,3.08,No,,2,154,Yes,No,Supportive care,10,31
NCT95921715,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 3,457,Fatigue,Skin disorders,No,Mild,457,65,65,14.22,No,,1,163,Yes,Yes,Treatment interruption,7,48
NCT29876496,Durvalumab,Anti-PD-L1,Melanoma,Phase 3,23,Neutropenia,Blood disorders,No,Severe,23,4,6,17.39,No,,7,265,Yes,No,Treatment interruption,23,23
NCT60814177,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,33,Pneumonitis,Respiratory disorders,No,Moderate,33,3,7,9.09,No,,16,340,Yes,Yes,Treatment interruption,5,84
NCT67809312,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,256,Arthralgia,Hepatobiliary disorders,No,Mild,256,6,11,2.34,No,,19,232,No,No,Discontinuation,27,90
NCT75522449,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,460,Hypothyroidism,Endocrine disorders,No,Moderate,460,111,111,24.13,No,,17,45,Yes,No,Dose reduction,6,81
NCT59670665,Durvalumab,Anti-PD-L1,Melanoma,Phase 4,273,Hepatotoxicity,Respiratory disorders,Yes,Moderate,273,46,47,16.85,Yes,Lack of efficacy,3,102,Yes,Yes,Discontinuation,8,71
NCT37367959,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,108,Cardiotoxicity,Hepatobiliary disorders,No,Mild,108,25,30,23.15,No,,4,338,No,Yes,Dose reduction,22,67
NCT81691297,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 2,391,Hypothyroidism,Gastrointestinal disorders,No,Mild,391,2,4,0.51,No,,10,337,No,No,Supportive care,19,36
NCT36204559,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,38,Neutropenia,Cardiac disorders,No,Mild,38,2,7,5.26,No,,1,32,No,No,Supportive care,8,77
NCT20259637,Durvalumab,Anti-PD-L1,Multiple Sclerosis,Phase 2,276,Thrombocytopenia,Respiratory disorders,No,Moderate,276,38,43,13.77,No,,11,221,Yes,No,Treatment interruption,11,75
NCT87927677,Durvalumab,Anti-PD-L1,Melanoma,Phase 3,73,Hypothyroidism,Endocrine disorders,No,Severe,73,15,19,20.55,Yes,Lack of efficacy,1,154,Yes,Yes,Treatment interruption,7,85
NCT74061791,Durvalumab,Anti-PD-L1,Melanoma,Phase 4,293,Diarrhea,Cardiac disorders,No,Mild,293,35,36,11.95,No,,19,198,Yes,No,Treatment interruption,6,16
NCT37198059,Durvalumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,296,Pneumonitis,Blood disorders,No,Mild,296,10,13,3.38,No,,13,336,Yes,Yes,Supportive care,19,42
NCT90837787,Durvalumab,Anti-PD-L1,Multiple Myeloma,Phase 1,266,Diarrhea,Musculoskeletal disorders,No,Moderate,266,5,6,1.88,No,,11,361,Yes,Yes,Discontinuation,17,10
NCT50448457,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,177,Diarrhea,Gastrointestinal disorders,Yes,Mild,177,35,38,19.77,No,,2,85,Yes,Yes,Dose reduction,4,26
NCT68600829,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 3,49,Pneumonitis,Gastrointestinal disorders,No,Mild,49,11,16,22.45,No,,8,289,No,Yes,Supportive care,27,16
NCT70522261,Durvalumab,Anti-PD-L1,Colorectal Cancer,Phase 1,235,Hyperthyroidism,Gastrointestinal disorders,Yes,Mild,235,8,10,3.4,Yes,Competition,16,75,Yes,No,Supportive care,2,57
NCT70541910,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,128,Hepatotoxicity,Skin disorders,No,Severe,128,7,7,5.47,No,,3,52,Yes,Yes,Dose reduction,10,61
NCT10962611,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,244,Anemia,Gastrointestinal disorders,No,Moderate,244,72,74,29.51,No,,11,329,Yes,No,Discontinuation,23,6
NCT17349611,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,385,Cardiotoxicity,Hepatobiliary disorders,No,Mild,385,62,64,16.1,No,,10,217,No,Yes,Supportive care,18,86
NCT77331436,Avelumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,482,Colitis,Musculoskeletal disorders,No,Severe,482,81,86,16.8,Yes,Safety concerns,6,70,Yes,Yes,Discontinuation,27,58
NCT66253900,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 4,50,Hyperthyroidism,General disorders,No,Severe,50,7,8,14.0,No,,20,329,Yes,No,Dose reduction,30,47
NCT94406633,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 4,32,Pneumonitis,Cardiac disorders,No,Severe,32,6,7,18.75,No,,18,264,No,Yes,Discontinuation,9,85
NCT63426068,Avelumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,338,Hyperthyroidism,Skin disorders,No,Severe,338,80,82,23.67,Yes,Competition,5,324,No,No,Dose reduction,19,30
NCT14333423,Avelumab,Anti-PD-L1,Melanoma,Phase 2,142,Colitis,Endocrine disorders,No,Moderate,142,11,15,7.75,No,,8,82,Yes,No,Dose reduction,13,28
NCT58805701,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,350,Hypothyroidism,Musculoskeletal disorders,No,Mild,350,72,72,20.57,Yes,Lack of efficacy,8,39,Yes,Yes,Supportive care,16,24
NCT82151852,Avelumab,Anti-PD-L1,Melanoma,Phase 3,63,Pneumonitis,General disorders,No,Moderate,63,9,10,14.29,No,,12,80,No,No,Dose reduction,24,22
NCT53322525,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 1,77,Anemia,General disorders,No,Severe,77,5,9,6.49,Yes,Regulatory issues,9,294,No,Yes,Dose reduction,27,5
NCT48032700,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,226,Cardiotoxicity,Blood disorders,No,Severe,226,9,11,3.98,No,,3,97,Yes,No,Supportive care,30,83
NCT69453871,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,313,Nausea,General disorders,No,Severe,313,57,61,18.21,No,,5,215,Yes,Yes,Supportive care,29,38
NCT30508079,Avelumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,180,Rash,Cardiac disorders,Yes,Moderate,180,6,9,3.33,No,,20,194,Yes,Yes,Dose reduction,4,76
NCT96148078,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,385,Hypothyroidism,Respiratory disorders,No,Moderate,385,45,45,11.69,No,,5,201,Yes,Yes,Treatment interruption,14,35
NCT29975598,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,296,Arthralgia,Respiratory disorders,No,Mild,296,5,8,1.69,No,,3,60,No,No,Supportive care,12,1
NCT17791764,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,334,Neutropenia,Hepatobiliary disorders,No,Mild,334,38,38,11.38,No,,2,247,Yes,No,Dose reduction,15,82
NCT39992930,Avelumab,Anti-PD-L1,Multiple Sclerosis,Phase 4,68,Hepatotoxicity,Endocrine disorders,Yes,Moderate,68,7,7,10.29,No,,8,135,Yes,Yes,Dose reduction,18,87
NCT68206690,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,139,Colitis,Endocrine disorders,No,Moderate,139,38,42,27.34,No,,14,363,Yes,Yes,Discontinuation,28,46
NCT44324729,Avelumab,Anti-PD-L1,Melanoma,Phase 2,66,Fatigue,Hepatobiliary disorders,No,Moderate,66,7,7,10.61,No,,13,116,No,Yes,Dose reduction,21,51
NCT70043134,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 4,140,Pneumonitis,Hepatobiliary disorders,No,Severe,140,37,41,26.43,No,,2,266,Yes,Yes,Supportive care,5,58
NCT59438556,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 3,180,Infusion-related reaction,Blood disorders,No,Mild,180,7,11,3.89,No,,17,359,Yes,Yes,Discontinuation,6,32
NCT59662044,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,428,Colitis,Hepatobiliary disorders,No,Mild,428,26,31,6.07,No,,3,249,Yes,Yes,Supportive care,21,71
NCT31541248,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,45,Neutropenia,Hepatobiliary disorders,No,Moderate,45,6,8,13.33,No,,11,204,No,No,Treatment interruption,10,66
NCT54505669,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,286,Fatigue,Respiratory disorders,Yes,Moderate,286,75,79,26.22,No,,2,362,No,No,Supportive care,24,47
NCT90868233,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 2,271,Cardiotoxicity,Gastrointestinal disorders,No,Moderate,271,73,78,26.94,No,,7,174,No,No,Supportive care,26,53
NCT11925096,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 1,170,Hyperthyroidism,Hepatobiliary disorders,No,Severe,170,6,7,3.53,No,,12,85,No,No,Discontinuation,24,85
NCT49391835,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,178,Hypothyroidism,Respiratory disorders,Yes,Severe,178,28,31,15.73,Yes,Competition,13,247,No,Yes,Supportive care,14,64
NCT61205678,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,250,Hypothyroidism,Cardiac disorders,Yes,Moderate,250,10,14,4.0,No,,16,302,No,Yes,Dose reduction,27,41
NCT92614713,Avelumab,Anti-PD-L1,Melanoma,Phase 2,425,Anemia,Gastrointestinal disorders,No,Moderate,425,111,111,26.12,No,,6,37,Yes,No,Treatment interruption,26,75
NCT19898735,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,325,Nausea,Endocrine disorders,Yes,Severe,325,77,81,23.69,Yes,Lack of efficacy,12,124,Yes,No,Dose reduction,20,39
NCT96166387,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 3,285,Nausea,Gastrointestinal disorders,Yes,Mild,285,79,83,27.72,No,,16,155,Yes,Yes,Discontinuation,20,55
NCT89722477,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 1,156,Hepatotoxicity,Gastrointestinal disorders,Yes,Moderate,156,46,49,29.49,No,,13,177,No,Yes,Treatment interruption,3,10
NCT56977624,Avelumab,Anti-PD-L1,Melanoma,Phase 1,348,Colitis,Hepatobiliary disorders,No,Mild,348,39,44,11.21,No,,16,343,Yes,No,Discontinuation,8,36
NCT62153847,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,292,Pneumonitis,Musculoskeletal disorders,No,Mild,292,16,19,5.48,Yes,Lack of efficacy,13,154,Yes,No,Supportive care,2,88
NCT94697658,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,117,Colitis,Blood disorders,No,Moderate,117,14,14,11.97,No,,8,343,Yes,Yes,Supportive care,28,69
NCT44224084,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 4,338,Rash,Musculoskeletal disorders,Yes,Moderate,338,45,47,13.31,Yes,Regulatory issues,4,238,Yes,Yes,Treatment interruption,2,75
NCT15272689,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,238,Fatigue,General disorders,No,Mild,238,58,59,24.37,No,,12,321,No,No,Discontinuation,25,11
NCT87085201,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,355,Infusion-related reaction,Gastrointestinal disorders,Yes,Moderate,355,48,53,13.52,No,,7,208,No,No,Dose reduction,15,19
NCT19412021,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,25,Fatigue,Blood disorders,No,Severe,25,2,5,8.0,No,,5,166,Yes,No,Treatment interruption,13,31
NCT79791282,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 3,124,Diarrhea,Hepatobiliary disorders,No,Mild,124,35,35,28.23,No,,9,141,Yes,Yes,Treatment interruption,11,14
NCT18211132,Avelumab,Anti-PD-L1,Multiple Sclerosis,Phase 2,232,Fatigue,Hepatobiliary disorders,Yes,Severe,232,36,41,15.52,Yes,Lack of efficacy,14,351,No,Yes,Supportive care,1,12
NCT98327268,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 3,303,Hepatotoxicity,Endocrine disorders,No,Mild,303,61,65,20.13,No,,5,60,No,No,Supportive care,4,16
NCT47177086,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,318,Cardiotoxicity,Musculoskeletal disorders,Yes,Severe,318,43,48,13.52,Yes,Lack of efficacy,5,344,Yes,No,Supportive care,16,9
NCT42408188,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,418,Cardiotoxicity,General disorders,No,Moderate,418,42,43,10.05,No,,4,257,Yes,No,Discontinuation,10,22
NCT21464306,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,409,Anemia,Gastrointestinal disorders,No,Mild,409,10,10,2.44,No,,5,181,Yes,Yes,Treatment interruption,3,13
NCT94583006,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 1,73,Colitis,Respiratory disorders,No,Mild,73,4,7,5.48,No,,11,261,Yes,Yes,Discontinuation,5,5
NCT55640053,Avelumab,Anti-PD-L1,Melanoma,Phase 3,189,Cardiotoxicity,Musculoskeletal disorders,Yes,Severe,189,52,56,27.51,No,,3,68,Yes,Yes,Treatment interruption,10,77
NCT63674150,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 1,30,Hyperthyroidism,Hepatobiliary disorders,No,Moderate,30,6,6,20.0,No,,14,153,Yes,No,Dose reduction,18,2
NCT24162689,Avelumab,Anti-PD-L1,Melanoma,Phase 2,450,Cardiotoxicity,Respiratory disorders,No,Severe,450,96,100,21.33,Yes,Competition,13,158,Yes,No,Dose reduction,17,53
NCT52788504,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 3,367,Hypothyroidism,General disorders,No,Severe,367,35,39,9.54,No,,3,194,Yes,Yes,Supportive care,26,19
NCT42637630,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,243,Infusion-related reaction,Cardiac disorders,No,Severe,243,37,40,15.23,Yes,Competition,8,303,No,No,Discontinuation,9,8
NCT79786426,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 2,369,Fatigue,Hepatobiliary disorders,No,Mild,369,107,107,29.0,Yes,Competition,8,38,No,No,Treatment interruption,29,31
NCT26520156,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 2,259,Neutropenia,Gastrointestinal disorders,Yes,Mild,259,32,34,12.36,No,,4,135,Yes,Yes,Supportive care,4,45
NCT52579359,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 4,179,Hyperthyroidism,Musculoskeletal disorders,No,Mild,179,16,18,8.94,No,,10,114,Yes,Yes,Treatment interruption,19,13
NCT36033216,Avelumab,Anti-PD-L1,Melanoma,Phase 3,403,Infusion-related reaction,Endocrine disorders,No,Mild,403,98,103,24.32,No,,2,133,No,No,Treatment interruption,4,5
NCT54395145,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,83,Pneumonitis,Endocrine disorders,No,Moderate,83,17,22,20.48,No,,14,250,No,No,Treatment interruption,17,9
NCT30066136,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,496,Pneumonitis,Respiratory disorders,Yes,Severe,496,12,13,2.42,Yes,Competition,19,272,Yes,No,Discontinuation,9,28
NCT48983391,Avelumab,Anti-PD-L1,Melanoma,Phase 4,120,Pneumonitis,Respiratory disorders,No,Moderate,120,14,15,11.67,No,,9,160,Yes,Yes,Supportive care,6,65
NCT15558817,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 2,192,Infusion-related reaction,Musculoskeletal disorders,No,Mild,192,31,35,16.15,No,,11,252,Yes,No,Discontinuation,18,86
NCT14108834,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 1,310,Anemia,Hepatobiliary disorders,No,Moderate,310,65,70,20.97,No,,17,179,No,Yes,Treatment interruption,21,43
NCT84503041,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 2,180,Hepatotoxicity,Cardiac disorders,No,Moderate,180,28,30,15.56,No,,15,207,Yes,No,Dose reduction,30,56
NCT35921219,Avelumab,Anti-PD-L1,Non-Hodgkin Lymphoma,Phase 1,257,Colitis,Skin disorders,No,Moderate,257,68,69,26.46,No,,4,184,No,No,Dose reduction,21,29
NCT65605336,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,387,Anemia,Endocrine disorders,Yes,Moderate,387,54,58,13.95,No,,16,316,No,No,Treatment interruption,20,39
NCT14516845,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,48,Rash,Blood disorders,No,Moderate,48,3,3,6.25,No,,19,195,No,No,Treatment interruption,27,82
NCT21119566,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,246,Hepatotoxicity,Gastrointestinal disorders,No,Severe,246,53,53,21.54,Yes,Competition,17,48,No,No,Treatment interruption,27,2
NCT26912471,Avelumab,Anti-PD-L1,Melanoma,Phase 4,338,Cardiotoxicity,Cardiac disorders,No,Moderate,338,81,84,23.96,No,,7,326,Yes,No,Discontinuation,12,56
NCT76916460,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,284,Cardiotoxicity,General disorders,No,Severe,284,72,74,25.35,No,,8,187,No,Yes,Supportive care,20,75
NCT67191462,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,131,Pneumonitis,General disorders,No,Mild,131,19,21,14.5,No,,9,237,Yes,No,Dose reduction,7,51
NCT93688773,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 4,80,Diarrhea,Musculoskeletal disorders,Yes,Mild,80,19,19,23.75,No,,7,86,No,Yes,Discontinuation,29,75
NCT48861141,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 4,162,Fatigue,Cardiac disorders,No,Mild,162,33,36,20.37,No,,11,313,No,Yes,Discontinuation,25,57
NCT34745991,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 2,215,Nausea,Blood disorders,No,Moderate,215,24,28,11.16,No,,14,130,Yes,Yes,Discontinuation,10,1
NCT12183390,Avelumab,Anti-PD-L1,Rheumatoid Arthritis,Phase 3,296,Nausea,Gastrointestinal disorders,No,Mild,296,19,23,6.42,No,,4,98,No,No,Dose reduction,3,70
NCT25097988,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,213,Thrombocytopenia,Gastrointestinal disorders,No,Mild,213,27,32,12.68,No,,11,197,Yes,No,Dose reduction,26,67
NCT79863772,Avelumab,Anti-PD-L1,Multiple Sclerosis,Phase 1,37,Arthralgia,Hepatobiliary disorders,No,Mild,37,3,8,8.11,No,,8,42,Yes,No,Supportive care,10,34
NCT31953407,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,379,Neutropenia,Endocrine disorders,No,Severe,379,83,83,21.9,No,,11,215,Yes,Yes,Discontinuation,18,1
NCT38330072,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 2,361,Hyperthyroidism,Musculoskeletal disorders,No,Mild,361,91,94,25.21,No,,19,65,No,No,Treatment interruption,6,72
NCT77410415,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,267,Cardiotoxicity,Endocrine disorders,No,Moderate,267,24,29,8.99,No,,4,188,Yes,No,Dose reduction,9,4
NCT80147546,Avelumab,Anti-PD-L1,Colorectal Cancer,Phase 2,356,Nausea,Cardiac disorders,No,Mild,356,101,105,28.37,No,,4,350,No,No,Dose reduction,2,1
NCT36562337,Avelumab,Anti-PD-L1,Multiple Myeloma,Phase 4,87,Thrombocytopenia,Blood disorders,No,Mild,87,15,19,17.24,No,,18,139,Yes,Yes,Treatment interruption,16,70
NCT80423476,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 2,53,Thrombocytopenia,Gastrointestinal disorders,No,Moderate,53,2,5,3.77,Yes,Regulatory issues,5,197,Yes,No,Discontinuation,29,44
NCT93757565,Bevacizumab,Anti-VEGF,Melanoma,Phase 1,360,Cardiotoxicity,Endocrine disorders,No,Mild,360,79,84,21.94,No,,20,240,Yes,No,Treatment interruption,16,37
NCT85396031,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,390,Diarrhea,Skin disorders,No,Moderate,390,39,40,10.0,Yes,Competition,19,106,Yes,No,Supportive care,5,46
NCT46054122,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,377,Hypothyroidism,Cardiac disorders,Yes,Severe,377,69,69,18.3,Yes,Regulatory issues,15,107,Yes,No,Discontinuation,24,16
NCT32791003,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,161,Infusion-related reaction,Blood disorders,No,Severe,161,35,37,21.74,No,,8,214,No,No,Dose reduction,25,10
NCT47367771,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,44,Nausea,Gastrointestinal disorders,No,Severe,44,13,17,29.55,Yes,Competition,6,301,Yes,No,Supportive care,22,66
NCT69267420,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 4,365,Pneumonitis,Musculoskeletal disorders,No,Mild,365,44,49,12.05,No,,3,343,No,Yes,Dose reduction,20,15
NCT41379644,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 1,396,Diarrhea,General disorders,Yes,Mild,396,31,33,7.83,No,,6,223,No,No,Treatment interruption,6,13
NCT55328600,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,448,Thrombocytopenia,Skin disorders,No,Mild,448,1,6,0.22,No,,17,38,No,No,Dose reduction,15,75
NCT68238864,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 3,497,Neutropenia,Respiratory disorders,No,Moderate,497,55,57,11.07,No,,16,362,Yes,No,Supportive care,7,28
NCT99539569,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 2,188,Rash,Gastrointestinal disorders,Yes,Severe,188,49,50,26.06,No,,4,121,Yes,Yes,Dose reduction,5,83
NCT58827719,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 1,258,Colitis,Hepatobiliary disorders,No,Mild,258,60,65,23.26,No,,1,353,No,No,Supportive care,25,42
NCT84895455,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 1,499,Hyperthyroidism,Blood disorders,No,Mild,499,103,103,20.64,No,,8,225,Yes,Yes,Treatment interruption,3,11
NCT43614234,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 3,93,Fatigue,Gastrointestinal disorders,No,Severe,93,21,21,22.58,No,,10,326,Yes,No,Discontinuation,21,39
NCT34717158,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,82,Anemia,Endocrine disorders,No,Moderate,82,9,10,10.98,No,,6,196,No,No,Discontinuation,23,90
NCT56515294,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 2,99,Infusion-related reaction,Hepatobiliary disorders,No,Severe,99,12,12,12.12,No,,15,73,No,Yes,Treatment interruption,12,18
NCT93774266,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,433,Hypothyroidism,Gastrointestinal disorders,No,Mild,433,112,113,25.87,No,,2,96,No,Yes,Dose reduction,13,3
NCT19011398,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,151,Rash,Blood disorders,Yes,Moderate,151,31,31,20.53,No,,15,172,No,No,Treatment interruption,15,56
NCT16628893,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 4,38,Hypothyroidism,Cardiac disorders,No,Mild,38,8,12,21.05,No,,18,341,Yes,No,Discontinuation,19,16
NCT64152104,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 3,39,Neutropenia,Skin disorders,No,Mild,39,8,11,20.51,No,,12,156,No,No,Dose reduction,6,90
NCT85283215,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,110,Fatigue,Hepatobiliary disorders,No,Moderate,110,16,16,14.55,No,,14,232,No,Yes,Supportive care,4,90
NCT11196377,Bevacizumab,Anti-VEGF,Melanoma,Phase 2,181,Fatigue,Blood disorders,No,Moderate,181,14,14,7.73,No,,15,239,Yes,Yes,Dose reduction,27,24
NCT65224817,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,104,Pneumonitis,Cardiac disorders,No,Mild,104,2,7,1.92,No,,6,78,Yes,No,Dose reduction,23,29
NCT65528201,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 2,477,Hypothyroidism,Skin disorders,Yes,Mild,477,62,65,13.0,No,,19,35,Yes,Yes,Discontinuation,11,2
NCT13342225,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,226,Thrombocytopenia,Gastrointestinal disorders,Yes,Moderate,226,21,22,9.29,No,,18,315,No,No,Dose reduction,15,15
NCT61292669,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 2,169,Rash,Endocrine disorders,No,Mild,169,30,32,17.75,No,,3,307,No,No,Supportive care,1,84
NCT80338191,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 1,316,Thrombocytopenia,Hepatobiliary disorders,Yes,Severe,316,65,67,20.57,Yes,Lack of efficacy,7,363,No,No,Discontinuation,25,49
NCT79416862,Bevacizumab,Anti-VEGF,Melanoma,Phase 3,340,Nausea,Endocrine disorders,No,Mild,340,12,13,3.53,No,,12,219,Yes,No,Dose reduction,4,83
NCT75922823,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 4,298,Diarrhea,Hepatobiliary disorders,No,Severe,298,59,64,19.8,Yes,Lack of efficacy,16,86,No,Yes,Supportive care,28,76
NCT52438687,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 2,349,Fatigue,Musculoskeletal disorders,No,Moderate,349,59,63,16.91,No,,5,144,No,No,Treatment interruption,4,70
NCT75785915,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 2,343,Hyperthyroidism,Musculoskeletal disorders,Yes,Mild,343,80,81,23.32,No,,1,136,Yes,No,Treatment interruption,12,61
NCT99411809,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,116,Hepatotoxicity,General disorders,No,Moderate,116,9,9,7.76,No,,1,235,No,Yes,Discontinuation,23,8
NCT34255392,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 1,458,Hyperthyroidism,Cardiac disorders,No,Severe,458,39,43,8.52,Yes,Lack of efficacy,11,65,No,Yes,Dose reduction,14,7
NCT49902764,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,201,Hepatotoxicity,Gastrointestinal disorders,Yes,Moderate,201,16,20,7.96,No,,17,93,No,No,Supportive care,19,50
NCT71849452,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 3,423,Diarrhea,Blood disorders,Yes,Severe,423,101,102,23.88,Yes,Safety concerns,7,306,No,Yes,Discontinuation,14,16
NCT20378274,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 2,407,Arthralgia,Respiratory disorders,Yes,Severe,407,24,28,5.9,No,,2,82,No,Yes,Dose reduction,21,84
NCT91124510,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,248,Nausea,Blood disorders,No,Severe,248,15,17,6.05,No,,11,32,Yes,Yes,Dose reduction,29,87
NCT57640502,Bevacizumab,Anti-VEGF,Melanoma,Phase 1,78,Neutropenia,Endocrine disorders,No,Moderate,78,15,17,19.23,No,,17,99,Yes,No,Discontinuation,21,40
NCT26283037,Bevacizumab,Anti-VEGF,Breast Cancer,Phase 3,159,Nausea,Endocrine disorders,No,Mild,159,5,10,3.14,No,,20,330,Yes,No,Dose reduction,29,13
NCT89759826,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 1,191,Pneumonitis,Hepatobiliary disorders,No,Mild,191,53,58,27.75,No,,16,216,Yes,Yes,Supportive care,9,43
NCT57477828,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 1,191,Diarrhea,Endocrine disorders,No,Mild,191,39,44,20.42,No,,5,352,Yes,Yes,Dose reduction,22,22
NCT19849597,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,248,Arthralgia,General disorders,No,Moderate,248,29,32,11.69,No,,2,134,Yes,Yes,Discontinuation,15,51
NCT31947749,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 4,144,Hypothyroidism,Cardiac disorders,No,Moderate,144,21,25,14.58,No,,6,173,Yes,Yes,Supportive care,24,14
NCT69297600,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,334,Pneumonitis,Gastrointestinal disorders,Yes,Mild,334,94,96,28.14,Yes,Regulatory issues,20,336,No,Yes,Dose reduction,14,49
NCT50677056,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 1,59,Nausea,Endocrine disorders,No,Mild,59,7,10,11.86,No,,14,104,No,Yes,Dose reduction,4,27
NCT33261615,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 4,383,Pneumonitis,Endocrine disorders,No,Severe,383,57,62,14.88,No,,15,217,No,No,Dose reduction,29,76
NCT91815578,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,407,Hepatotoxicity,Cardiac disorders,No,Mild,407,48,52,11.79,No,,13,110,No,No,Treatment interruption,24,83
NCT32163477,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,349,Rash,Hepatobiliary disorders,No,Severe,349,19,22,5.44,Yes,Regulatory issues,12,160,No,No,Treatment interruption,9,48
NCT50200358,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 4,274,Cardiotoxicity,Blood disorders,No,Mild,274,25,28,9.12,No,,5,85,Yes,Yes,Treatment interruption,30,2
NCT80893413,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 2,113,Pneumonitis,Gastrointestinal disorders,No,Severe,113,19,23,16.81,No,,20,284,Yes,No,Treatment interruption,5,38
NCT34389384,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,434,Cardiotoxicity,Blood disorders,No,Severe,434,44,45,10.14,No,,14,344,Yes,Yes,Treatment interruption,2,75
NCT43049408,Bevacizumab,Anti-VEGF,Melanoma,Phase 1,339,Colitis,Blood disorders,No,Mild,339,17,19,5.01,No,,15,348,Yes,Yes,Supportive care,16,73
NCT11249192,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 1,274,Nausea,Skin disorders,No,Severe,274,74,78,27.01,No,,1,66,Yes,No,Discontinuation,2,69
NCT44131471,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 1,280,Hypothyroidism,Blood disorders,No,Mild,280,31,35,11.07,No,,15,245,No,No,Supportive care,28,15
NCT68292997,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,487,Colitis,Cardiac disorders,No,Moderate,487,57,60,11.7,No,,3,157,No,No,Treatment interruption,5,24
NCT16907279,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 4,212,Diarrhea,General disorders,No,Severe,212,60,62,28.3,No,,17,208,Yes,No,Supportive care,19,33
NCT72472125,Bevacizumab,Anti-VEGF,Melanoma,Phase 3,151,Neutropenia,Respiratory disorders,No,Moderate,151,18,18,11.92,No,,9,258,Yes,Yes,Supportive care,6,65
NCT85229808,Bevacizumab,Anti-VEGF,Melanoma,Phase 1,219,Infusion-related reaction,Endocrine disorders,Yes,Severe,219,62,65,28.31,No,,1,302,Yes,No,Supportive care,10,14
NCT82967613,Bevacizumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,466,Infusion-related reaction,Hepatobiliary disorders,Yes,Moderate,466,72,73,15.45,Yes,Lack of efficacy,16,38,Yes,Yes,Treatment interruption,9,81
NCT54770748,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 2,331,Nausea,Skin disorders,No,Mild,331,77,78,23.26,No,,18,104,No,No,Discontinuation,11,77
NCT41481788,Bevacizumab,Anti-VEGF,Multiple Sclerosis,Phase 2,191,Nausea,Gastrointestinal disorders,Yes,Moderate,191,24,24,12.57,Yes,Lack of efficacy,1,215,No,No,Treatment interruption,22,43
NCT64650096,Bevacizumab,Anti-VEGF,Multiple Myeloma,Phase 4,98,Anemia,Endocrine disorders,No,Severe,98,3,3,3.06,Yes,Safety concerns,9,64,Yes,Yes,Dose reduction,2,35
NCT43885103,Bevacizumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 1,500,Pneumonitis,Cardiac disorders,No,Mild,500,13,13,2.6,No,,5,142,Yes,Yes,Dose reduction,25,40
NCT52342129,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 4,174,Cardiotoxicity,Hepatobiliary disorders,No,Mild,174,47,50,27.01,No,,17,167,No,Yes,Dose reduction,28,18
NCT77427729,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 1,359,Pneumonitis,Musculoskeletal disorders,No,Moderate,359,4,8,1.11,No,,14,280,Yes,Yes,Treatment interruption,2,64
NCT26890506,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 1,64,Cardiotoxicity,Endocrine disorders,No,Mild,64,12,13,18.75,No,,17,244,Yes,Yes,Treatment interruption,12,6
NCT68936461,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 2,187,Thrombocytopenia,Cardiac disorders,No,Severe,187,37,42,19.79,Yes,Lack of efficacy,5,156,Yes,No,Supportive care,30,19
NCT85462322,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 2,390,Arthralgia,General disorders,No,Severe,390,92,92,23.59,No,,12,128,Yes,Yes,Discontinuation,13,52
NCT70383149,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,40,Hypothyroidism,General disorders,Yes,Severe,40,10,13,25.0,Yes,Competition,6,256,Yes,Yes,Discontinuation,27,28
NCT41938444,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 1,389,Arthralgia,Blood disorders,Yes,Severe,389,108,113,27.76,Yes,Competition,2,32,Yes,No,Dose reduction,12,17
NCT11635016,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 2,291,Neutropenia,General disorders,No,Mild,291,26,27,8.93,No,,11,290,Yes,Yes,Dose reduction,21,72
NCT59669344,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 2,253,Rash,Gastrointestinal disorders,No,Severe,253,37,39,14.62,No,,4,272,Yes,No,Dose reduction,12,48
NCT31941470,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 3,118,Diarrhea,Cardiac disorders,No,Severe,118,10,14,8.47,Yes,Regulatory issues,15,301,Yes,Yes,Discontinuation,5,7
NCT84955695,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 1,202,Hyperthyroidism,Blood disorders,Yes,Mild,202,27,31,13.37,No,,5,71,No,Yes,Discontinuation,3,38
NCT29860266,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,421,Colitis,Cardiac disorders,No,Moderate,421,94,98,22.33,No,,9,360,Yes,Yes,Treatment interruption,8,30
NCT12653266,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 1,395,Thrombocytopenia,Hepatobiliary disorders,No,Mild,395,45,49,11.39,No,,19,245,Yes,Yes,Treatment interruption,5,77
NCT85493594,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 1,388,Anemia,Respiratory disorders,No,Moderate,388,83,87,21.39,No,,6,87,Yes,No,Treatment interruption,13,17
NCT58839622,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 2,378,Diarrhea,General disorders,No,Severe,378,10,15,2.65,No,,12,282,Yes,Yes,Treatment interruption,2,6
NCT84731888,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,96,Infusion-related reaction,Respiratory disorders,No,Mild,96,10,10,10.42,No,,4,229,No,No,Supportive care,2,14
NCT96724069,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,227,Anemia,Hepatobiliary disorders,No,Severe,227,15,19,6.61,No,,10,53,Yes,Yes,Supportive care,21,74
NCT94356226,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 1,47,Hepatotoxicity,General disorders,No,Severe,47,12,15,25.53,No,,9,30,Yes,Yes,Treatment interruption,14,32
NCT12022678,Ramucirumab,Anti-VEGF,Melanoma,Phase 2,245,Arthralgia,Respiratory disorders,No,Moderate,245,47,48,19.18,No,,3,109,Yes,No,Supportive care,12,31
NCT41811159,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 1,147,Cardiotoxicity,Skin disorders,No,Moderate,147,43,44,29.25,Yes,Lack of efficacy,18,159,Yes,Yes,Treatment interruption,15,47
NCT86262098,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 3,314,Thrombocytopenia,Endocrine disorders,No,Mild,314,19,24,6.05,No,,2,155,Yes,Yes,Supportive care,17,14
NCT76869771,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 3,349,Infusion-related reaction,General disorders,No,Moderate,349,29,29,8.31,No,,20,360,Yes,No,Supportive care,23,72
NCT81125469,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 3,164,Arthralgia,Endocrine disorders,No,Mild,164,22,22,13.41,No,,20,92,Yes,No,Dose reduction,6,78
NCT44794473,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 4,272,Cardiotoxicity,Cardiac disorders,No,Severe,272,6,7,2.21,No,,9,300,Yes,No,Supportive care,5,17
NCT61543141,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,25,Pneumonitis,Blood disorders,No,Mild,25,4,6,16.0,No,,1,167,No,Yes,Discontinuation,4,53
NCT99195168,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 2,449,Arthralgia,Blood disorders,No,Mild,449,130,131,28.95,No,,18,88,No,No,Dose reduction,17,9
NCT13419233,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 4,289,Anemia,General disorders,No,Severe,289,41,43,14.19,No,,16,357,Yes,Yes,Supportive care,6,6
NCT87866841,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,39,Arthralgia,Gastrointestinal disorders,No,Mild,39,8,13,20.51,No,,18,111,No,Yes,Discontinuation,19,70
NCT30211136,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 2,288,Hypothyroidism,Musculoskeletal disorders,No,Moderate,288,45,46,15.62,No,,8,350,No,Yes,Discontinuation,5,30
NCT43593843,Ramucirumab,Anti-VEGF,Melanoma,Phase 4,402,Hypothyroidism,General disorders,No,Mild,402,119,121,29.6,No,,11,351,Yes,No,Discontinuation,18,79
NCT97934978,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 1,165,Fatigue,Gastrointestinal disorders,Yes,Moderate,165,22,24,13.33,No,,18,312,No,No,Discontinuation,11,84
NCT99568867,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 4,364,Neutropenia,Blood disorders,No,Severe,364,38,39,10.44,No,,8,239,Yes,No,Discontinuation,19,60
NCT99329532,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 2,304,Colitis,Endocrine disorders,Yes,Mild,304,34,38,11.18,No,,8,196,No,No,Supportive care,8,6
NCT37773214,Ramucirumab,Anti-VEGF,Melanoma,Phase 3,278,Thrombocytopenia,General disorders,No,Moderate,278,66,68,23.74,No,,7,112,No,Yes,Dose reduction,21,20
NCT52206029,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,195,Arthralgia,Respiratory disorders,No,Severe,195,24,26,12.31,Yes,Lack of efficacy,13,123,No,Yes,Discontinuation,6,43
NCT85248747,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 1,27,Hyperthyroidism,Skin disorders,No,Mild,27,2,5,7.41,No,,20,98,No,Yes,Treatment interruption,28,18
NCT66824829,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 2,205,Hypothyroidism,Endocrine disorders,No,Mild,205,58,61,28.29,No,,20,266,No,No,Treatment interruption,9,45
NCT45261317,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,249,Anemia,Musculoskeletal disorders,Yes,Mild,249,22,27,8.84,No,,3,174,No,Yes,Supportive care,16,54
NCT64631771,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 2,252,Cardiotoxicity,Blood disorders,No,Moderate,252,25,28,9.92,No,,17,250,Yes,No,Discontinuation,14,83
NCT11059741,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 2,324,Neutropenia,Blood disorders,No,Moderate,324,85,89,26.23,No,,18,145,Yes,Yes,Discontinuation,7,62
NCT12281355,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 1,165,Anemia,Skin disorders,Yes,Mild,165,2,4,1.21,No,,20,208,No,Yes,Supportive care,11,16
NCT54869201,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 3,454,Cardiotoxicity,General disorders,No,Mild,454,54,57,11.89,No,,14,347,No,No,Treatment interruption,2,57
NCT43107529,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 3,338,Hepatotoxicity,Skin disorders,No,Mild,338,60,64,17.75,No,,3,303,Yes,No,Dose reduction,18,5
NCT89085107,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 4,111,Hyperthyroidism,General disorders,No,Severe,111,32,35,28.83,Yes,Lack of efficacy,11,34,Yes,Yes,Treatment interruption,13,83
NCT51129855,Ramucirumab,Anti-VEGF,Melanoma,Phase 4,120,Infusion-related reaction,Skin disorders,No,Mild,120,7,12,5.83,No,,19,104,No,No,Discontinuation,23,80
NCT18571864,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 2,284,Infusion-related reaction,Skin disorders,No,Severe,284,10,11,3.52,No,,5,184,Yes,No,Discontinuation,1,90
NCT81415586,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 4,290,Cardiotoxicity,Hepatobiliary disorders,No,Mild,290,30,35,10.34,No,,20,101,Yes,No,Dose reduction,28,35
NCT42200386,Ramucirumab,Anti-VEGF,Melanoma,Phase 3,379,Pneumonitis,Skin disorders,No,Moderate,379,75,75,19.79,No,,11,226,No,No,Discontinuation,28,78
NCT15062813,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 1,482,Cardiotoxicity,Cardiac disorders,No,Moderate,482,119,121,24.69,No,,8,73,No,Yes,Supportive care,23,46
NCT62194369,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 1,476,Thrombocytopenia,Hepatobiliary disorders,No,Severe,476,42,43,8.82,No,,18,293,No,Yes,Discontinuation,16,13
NCT31184567,Ramucirumab,Anti-VEGF,Melanoma,Phase 4,469,Pneumonitis,Skin disorders,No,Moderate,469,17,19,3.62,No,,14,237,No,Yes,Treatment interruption,24,19
NCT63853420,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 3,348,Fatigue,Respiratory disorders,No,Severe,348,25,29,7.18,No,,14,272,No,No,Discontinuation,3,12
NCT20048912,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 1,419,Pneumonitis,Musculoskeletal disorders,No,Moderate,419,84,87,20.05,No,,1,82,No,Yes,Discontinuation,29,16
NCT82347789,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 1,263,Diarrhea,General disorders,No,Mild,263,8,9,3.04,No,,15,215,No,Yes,Discontinuation,23,6
NCT28964221,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 2,261,Nausea,Blood disorders,Yes,Mild,261,34,35,13.03,No,,20,211,Yes,Yes,Discontinuation,24,89
NCT43067427,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 2,244,Hypothyroidism,Blood disorders,No,Mild,244,13,15,5.33,No,,14,110,Yes,No,Discontinuation,22,2
NCT55076860,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 4,460,Anemia,Musculoskeletal disorders,No,Mild,460,18,21,3.91,No,,14,365,No,Yes,Discontinuation,15,85
NCT21929705,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 3,191,Fatigue,Respiratory disorders,No,Mild,191,9,14,4.71,No,,17,211,No,No,Treatment interruption,20,13
NCT86423068,Ramucirumab,Anti-VEGF,Melanoma,Phase 1,216,Rash,Hepatobiliary disorders,No,Moderate,216,11,15,5.09,Yes,Regulatory issues,17,206,No,Yes,Discontinuation,9,56
NCT82765857,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 4,116,Hepatotoxicity,General disorders,No,Severe,116,31,34,26.72,Yes,Competition,14,88,No,Yes,Dose reduction,3,29
NCT86793098,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 1,347,Colitis,Cardiac disorders,No,Moderate,347,1,4,0.29,No,,12,94,No,Yes,Supportive care,7,88
NCT92997033,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 1,298,Colitis,Gastrointestinal disorders,No,Mild,298,22,25,7.38,No,,3,258,No,No,Discontinuation,7,18
NCT14681342,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 4,384,Hyperthyroidism,Cardiac disorders,No,Moderate,384,112,117,29.17,No,,14,281,Yes,Yes,Treatment interruption,19,3
NCT43875572,Ramucirumab,Anti-VEGF,Lung Cancer,Phase 1,311,Fatigue,Hepatobiliary disorders,No,Mild,311,27,29,8.68,No,,13,143,No,No,Discontinuation,23,32
NCT40036810,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 1,278,Arthralgia,Blood disorders,No,Mild,278,4,6,1.44,No,,5,179,No,No,Treatment interruption,25,56
NCT58371140,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 1,458,Diarrhea,Gastrointestinal disorders,No,Severe,458,124,128,27.07,No,,11,83,No,No,Supportive care,21,78
NCT75764945,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 1,376,Hypothyroidism,Cardiac disorders,No,Moderate,376,106,111,28.19,No,,10,143,Yes,No,Dose reduction,17,77
NCT75061710,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 2,53,Hyperthyroidism,Hepatobiliary disorders,No,Moderate,53,11,14,20.75,No,,14,345,Yes,No,Dose reduction,5,48
NCT69191721,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 2,354,Neutropenia,Skin disorders,No,Mild,354,5,7,1.41,No,,13,240,Yes,No,Supportive care,16,24
NCT22396277,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 4,410,Thrombocytopenia,Hepatobiliary disorders,Yes,Severe,410,58,60,14.15,Yes,Safety concerns,6,224,No,Yes,Treatment interruption,13,55
NCT89900678,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,88,Colitis,Hepatobiliary disorders,No,Severe,88,15,18,17.05,No,,5,310,Yes,Yes,Discontinuation,12,75
NCT15081422,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 4,124,Diarrhea,Respiratory disorders,No,Mild,124,31,31,25.0,No,,1,209,Yes,No,Supportive care,2,63
NCT58639431,Ramucirumab,Anti-VEGF,Multiple Myeloma,Phase 3,262,Arthralgia,General disorders,No,Severe,262,19,21,7.25,No,,3,183,Yes,Yes,Supportive care,28,64
NCT92308897,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 1,371,Hyperthyroidism,Blood disorders,No,Moderate,371,21,25,5.66,No,,20,144,No,Yes,Supportive care,9,14
NCT52110513,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 4,417,Anemia,General disorders,No,Mild,417,63,65,15.11,No,,17,165,No,Yes,Discontinuation,27,33
NCT34337607,Ramucirumab,Anti-VEGF,Breast Cancer,Phase 4,93,Hyperthyroidism,Endocrine disorders,No,Moderate,93,25,26,26.88,No,,10,190,Yes,No,Treatment interruption,9,70
NCT32632349,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 3,167,Arthralgia,Gastrointestinal disorders,No,Moderate,167,37,40,22.16,Yes,Regulatory issues,13,294,No,Yes,Treatment interruption,20,33
NCT44083830,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 4,337,Anemia,Respiratory disorders,No,Severe,337,12,17,3.56,Yes,Lack of efficacy,6,324,Yes,Yes,Treatment interruption,16,30
NCT58896739,Ramucirumab,Anti-VEGF,Melanoma,Phase 1,317,Arthralgia,Endocrine disorders,No,Moderate,317,71,74,22.4,No,,13,268,No,No,Treatment interruption,25,77
NCT28066525,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 4,186,Hypothyroidism,Hepatobiliary disorders,No,Mild,186,8,9,4.3,No,,3,102,No,Yes,Dose reduction,3,38
NCT60877757,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 4,306,Fatigue,Cardiac disorders,No,Severe,306,1,2,0.33,Yes,Competition,4,362,Yes,No,Dose reduction,2,4
NCT49918927,Ramucirumab,Anti-VEGF,Non-Hodgkin Lymphoma,Phase 3,187,Arthralgia,Respiratory disorders,No,Mild,187,39,41,20.86,No,,18,49,No,No,Discontinuation,11,23
NCT47044805,Ramucirumab,Anti-VEGF,Colorectal Cancer,Phase 4,395,Hypothyroidism,Skin disorders,No,Mild,395,68,69,17.22,No,,5,175,Yes,No,Treatment interruption,16,42
NCT21805943,Ramucirumab,Anti-VEGF,Multiple Sclerosis,Phase 3,184,Thrombocytopenia,General disorders,No,Mild,184,52,53,28.26,No,,15,286,Yes,Yes,Discontinuation,16,60
NCT22572437,Ramucirumab,Anti-VEGF,Rheumatoid Arthritis,Phase 3,124,Hepatotoxicity,Skin disorders,No,Moderate,124,23,25,18.55,No,,20,43,No,No,Dose reduction,29,44
NCT22887864,Cetuximab,Anti-EGFR,Breast Cancer,Phase 3,359,Rash,Skin disorders,No,Mild,359,46,46,12.81,No,,2,262,No,No,Supportive care,22,79
NCT38053835,Cetuximab,Anti-EGFR,Melanoma,Phase 3,460,Hypothyroidism,Endocrine disorders,No,Severe,460,85,88,18.48,No,,4,267,Yes,Yes,Supportive care,26,50
NCT36594397,Cetuximab,Anti-EGFR,Rheumatoid Arthritis,Phase 2,397,Thrombocytopenia,Hepatobiliary disorders,No,Mild,397,70,71,17.63,No,,20,358,Yes,No,Supportive care,24,23
NCT70714289,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 3,414,Arthralgia,Musculoskeletal disorders,Yes,Mild,414,42,45,10.14,No,,14,295,No,No,Treatment interruption,22,5
NCT68214106,Cetuximab,Anti-EGFR,Breast Cancer,Phase 2,260,Neutropenia,Skin disorders,Yes,Mild,260,64,69,24.62,No,,20,187,Yes,No,Supportive care,30,48
NCT21300996,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,81,Diarrhea,Blood disorders,No,Mild,81,2,7,2.47,No,,1,115,Yes,No,Supportive care,17,1
NCT18244790,Cetuximab,Anti-EGFR,Melanoma,Phase 1,410,Arthralgia,Cardiac disorders,Yes,Moderate,410,36,39,8.78,Yes,Competition,3,184,No,Yes,Treatment interruption,21,39
NCT45160354,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 4,416,Colitis,Blood disorders,Yes,Mild,416,32,35,7.69,No,,4,299,Yes,No,Discontinuation,4,39
NCT40516801,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 1,20,Pneumonitis,Skin disorders,No,Severe,20,5,5,25.0,Yes,Lack of efficacy,14,92,No,No,Dose reduction,28,10
NCT39795610,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 4,65,Colitis,Respiratory disorders,No,Moderate,65,8,11,12.31,Yes,Competition,1,295,Yes,Yes,Treatment interruption,2,74
NCT37317036,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 3,303,Hyperthyroidism,Hepatobiliary disorders,No,Mild,303,2,4,0.66,No,,17,112,No,Yes,Discontinuation,2,4
NCT41340608,Cetuximab,Anti-EGFR,Lung Cancer,Phase 3,481,Pneumonitis,Endocrine disorders,No,Mild,481,92,92,19.13,Yes,Regulatory issues,6,229,Yes,No,Dose reduction,17,26
NCT95823121,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 4,270,Cardiotoxicity,Blood disorders,No,Mild,270,27,32,10.0,No,,17,251,Yes,Yes,Dose reduction,2,6
NCT39711297,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 4,435,Hyperthyroidism,Skin disorders,No,Severe,435,72,73,16.55,Yes,Safety concerns,5,170,Yes,Yes,Treatment interruption,17,1
NCT98913486,Cetuximab,Anti-EGFR,Melanoma,Phase 4,269,Thrombocytopenia,Endocrine disorders,No,Mild,269,55,56,20.45,No,,2,254,Yes,Yes,Discontinuation,9,23
NCT11357110,Cetuximab,Anti-EGFR,Breast Cancer,Phase 4,262,Hyperthyroidism,Blood disorders,No,Severe,262,66,67,25.19,No,,6,338,No,Yes,Treatment interruption,16,65
NCT48137078,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 4,186,Colitis,Cardiac disorders,No,Severe,186,14,14,7.53,No,,17,241,Yes,No,Treatment interruption,20,2
NCT79149176,Cetuximab,Anti-EGFR,Breast Cancer,Phase 2,199,Arthralgia,Cardiac disorders,No,Moderate,199,31,33,15.58,No,,10,184,Yes,No,Discontinuation,22,86
NCT75916486,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 4,68,Hyperthyroidism,General disorders,No,Severe,68,7,11,10.29,No,,18,361,Yes,Yes,Treatment interruption,4,42
NCT29074408,Cetuximab,Anti-EGFR,Lung Cancer,Phase 3,200,Infusion-related reaction,General disorders,Yes,Severe,200,2,7,1.0,Yes,Regulatory issues,7,65,No,No,Discontinuation,17,65
NCT27516768,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 2,325,Hypothyroidism,General disorders,No,Moderate,325,95,96,29.23,No,,1,317,No,No,Dose reduction,8,44
NCT96944005,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,308,Fatigue,Musculoskeletal disorders,No,Mild,308,69,73,22.4,No,,15,308,No,No,Treatment interruption,15,65
NCT51814448,Cetuximab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,445,Rash,Cardiac disorders,No,Severe,445,44,48,9.89,No,,8,51,No,Yes,Treatment interruption,30,50
NCT33232693,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 2,43,Fatigue,Hepatobiliary disorders,No,Mild,43,1,5,2.33,No,,6,143,No,No,Dose reduction,16,41
NCT40752278,Cetuximab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 2,188,Thrombocytopenia,Respiratory disorders,No,Mild,188,6,7,3.19,No,,19,88,No,No,Treatment interruption,5,24
NCT93862654,Cetuximab,Anti-EGFR,Melanoma,Phase 4,455,Neutropenia,Endocrine disorders,No,Severe,455,104,109,22.86,Yes,Safety concerns,8,219,Yes,No,Dose reduction,30,55
NCT34893333,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 3,54,Neutropenia,Respiratory disorders,No,Moderate,54,8,9,14.81,No,,16,220,No,No,Dose reduction,30,1
NCT59197311,Cetuximab,Anti-EGFR,Melanoma,Phase 2,327,Thrombocytopenia,General disorders,No,Severe,327,83,88,25.38,Yes,Regulatory issues,16,207,Yes,Yes,Supportive care,14,50
NCT61496622,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 4,224,Fatigue,Respiratory disorders,No,Mild,224,2,4,0.89,No,,3,186,Yes,No,Supportive care,6,39
NCT28935603,Cetuximab,Anti-EGFR,Rheumatoid Arthritis,Phase 2,166,Colitis,General disorders,No,Mild,166,11,13,6.63,No,,12,92,No,No,Treatment interruption,11,19
NCT63074247,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 2,182,Nausea,Respiratory disorders,No,Mild,182,32,32,17.58,No,,1,121,Yes,Yes,Treatment interruption,16,81
NCT57274319,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 3,50,Anemia,Blood disorders,Yes,Severe,50,4,7,8.0,Yes,Lack of efficacy,5,107,Yes,No,Discontinuation,4,3
NCT73234363,Cetuximab,Anti-EGFR,Melanoma,Phase 1,284,Fatigue,Cardiac disorders,Yes,Mild,284,31,34,10.92,No,,8,234,No,Yes,Discontinuation,16,65
NCT93365684,Cetuximab,Anti-EGFR,Melanoma,Phase 3,495,Hyperthyroidism,Cardiac disorders,No,Mild,495,42,42,8.48,No,,11,69,Yes,No,Discontinuation,23,21
NCT44212196,Cetuximab,Anti-EGFR,Breast Cancer,Phase 4,21,Diarrhea,Endocrine disorders,No,Mild,21,1,3,4.76,No,,3,220,No,Yes,Discontinuation,30,86
NCT55690489,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 1,196,Anemia,Endocrine disorders,No,Mild,196,46,46,23.47,No,,1,244,Yes,No,Treatment interruption,19,34
NCT53681919,Cetuximab,Anti-EGFR,Melanoma,Phase 2,389,Anemia,Cardiac disorders,No,Severe,389,51,52,13.11,Yes,Competition,4,253,Yes,Yes,Treatment interruption,21,72
NCT26990102,Cetuximab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,136,Neutropenia,Endocrine disorders,No,Mild,136,3,7,2.21,No,,18,331,No,No,Dose reduction,6,29
NCT68940665,Cetuximab,Anti-EGFR,Melanoma,Phase 3,330,Rash,Endocrine disorders,Yes,Mild,330,14,19,4.24,No,,2,205,No,No,Discontinuation,11,86
NCT44968745,Cetuximab,Anti-EGFR,Breast Cancer,Phase 3,127,Neutropenia,Hepatobiliary disorders,No,Mild,127,29,29,22.83,No,,20,76,Yes,Yes,Treatment interruption,7,43
NCT18661647,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 2,123,Anemia,Gastrointestinal disorders,No,Mild,123,20,24,16.26,No,,19,215,No,Yes,Discontinuation,28,67
NCT59279718,Cetuximab,Anti-EGFR,Lung Cancer,Phase 2,378,Hepatotoxicity,Respiratory disorders,Yes,Mild,378,61,65,16.14,No,,12,124,Yes,No,Supportive care,9,65
NCT91540163,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,230,Infusion-related reaction,Respiratory disorders,No,Severe,230,20,25,8.7,Yes,Regulatory issues,17,115,Yes,Yes,Discontinuation,11,22
NCT84484461,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 3,233,Fatigue,Skin disorders,No,Mild,233,38,42,16.31,No,,4,353,Yes,No,Supportive care,20,49
NCT78994744,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 2,121,Arthralgia,Blood disorders,No,Mild,121,19,24,15.7,No,,12,331,Yes,No,Discontinuation,30,66
NCT42508285,Cetuximab,Anti-EGFR,Melanoma,Phase 1,435,Rash,Skin disorders,No,Severe,435,48,51,11.03,No,,19,139,No,No,Supportive care,19,35
NCT80478764,Cetuximab,Anti-EGFR,Multiple Myeloma,Phase 3,360,Fatigue,Blood disorders,No,Mild,360,51,54,14.17,No,,18,111,Yes,Yes,Discontinuation,20,62
NCT74357501,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 4,57,Hypothyroidism,Endocrine disorders,No,Mild,57,5,5,8.77,No,,16,102,No,Yes,Dose reduction,9,85
NCT95661567,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 3,369,Pneumonitis,Musculoskeletal disorders,No,Mild,369,62,65,16.8,No,,15,304,Yes,No,Dose reduction,5,51
NCT93479490,Cetuximab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,262,Nausea,Skin disorders,No,Mild,262,11,12,4.2,No,,7,148,No,Yes,Discontinuation,19,11
NCT65594786,Cetuximab,Anti-EGFR,Lung Cancer,Phase 2,145,Hepatotoxicity,Endocrine disorders,No,Severe,145,26,26,17.93,No,,4,330,Yes,Yes,Supportive care,21,21
NCT98151280,Cetuximab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,124,Hyperthyroidism,Gastrointestinal disorders,No,Moderate,124,3,8,2.42,Yes,Regulatory issues,18,109,No,No,Discontinuation,6,14
NCT93070268,Cetuximab,Anti-EGFR,Breast Cancer,Phase 3,264,Fatigue,General disorders,No,Mild,264,16,21,6.06,No,,4,338,No,No,Dose reduction,26,50
NCT59972498,Cetuximab,Anti-EGFR,Rheumatoid Arthritis,Phase 2,167,Nausea,Gastrointestinal disorders,Yes,Severe,167,25,27,14.97,Yes,Competition,1,350,No,No,Discontinuation,5,74
NCT23932670,Cetuximab,Anti-EGFR,Rheumatoid Arthritis,Phase 1,307,Anemia,Gastrointestinal disorders,Yes,Moderate,307,33,37,10.75,No,,1,42,Yes,Yes,Supportive care,6,15
NCT42726965,Cetuximab,Anti-EGFR,Breast Cancer,Phase 3,205,Pneumonitis,Respiratory disorders,Yes,Moderate,205,47,49,22.93,No,,2,296,No,No,Supportive care,2,8
NCT74933941,Cetuximab,Anti-EGFR,Colorectal Cancer,Phase 1,126,Thrombocytopenia,Musculoskeletal disorders,No,Moderate,126,23,23,18.25,No,,12,75,Yes,Yes,Treatment interruption,11,76
NCT91128655,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 4,198,Rash,Hepatobiliary disorders,No,Severe,198,25,25,12.63,Yes,Safety concerns,14,261,No,Yes,Treatment interruption,7,81
NCT25065746,Cetuximab,Anti-EGFR,Multiple Sclerosis,Phase 2,402,Fatigue,Cardiac disorders,No,Mild,402,34,38,8.46,No,,16,296,Yes,No,Dose reduction,26,77
NCT80948745,Cetuximab,Anti-EGFR,Melanoma,Phase 1,27,Diarrhea,Cardiac disorders,No,Severe,27,5,7,18.52,No,,8,225,No,Yes,Dose reduction,15,63
NCT80834781,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,145,Colitis,Hepatobiliary disorders,Yes,Severe,145,30,34,20.69,Yes,Regulatory issues,19,208,No,No,Discontinuation,23,45
NCT81299662,Panitumumab,Anti-EGFR,Melanoma,Phase 4,302,Thrombocytopenia,Endocrine disorders,Yes,Moderate,302,86,89,28.48,No,,20,31,No,Yes,Supportive care,16,20
NCT12490058,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 1,246,Hyperthyroidism,Endocrine disorders,No,Mild,246,58,61,23.58,No,,4,352,No,No,Discontinuation,10,86
NCT80709414,Panitumumab,Anti-EGFR,Breast Cancer,Phase 3,280,Nausea,Skin disorders,No,Mild,280,34,38,12.14,No,,18,326,Yes,No,Dose reduction,8,62
NCT15729526,Panitumumab,Anti-EGFR,Breast Cancer,Phase 4,193,Hyperthyroidism,Endocrine disorders,No,Mild,193,28,33,14.51,No,,1,304,Yes,Yes,Discontinuation,9,4
NCT81718000,Panitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,388,Rash,Skin disorders,No,Moderate,388,64,67,16.49,No,,10,276,No,No,Supportive care,27,48
NCT91339031,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 3,466,Rash,Hepatobiliary disorders,Yes,Severe,466,47,47,10.09,No,,4,344,No,No,Treatment interruption,28,66
NCT63297102,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,153,Neutropenia,Endocrine disorders,Yes,Severe,153,6,11,3.92,Yes,Regulatory issues,1,108,Yes,No,Treatment interruption,17,81
NCT36483307,Panitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 4,473,Thrombocytopenia,Gastrointestinal disorders,Yes,Moderate,473,6,6,1.27,No,,13,332,Yes,No,Dose reduction,19,66
NCT13689630,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 2,58,Anemia,Skin disorders,No,Moderate,58,4,4,6.9,No,,8,292,Yes,No,Dose reduction,13,8
NCT57817025,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,404,Fatigue,Blood disorders,No,Moderate,404,119,124,29.46,Yes,Regulatory issues,6,111,Yes,Yes,Discontinuation,5,50
NCT42602431,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 1,325,Thrombocytopenia,General disorders,No,Moderate,325,25,26,7.69,No,,4,117,No,No,Dose reduction,2,56
NCT90378961,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 2,254,Hyperthyroidism,Respiratory disorders,No,Mild,254,39,39,15.35,No,,2,82,No,Yes,Supportive care,11,63
NCT78158099,Panitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 1,323,Infusion-related reaction,Respiratory disorders,Yes,Mild,323,63,68,19.5,No,,7,331,No,No,Discontinuation,29,10
NCT95103353,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 3,56,Anemia,Gastrointestinal disorders,No,Mild,56,7,7,12.5,No,,9,342,Yes,Yes,Discontinuation,22,75
NCT88811180,Panitumumab,Anti-EGFR,Lung Cancer,Phase 2,229,Nausea,General disorders,Yes,Moderate,229,12,15,5.24,Yes,Competition,1,197,No,No,Treatment interruption,29,77
NCT15060882,Panitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,264,Hyperthyroidism,Skin disorders,No,Mild,264,69,74,26.14,No,,1,154,No,No,Discontinuation,6,20
NCT20615070,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 1,362,Arthralgia,Cardiac disorders,Yes,Severe,362,3,3,0.83,Yes,Competition,19,250,Yes,No,Treatment interruption,3,77
NCT78425567,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 3,29,Rash,General disorders,No,Mild,29,3,5,10.34,No,,13,263,No,No,Discontinuation,12,81
NCT94487207,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 2,58,Thrombocytopenia,Blood disorders,No,Moderate,58,16,16,27.59,No,,13,218,No,Yes,Dose reduction,27,12
NCT22804919,Panitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 4,349,Nausea,Hepatobiliary disorders,No,Moderate,349,71,72,20.34,Yes,Competition,13,228,No,Yes,Supportive care,12,29
NCT21177264,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 2,260,Hepatotoxicity,Musculoskeletal disorders,Yes,Moderate,260,10,11,3.85,No,,13,162,No,No,Supportive care,30,55
NCT70255504,Panitumumab,Anti-EGFR,Melanoma,Phase 4,59,Hepatotoxicity,Skin disorders,Yes,Severe,59,4,4,6.78,No,,17,223,Yes,Yes,Treatment interruption,13,44
NCT97292232,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 4,302,Colitis,Cardiac disorders,No,Mild,302,3,4,0.99,No,,19,137,No,Yes,Discontinuation,14,35
NCT45415647,Panitumumab,Anti-EGFR,Lung Cancer,Phase 4,100,Colitis,Endocrine disorders,No,Moderate,100,6,9,6.0,No,,11,347,Yes,Yes,Discontinuation,11,15
NCT52598785,Panitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,46,Fatigue,Blood disorders,No,Severe,46,4,5,8.7,No,,14,185,No,No,Dose reduction,13,33
NCT14639575,Panitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,186,Rash,Skin disorders,Yes,Moderate,186,1,3,0.54,Yes,Competition,17,173,Yes,No,Discontinuation,15,75
NCT39450814,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 4,296,Colitis,Hepatobiliary disorders,No,Mild,296,49,52,16.55,No,,10,65,Yes,No,Treatment interruption,20,62
NCT48459725,Panitumumab,Anti-EGFR,Breast Cancer,Phase 1,299,Rash,Blood disorders,No,Mild,299,39,42,13.04,No,,4,280,Yes,Yes,Treatment interruption,27,63
NCT29537098,Panitumumab,Anti-EGFR,Lung Cancer,Phase 3,122,Fatigue,Cardiac disorders,No,Mild,122,15,16,12.3,No,,7,238,No,No,Discontinuation,3,31
NCT40067201,Panitumumab,Anti-EGFR,Melanoma,Phase 2,124,Colitis,Gastrointestinal disorders,No,Mild,124,13,17,10.48,No,,12,235,No,No,Discontinuation,7,31
NCT34673168,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 4,478,Arthralgia,Hepatobiliary disorders,No,Mild,478,21,26,4.39,No,,5,118,No,No,Dose reduction,5,7
NCT37760051,Panitumumab,Anti-EGFR,Melanoma,Phase 4,276,Cardiotoxicity,Cardiac disorders,Yes,Mild,276,70,74,25.36,No,,10,311,No,No,Treatment interruption,6,14
NCT50003865,Panitumumab,Anti-EGFR,Breast Cancer,Phase 1,216,Colitis,Hepatobiliary disorders,No,Moderate,216,25,25,11.57,No,,5,334,Yes,Yes,Dose reduction,19,20
NCT24606994,Panitumumab,Anti-EGFR,Melanoma,Phase 4,264,Neutropenia,Cardiac disorders,No,Mild,264,50,52,18.94,No,,3,74,No,Yes,Supportive care,9,89
NCT51813752,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 1,134,Diarrhea,Respiratory disorders,No,Mild,134,21,26,15.67,No,,18,119,No,No,Discontinuation,11,33
NCT58713318,Panitumumab,Anti-EGFR,Breast Cancer,Phase 4,152,Diarrhea,Respiratory disorders,No,Mild,152,38,39,25.0,No,,7,281,Yes,No,Supportive care,22,75
NCT26663116,Panitumumab,Anti-EGFR,Melanoma,Phase 1,49,Infusion-related reaction,Blood disorders,Yes,Moderate,49,13,17,26.53,Yes,Lack of efficacy,10,220,No,Yes,Treatment interruption,15,2
NCT87694114,Panitumumab,Anti-EGFR,Multiple Sclerosis,Phase 2,194,Colitis,Blood disorders,Yes,Mild,194,12,13,6.19,No,,8,53,No,No,Discontinuation,23,22
NCT64352537,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 4,442,Rash,General disorders,No,Mild,442,70,72,15.84,No,,12,48,No,Yes,Dose reduction,30,42
NCT93977893,Panitumumab,Anti-EGFR,Melanoma,Phase 3,471,Hypothyroidism,Cardiac disorders,No,Mild,471,76,78,16.14,No,,20,153,Yes,Yes,Dose reduction,18,54
NCT83011059,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,364,Thrombocytopenia,Endocrine disorders,No,Mild,364,51,56,14.01,No,,4,134,No,Yes,Treatment interruption,22,65
NCT93830331,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 1,394,Colitis,General disorders,No,Severe,394,96,99,24.37,No,,20,267,Yes,Yes,Treatment interruption,19,85
NCT90686438,Panitumumab,Anti-EGFR,Melanoma,Phase 1,27,Hypothyroidism,Blood disorders,Yes,Moderate,27,8,11,29.63,Yes,Regulatory issues,10,258,No,No,Treatment interruption,22,25
NCT22618435,Panitumumab,Anti-EGFR,Lung Cancer,Phase 2,296,Hyperthyroidism,Endocrine disorders,No,Severe,296,10,11,3.38,Yes,Lack of efficacy,8,39,Yes,Yes,Supportive care,17,31
NCT67800935,Panitumumab,Anti-EGFR,Melanoma,Phase 4,134,Thrombocytopenia,Endocrine disorders,No,Moderate,134,13,17,9.7,No,,10,155,Yes,No,Supportive care,16,63
NCT73831442,Panitumumab,Anti-EGFR,Breast Cancer,Phase 3,345,Diarrhea,Hepatobiliary disorders,No,Severe,345,41,43,11.88,Yes,Safety concerns,13,190,Yes,Yes,Dose reduction,13,30
NCT24499308,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 3,402,Arthralgia,Hepatobiliary disorders,No,Mild,402,102,105,25.37,No,,2,130,Yes,No,Discontinuation,16,23
NCT65946857,Panitumumab,Anti-EGFR,Colorectal Cancer,Phase 1,130,Hyperthyroidism,Hepatobiliary disorders,Yes,Moderate,130,19,24,14.62,Yes,Competition,14,54,No,Yes,Treatment interruption,29,82
NCT70920841,Panitumumab,Anti-EGFR,Lung Cancer,Phase 1,492,Diarrhea,Skin disorders,No,Severe,492,65,67,13.21,No,,17,207,Yes,Yes,Discontinuation,8,9
NCT23608823,Panitumumab,Anti-EGFR,Lung Cancer,Phase 1,140,Fatigue,General disorders,No,Severe,140,37,42,26.43,No,,7,161,Yes,No,Dose reduction,23,1
NCT72464738,Panitumumab,Anti-EGFR,Lung Cancer,Phase 2,247,Thrombocytopenia,Blood disorders,No,Moderate,247,17,20,6.88,No,,3,224,Yes,Yes,Treatment interruption,25,7
NCT90931514,Panitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,283,Anemia,Endocrine disorders,No,Mild,283,61,62,21.55,No,,3,218,Yes,No,Supportive care,26,10
NCT60093626,Panitumumab,Anti-EGFR,Multiple Myeloma,Phase 3,433,Arthralgia,Hepatobiliary disorders,Yes,Mild,433,68,73,15.7,No,,9,182,Yes,Yes,Supportive care,13,87
NCT26967314,Panitumumab,Anti-EGFR,Melanoma,Phase 1,136,Hyperthyroidism,Musculoskeletal disorders,Yes,Severe,136,1,6,0.74,Yes,Competition,14,174,No,No,Dose reduction,14,21
NCT95441107,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 2,35,Neutropenia,Musculoskeletal disorders,No,Severe,35,2,7,5.71,No,,20,104,No,Yes,Treatment interruption,2,26
NCT55322371,Necitumumab,Anti-EGFR,Melanoma,Phase 4,170,Fatigue,Gastrointestinal disorders,No,Mild,170,20,20,11.76,No,,17,356,Yes,Yes,Treatment interruption,11,41
NCT69587290,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 3,112,Hypothyroidism,Respiratory disorders,No,Mild,112,30,31,26.79,No,,3,364,Yes,No,Discontinuation,1,23
NCT80896824,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,471,Diarrhea,Musculoskeletal disorders,No,Mild,471,84,87,17.83,No,,10,183,Yes,No,Treatment interruption,15,39
NCT56325529,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 4,348,Arthralgia,Cardiac disorders,Yes,Severe,348,54,57,15.52,Yes,Regulatory issues,7,264,No,Yes,Dose reduction,11,32
NCT72802654,Necitumumab,Anti-EGFR,Lung Cancer,Phase 2,41,Anemia,Gastrointestinal disorders,Yes,Moderate,41,5,7,12.2,No,,14,340,Yes,Yes,Discontinuation,26,6
NCT30515817,Necitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,236,Fatigue,Skin disorders,No,Moderate,236,64,64,27.12,Yes,Regulatory issues,6,295,No,Yes,Supportive care,18,19
NCT77103602,Necitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,268,Rash,Endocrine disorders,No,Severe,268,65,67,24.25,No,,12,104,No,Yes,Dose reduction,8,12
NCT20996181,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 2,67,Fatigue,Gastrointestinal disorders,No,Mild,67,14,15,20.9,No,,12,52,Yes,No,Discontinuation,16,23
NCT61037407,Necitumumab,Anti-EGFR,Lung Cancer,Phase 4,196,Pneumonitis,Respiratory disorders,No,Severe,196,7,10,3.57,No,,6,99,No,No,Supportive care,14,74
NCT31643152,Necitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 3,125,Diarrhea,Blood disorders,No,Mild,125,6,11,4.8,No,,9,313,Yes,No,Treatment interruption,23,30
NCT61111678,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 2,449,Hypothyroidism,Skin disorders,No,Moderate,449,21,23,4.68,No,,20,83,Yes,Yes,Treatment interruption,5,7
NCT97833409,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,68,Pneumonitis,Blood disorders,No,Mild,68,2,6,2.94,No,,1,272,No,Yes,Treatment interruption,8,14
NCT98714884,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 1,381,Cardiotoxicity,Musculoskeletal disorders,No,Mild,381,102,105,26.77,No,,19,190,Yes,No,Supportive care,5,57
NCT33550902,Necitumumab,Anti-EGFR,Breast Cancer,Phase 1,373,Nausea,General disorders,Yes,Severe,373,64,67,17.16,Yes,Regulatory issues,4,347,Yes,No,Discontinuation,4,24
NCT59496881,Necitumumab,Anti-EGFR,Lung Cancer,Phase 3,70,Pneumonitis,Gastrointestinal disorders,No,Moderate,70,5,9,7.14,No,,14,147,No,No,Treatment interruption,17,28
NCT74825378,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 1,204,Nausea,Cardiac disorders,No,Moderate,204,9,13,4.41,No,,17,296,No,No,Dose reduction,22,73
NCT36505541,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 3,184,Anemia,General disorders,No,Mild,184,16,21,8.7,No,,12,254,Yes,Yes,Supportive care,2,40
NCT49022010,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 1,237,Anemia,Endocrine disorders,No,Mild,237,10,14,4.22,No,,14,363,No,No,Treatment interruption,10,28
NCT92551895,Necitumumab,Anti-EGFR,Lung Cancer,Phase 1,178,Infusion-related reaction,Respiratory disorders,No,Moderate,178,3,3,1.69,No,,12,220,No,No,Supportive care,25,73
NCT17510981,Necitumumab,Anti-EGFR,Lung Cancer,Phase 2,115,Hyperthyroidism,Musculoskeletal disorders,No,Moderate,115,7,8,6.09,No,,11,156,No,No,Dose reduction,4,67
NCT70169039,Necitumumab,Anti-EGFR,Melanoma,Phase 2,413,Hepatotoxicity,Blood disorders,No,Moderate,413,58,58,14.04,No,,17,205,Yes,Yes,Discontinuation,2,63
NCT82426530,Necitumumab,Anti-EGFR,Lung Cancer,Phase 1,332,Nausea,Skin disorders,Yes,Moderate,332,17,21,5.12,No,,20,223,No,Yes,Discontinuation,8,17
NCT68190741,Necitumumab,Anti-EGFR,Breast Cancer,Phase 3,410,Hyperthyroidism,Cardiac disorders,No,Mild,410,109,112,26.59,No,,16,365,No,No,Dose reduction,30,77
NCT71785477,Necitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 2,115,Anemia,Skin disorders,No,Moderate,115,32,36,27.83,Yes,Regulatory issues,19,209,Yes,No,Treatment interruption,30,64
NCT13577745,Necitumumab,Anti-EGFR,Lung Cancer,Phase 1,443,Neutropenia,General disorders,No,Severe,443,88,88,19.86,Yes,Safety concerns,3,264,Yes,Yes,Supportive care,24,63
NCT53475351,Necitumumab,Anti-EGFR,Breast Cancer,Phase 3,238,Hypothyroidism,Endocrine disorders,No,Moderate,238,62,64,26.05,No,,19,258,No,Yes,Dose reduction,27,54
NCT99269796,Necitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 4,223,Cardiotoxicity,Skin disorders,No,Mild,223,21,26,9.42,No,,16,49,No,Yes,Treatment interruption,8,56
NCT63250969,Necitumumab,Anti-EGFR,Lung Cancer,Phase 4,310,Cardiotoxicity,General disorders,No,Severe,310,3,8,0.97,Yes,Lack of efficacy,4,331,Yes,Yes,Discontinuation,7,84
NCT92955497,Necitumumab,Anti-EGFR,Melanoma,Phase 1,118,Hypothyroidism,Skin disorders,Yes,Severe,118,33,33,27.97,Yes,Competition,1,341,No,No,Treatment interruption,24,62
NCT87518886,Necitumumab,Anti-EGFR,Rheumatoid Arthritis,Phase 1,418,Rash,Gastrointestinal disorders,Yes,Moderate,418,13,17,3.11,No,,17,357,No,Yes,Dose reduction,5,33
NCT40214552,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 3,320,Diarrhea,Musculoskeletal disorders,Yes,Mild,320,17,18,5.31,No,,6,230,No,Yes,Treatment interruption,28,21
NCT63232559,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 4,414,Arthralgia,Blood disorders,No,Mild,414,94,96,22.71,No,,13,289,No,Yes,Dose reduction,3,2
NCT72450070,Necitumumab,Anti-EGFR,Lung Cancer,Phase 4,303,Arthralgia,Gastrointestinal disorders,No,Severe,303,42,44,13.86,No,,20,282,Yes,No,Treatment interruption,12,59
NCT86618307,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 2,381,Colitis,Gastrointestinal disorders,Yes,Moderate,381,25,30,6.56,No,,10,70,No,No,Discontinuation,12,67
NCT37590425,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 1,343,Neutropenia,Cardiac disorders,No,Mild,343,75,75,21.87,No,,3,136,No,Yes,Dose reduction,5,11
NCT61870936,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 4,407,Neutropenia,Respiratory disorders,No,Mild,407,44,45,10.81,No,,10,256,Yes,Yes,Dose reduction,9,10
NCT73941169,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 4,275,Hepatotoxicity,Skin disorders,No,Mild,275,58,58,21.09,No,,16,128,Yes,No,Treatment interruption,27,85
NCT63401855,Necitumumab,Anti-EGFR,Breast Cancer,Phase 1,57,Hepatotoxicity,Cardiac disorders,No,Severe,57,9,12,15.79,No,,17,32,Yes,Yes,Supportive care,12,40
NCT54628723,Necitumumab,Anti-EGFR,Breast Cancer,Phase 1,314,Arthralgia,Hepatobiliary disorders,No,Severe,314,46,48,14.65,No,,11,125,Yes,Yes,Dose reduction,12,58
NCT25517357,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 3,92,Hepatotoxicity,Musculoskeletal disorders,No,Mild,92,19,24,20.65,No,,5,263,Yes,Yes,Treatment interruption,27,42
NCT67070474,Necitumumab,Anti-EGFR,Lung Cancer,Phase 1,470,Pneumonitis,Respiratory disorders,Yes,Severe,470,100,105,21.28,Yes,Regulatory issues,18,191,Yes,No,Dose reduction,18,72
NCT82881746,Necitumumab,Anti-EGFR,Breast Cancer,Phase 3,98,Hepatotoxicity,General disorders,No,Severe,98,9,11,9.18,No,,3,159,No,No,Supportive care,7,54
NCT83446098,Necitumumab,Anti-EGFR,Breast Cancer,Phase 2,23,Neutropenia,Skin disorders,Yes,Moderate,23,4,7,17.39,No,,19,170,No,No,Dose reduction,14,32
NCT67879274,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 1,193,Colitis,Cardiac disorders,No,Mild,193,3,3,1.55,No,,14,60,Yes,No,Dose reduction,5,22
NCT45419324,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 1,95,Cardiotoxicity,Blood disorders,No,Mild,95,15,17,15.79,No,,14,114,No,Yes,Supportive care,22,22
NCT17998871,Necitumumab,Anti-EGFR,Melanoma,Phase 4,22,Nausea,Hepatobiliary disorders,No,Moderate,22,3,6,13.64,No,,4,168,Yes,Yes,Dose reduction,3,71
NCT91626620,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 3,398,Colitis,Endocrine disorders,Yes,Severe,398,51,53,12.81,No,,14,299,No,No,Treatment interruption,3,58
NCT10390673,Necitumumab,Anti-EGFR,Breast Cancer,Phase 3,479,Rash,Blood disorders,No,Mild,479,6,8,1.25,No,,11,228,No,Yes,Dose reduction,28,42
NCT19514623,Necitumumab,Anti-EGFR,Lung Cancer,Phase 3,57,Neutropenia,Skin disorders,No,Severe,57,10,10,17.54,No,,7,125,Yes,Yes,Dose reduction,5,62
NCT82440337,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 3,177,Anemia,Blood disorders,No,Moderate,177,14,14,7.91,No,,20,45,No,Yes,Dose reduction,13,60
NCT91342891,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 1,320,Arthralgia,Hepatobiliary disorders,No,Severe,320,7,7,2.19,Yes,Competition,11,315,Yes,No,Treatment interruption,23,53
NCT38012294,Necitumumab,Anti-EGFR,Lung Cancer,Phase 1,120,Diarrhea,General disorders,No,Mild,120,21,23,17.5,No,,9,186,Yes,No,Discontinuation,10,80
NCT49529404,Necitumumab,Anti-EGFR,Lung Cancer,Phase 2,38,Diarrhea,Blood disorders,No,Mild,38,4,4,10.53,No,,13,332,No,No,Supportive care,9,12
NCT66941986,Necitumumab,Anti-EGFR,Breast Cancer,Phase 2,361,Rash,General disorders,No,Mild,361,93,93,25.76,No,,9,320,No,No,Discontinuation,22,42
NCT99105658,Necitumumab,Anti-EGFR,Lung Cancer,Phase 2,223,Colitis,Respiratory disorders,No,Moderate,223,42,47,18.83,No,,6,125,Yes,Yes,Treatment interruption,18,6
NCT60875873,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 3,326,Diarrhea,Hepatobiliary disorders,Yes,Severe,326,90,91,27.61,Yes,Lack of efficacy,5,149,Yes,No,Dose reduction,13,28
NCT78774322,Necitumumab,Anti-EGFR,Melanoma,Phase 2,259,Hypothyroidism,Blood disorders,No,Mild,259,1,3,0.39,No,,18,270,Yes,No,Dose reduction,19,60
NCT84325070,Necitumumab,Anti-EGFR,Breast Cancer,Phase 3,425,Diarrhea,Endocrine disorders,No,Mild,425,9,14,2.12,No,,7,152,No,No,Supportive care,8,40
NCT74210844,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 2,156,Rash,Cardiac disorders,No,Moderate,156,35,37,22.44,No,,8,271,No,No,Treatment interruption,26,13
NCT84269631,Necitumumab,Anti-EGFR,Colorectal Cancer,Phase 1,425,Colitis,Cardiac disorders,No,Mild,425,14,15,3.29,Yes,Competition,20,171,No,No,Supportive care,24,4
NCT15580058,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 4,200,Neutropenia,Blood disorders,No,Moderate,200,36,41,18.0,No,,2,103,Yes,Yes,Supportive care,19,19
NCT40608146,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,131,Colitis,Endocrine disorders,No,Mild,131,32,32,24.43,No,,16,316,Yes,No,Dose reduction,20,52
NCT19990521,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,491,Hyperthyroidism,Endocrine disorders,No,Mild,491,121,125,24.64,No,,12,52,No,No,Discontinuation,1,1
NCT53224237,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 2,410,Fatigue,General disorders,No,Severe,410,16,20,3.9,No,,1,62,No,Yes,Treatment interruption,9,58
NCT19259389,Necitumumab,Anti-EGFR,Lung Cancer,Phase 1,482,Cardiotoxicity,Endocrine disorders,No,Mild,482,124,128,25.73,No,,7,354,Yes,Yes,Supportive care,8,10
NCT40777658,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 1,398,Infusion-related reaction,General disorders,No,Mild,398,53,55,13.32,No,,14,331,Yes,Yes,Supportive care,1,70
NCT35515632,Necitumumab,Anti-EGFR,Multiple Myeloma,Phase 2,181,Neutropenia,Endocrine disorders,No,Mild,181,5,10,2.76,No,,4,110,No,No,Supportive care,2,57
NCT94304760,Necitumumab,Anti-EGFR,Lung Cancer,Phase 4,431,Hepatotoxicity,General disorders,No,Severe,431,73,74,16.94,Yes,Competition,18,260,No,Yes,Supportive care,29,43
NCT44318779,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 1,424,Arthralgia,General disorders,No,Mild,424,24,24,5.66,No,,10,332,No,Yes,Dose reduction,9,30
NCT55508655,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 4,315,Fatigue,Endocrine disorders,Yes,Mild,315,79,82,25.08,No,,19,271,Yes,Yes,Treatment interruption,2,15
NCT42690199,Necitumumab,Anti-EGFR,Non-Hodgkin Lymphoma,Phase 3,463,Pneumonitis,Hepatobiliary disorders,No,Mild,463,101,101,21.81,No,,9,219,Yes,Yes,Supportive care,21,41
NCT13788413,Necitumumab,Anti-EGFR,Multiple Sclerosis,Phase 1,356,Rash,Blood disorders,No,Mild,356,45,48,12.64,No,,9,147,No,No,Treatment interruption,22,90
NCT61685536,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 2,319,Nausea,Skin disorders,No,Mild,319,69,73,21.63,No,,9,264,No,Yes,Discontinuation,12,54
NCT78412762,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 3,214,Diarrhea,Skin disorders,Yes,Moderate,214,42,43,19.63,No,,15,191,No,No,Dose reduction,22,85
NCT49024894,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 1,196,Pneumonitis,Musculoskeletal disorders,No,Moderate,196,30,35,15.31,No,,11,337,Yes,Yes,Supportive care,1,29
NCT90065373,Alemtuzumab,Anti-CD52,Multiple Myeloma,Phase 1,489,Cardiotoxicity,Gastrointestinal disorders,No,Mild,489,64,67,13.09,No,,11,101,Yes,Yes,Treatment interruption,1,63
NCT82711357,Alemtuzumab,Anti-CD52,Multiple Myeloma,Phase 3,313,Hepatotoxicity,Hepatobiliary disorders,No,Mild,313,68,71,21.73,No,,11,71,No,Yes,Treatment interruption,26,63
NCT14557688,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 1,217,Arthralgia,Endocrine disorders,No,Mild,217,18,21,8.29,No,,20,159,No,No,Treatment interruption,27,76
NCT45124611,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 1,217,Infusion-related reaction,Musculoskeletal disorders,No,Severe,217,64,65,29.49,No,,2,226,Yes,Yes,Dose reduction,22,37
NCT22975290,Alemtuzumab,Anti-CD52,Rheumatoid Arthritis,Phase 1,122,Arthralgia,Blood disorders,No,Mild,122,16,19,13.11,No,,18,107,No,No,Dose reduction,9,43
NCT36818901,Alemtuzumab,Anti-CD52,Melanoma,Phase 2,60,Rash,Cardiac disorders,No,Mild,60,5,9,8.33,No,,9,265,No,No,Discontinuation,8,6
NCT42229114,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 1,209,Anemia,General disorders,No,Severe,209,48,53,22.97,No,,6,333,Yes,No,Treatment interruption,19,19
NCT65986908,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 1,281,Rash,Blood disorders,No,Moderate,281,23,26,8.19,No,,10,187,No,No,Supportive care,24,85
NCT53104879,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 1,452,Fatigue,Blood disorders,No,Moderate,452,134,137,29.65,No,,10,184,No,No,Treatment interruption,25,61
NCT45447848,Alemtuzumab,Anti-CD52,Melanoma,Phase 1,254,Anemia,General disorders,No,Moderate,254,56,58,22.05,Yes,Regulatory issues,15,107,Yes,Yes,Discontinuation,17,32
NCT21371094,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 3,437,Arthralgia,General disorders,Yes,Severe,437,66,70,15.1,Yes,Lack of efficacy,7,339,Yes,Yes,Dose reduction,3,86
NCT15950544,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 1,47,Anemia,Respiratory disorders,Yes,Severe,47,7,12,14.89,Yes,Regulatory issues,14,125,Yes,No,Discontinuation,3,21
NCT74381298,Alemtuzumab,Anti-CD52,Melanoma,Phase 4,261,Infusion-related reaction,General disorders,No,Severe,261,71,76,27.2,No,,16,97,No,No,Dose reduction,25,85
NCT87997412,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 1,335,Hyperthyroidism,Musculoskeletal disorders,Yes,Mild,335,56,59,16.72,No,,12,188,No,Yes,Treatment interruption,21,26
NCT66488995,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 4,222,Nausea,Hepatobiliary disorders,No,Moderate,222,43,47,19.37,No,,11,110,Yes,No,Dose reduction,1,21
NCT68083169,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 3,187,Neutropenia,Gastrointestinal disorders,No,Moderate,187,42,47,22.46,No,,12,173,Yes,Yes,Supportive care,23,67
NCT44126228,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 1,63,Colitis,Endocrine disorders,No,Moderate,63,16,21,25.4,Yes,Lack of efficacy,13,259,Yes,No,Supportive care,27,79
NCT34407287,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 1,32,Anemia,Musculoskeletal disorders,No,Moderate,32,5,10,15.62,No,,18,158,Yes,Yes,Supportive care,4,79
NCT65615504,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 3,372,Diarrhea,Gastrointestinal disorders,No,Severe,372,16,21,4.3,No,,2,75,No,No,Supportive care,21,71
NCT83074204,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 1,334,Infusion-related reaction,Skin disorders,No,Severe,334,20,23,5.99,No,,3,330,Yes,Yes,Treatment interruption,16,86
NCT55396984,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 2,100,Rash,Cardiac disorders,Yes,Moderate,100,6,11,6.0,No,,12,90,Yes,No,Discontinuation,15,79
NCT42077708,Alemtuzumab,Anti-CD52,Melanoma,Phase 1,378,Neutropenia,Skin disorders,No,Mild,378,29,29,7.67,No,,10,164,No,No,Discontinuation,6,42
NCT28989185,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 2,400,Arthralgia,Respiratory disorders,Yes,Severe,400,3,8,0.75,Yes,Safety concerns,14,248,Yes,Yes,Supportive care,28,32
NCT36910162,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 4,255,Hepatotoxicity,Endocrine disorders,No,Mild,255,49,54,19.22,No,,19,217,Yes,Yes,Treatment interruption,12,5
NCT46343118,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 3,186,Hepatotoxicity,Respiratory disorders,No,Moderate,186,3,8,1.61,No,,5,345,Yes,Yes,Treatment interruption,21,5
NCT14358503,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 3,169,Cardiotoxicity,Gastrointestinal disorders,No,Moderate,169,43,46,25.44,No,,16,178,Yes,Yes,Supportive care,2,32
NCT13497874,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 4,363,Rash,Hepatobiliary disorders,No,Moderate,363,21,25,5.79,No,,2,331,Yes,Yes,Treatment interruption,6,60
NCT73587325,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 3,381,Hepatotoxicity,Endocrine disorders,No,Moderate,381,65,65,17.06,No,,13,170,No,No,Treatment interruption,21,64
NCT47328003,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 4,139,Hypothyroidism,Endocrine disorders,Yes,Moderate,139,39,40,28.06,No,,4,87,No,Yes,Treatment interruption,24,42
NCT81534527,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 1,169,Hyperthyroidism,Musculoskeletal disorders,No,Mild,169,18,20,10.65,No,,4,241,No,Yes,Dose reduction,2,59
NCT35512156,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 2,299,Fatigue,Respiratory disorders,Yes,Moderate,299,83,88,27.76,Yes,Safety concerns,3,138,No,No,Dose reduction,28,65
NCT93483542,Alemtuzumab,Anti-CD52,Rheumatoid Arthritis,Phase 3,189,Anemia,Respiratory disorders,No,Moderate,189,44,49,23.28,No,,5,302,No,Yes,Treatment interruption,20,16
NCT89079504,Alemtuzumab,Anti-CD52,Melanoma,Phase 2,439,Pneumonitis,Endocrine disorders,No,Moderate,439,66,66,15.03,No,,9,182,No,No,Discontinuation,15,2
NCT13262908,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 3,487,Arthralgia,Blood disorders,No,Mild,487,13,16,2.67,No,,7,264,Yes,Yes,Treatment interruption,7,52
NCT18072789,Alemtuzumab,Anti-CD52,Multiple Myeloma,Phase 1,465,Hyperthyroidism,General disorders,Yes,Mild,465,108,108,23.23,No,,8,85,No,No,Discontinuation,20,64
NCT15312635,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 2,366,Diarrhea,Musculoskeletal disorders,No,Severe,366,39,40,10.66,Yes,Lack of efficacy,15,243,No,Yes,Discontinuation,25,83
NCT53038915,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 1,307,Arthralgia,General disorders,No,Severe,307,10,14,3.26,Yes,Regulatory issues,8,42,No,Yes,Supportive care,23,90
NCT91543818,Alemtuzumab,Anti-CD52,Melanoma,Phase 3,61,Fatigue,General disorders,No,Mild,61,9,13,14.75,No,,8,121,No,No,Dose reduction,25,61
NCT74851866,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 1,459,Anemia,Endocrine disorders,No,Severe,459,64,66,13.94,Yes,Competition,15,98,No,Yes,Discontinuation,15,73
NCT43300487,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 3,119,Colitis,Cardiac disorders,No,Mild,119,25,26,21.01,Yes,Lack of efficacy,1,273,No,Yes,Discontinuation,22,78
NCT49853867,Alemtuzumab,Anti-CD52,Non-Hodgkin Lymphoma,Phase 3,343,Rash,Hepatobiliary disorders,No,Moderate,343,25,26,7.29,No,,7,253,Yes,Yes,Treatment interruption,27,89
NCT89748168,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 3,20,Pneumonitis,Cardiac disorders,No,Mild,20,4,6,20.0,No,,12,234,No,Yes,Treatment interruption,21,16
NCT60212661,Alemtuzumab,Anti-CD52,Melanoma,Phase 4,433,Infusion-related reaction,Blood disorders,Yes,Mild,433,27,28,6.24,No,,4,273,No,No,Treatment interruption,14,12
NCT21189254,Alemtuzumab,Anti-CD52,Melanoma,Phase 3,170,Hypothyroidism,Gastrointestinal disorders,No,Severe,170,39,42,22.94,No,,4,110,No,No,Dose reduction,4,44
NCT63946896,Alemtuzumab,Anti-CD52,Rheumatoid Arthritis,Phase 4,144,Anemia,Cardiac disorders,No,Mild,144,17,18,11.81,No,,11,130,No,Yes,Discontinuation,27,56
NCT35875084,Alemtuzumab,Anti-CD52,Melanoma,Phase 2,114,Hepatotoxicity,Musculoskeletal disorders,Yes,Moderate,114,4,7,3.51,Yes,Competition,7,39,No,No,Dose reduction,6,58
NCT10884144,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 4,189,Colitis,Blood disorders,No,Moderate,189,29,32,15.34,No,,13,113,No,No,Treatment interruption,16,26
NCT48037005,Alemtuzumab,Anti-CD52,Rheumatoid Arthritis,Phase 2,244,Rash,Hepatobiliary disorders,No,Severe,244,41,45,16.8,No,,14,138,No,No,Dose reduction,7,44
NCT36460518,Alemtuzumab,Anti-CD52,Non-Hodgkin Lymphoma,Phase 2,205,Pneumonitis,Musculoskeletal disorders,No,Mild,205,39,44,19.02,No,,13,318,No,No,Discontinuation,9,86
NCT68282751,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 3,314,Fatigue,Cardiac disorders,No,Mild,314,49,52,15.61,No,,17,37,No,No,Dose reduction,8,85
NCT21572679,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 4,416,Hyperthyroidism,Gastrointestinal disorders,Yes,Severe,416,54,59,12.98,Yes,Regulatory issues,6,41,Yes,Yes,Supportive care,4,19
NCT87301999,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 1,59,Diarrhea,Cardiac disorders,No,Mild,59,16,16,27.12,No,,7,183,No,Yes,Discontinuation,15,27
NCT55000128,Alemtuzumab,Anti-CD52,Non-Hodgkin Lymphoma,Phase 3,61,Nausea,Blood disorders,No,Severe,61,16,16,26.23,Yes,Regulatory issues,17,43,No,No,Treatment interruption,17,33
NCT32612426,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 4,390,Hypothyroidism,Cardiac disorders,No,Mild,390,117,119,30.0,No,,19,359,No,No,Discontinuation,15,13
NCT47772541,Alemtuzumab,Anti-CD52,Lung Cancer,Phase 1,66,Neutropenia,Gastrointestinal disorders,No,Moderate,66,5,9,7.58,Yes,Lack of efficacy,20,271,Yes,Yes,Dose reduction,16,75
NCT98851670,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 2,240,Fatigue,General disorders,No,Severe,240,13,16,5.42,No,,17,76,Yes,Yes,Dose reduction,15,55
NCT12539640,Alemtuzumab,Anti-CD52,Melanoma,Phase 2,198,Fatigue,General disorders,No,Mild,198,16,17,8.08,No,,18,341,Yes,Yes,Treatment interruption,9,66
NCT77462983,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 1,88,Colitis,Hepatobiliary disorders,No,Mild,88,26,30,29.55,No,,8,265,No,No,Treatment interruption,29,30
NCT14390140,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 4,77,Hypothyroidism,Skin disorders,No,Severe,77,3,7,3.9,No,,7,51,No,Yes,Discontinuation,17,46
NCT54128179,Alemtuzumab,Anti-CD52,Rheumatoid Arthritis,Phase 3,48,Hyperthyroidism,Cardiac disorders,No,Moderate,48,1,1,2.08,No,,2,339,No,Yes,Supportive care,30,27
NCT84398374,Alemtuzumab,Anti-CD52,Rheumatoid Arthritis,Phase 1,43,Neutropenia,General disorders,No,Mild,43,2,3,4.65,No,,15,154,Yes,No,Treatment interruption,24,44
NCT94195609,Alemtuzumab,Anti-CD52,Multiple Sclerosis,Phase 2,299,Hepatotoxicity,Skin disorders,No,Moderate,299,84,84,28.09,No,,6,55,Yes,No,Supportive care,7,22
NCT53278638,Alemtuzumab,Anti-CD52,Colorectal Cancer,Phase 4,486,Rash,Cardiac disorders,No,Mild,486,61,62,12.55,No,,6,257,No,No,Treatment interruption,29,3
NCT13733341,Alemtuzumab,Anti-CD52,Non-Hodgkin Lymphoma,Phase 2,495,Neutropenia,Hepatobiliary disorders,No,Moderate,495,3,8,0.61,No,,7,245,Yes,Yes,Discontinuation,23,12
NCT32392852,Alemtuzumab,Anti-CD52,Breast Cancer,Phase 1,460,Colitis,Endocrine disorders,No,Mild,460,16,20,3.48,No,,14,251,Yes,Yes,Dose reduction,25,63
NCT15588893,Alemtuzumab,Anti-CD52,Non-Hodgkin Lymphoma,Phase 4,135,Fatigue,Cardiac disorders,Yes,Mild,135,6,9,4.44,No,,9,145,Yes,No,Supportive care,9,30
NCT24817824,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,234,Nausea,Respiratory disorders,No,Moderate,234,59,59,25.21,Yes,Competition,5,171,No,No,Supportive care,4,73
NCT76697982,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,230,Cardiotoxicity,Musculoskeletal disorders,No,Mild,230,10,13,4.35,No,,2,245,Yes,Yes,Treatment interruption,14,38
NCT35493857,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 3,195,Nausea,Gastrointestinal disorders,No,Severe,195,30,31,15.38,No,,20,83,No,No,Dose reduction,11,46
NCT63935238,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 1,303,Hypothyroidism,Blood disorders,No,Moderate,303,19,19,6.27,No,,19,46,Yes,No,Supportive care,30,82
NCT57288793,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,41,Arthralgia,Endocrine disorders,No,Severe,41,3,4,7.32,Yes,Regulatory issues,15,77,Yes,Yes,Supportive care,13,84
NCT87094398,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,180,Nausea,Hepatobiliary disorders,No,Mild,180,39,44,21.67,No,,18,41,Yes,Yes,Discontinuation,10,23
NCT43458471,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 1,182,Hepatotoxicity,Blood disorders,Yes,Moderate,182,4,8,2.2,No,,10,321,Yes,No,Discontinuation,8,31
NCT26878417,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 2,409,Infusion-related reaction,Musculoskeletal disorders,No,Moderate,409,100,104,24.45,No,,7,133,No,No,Treatment interruption,19,55
NCT27627078,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,362,Arthralgia,Hepatobiliary disorders,No,Mild,362,89,91,24.59,No,,16,266,Yes,No,Treatment interruption,23,19
NCT64831669,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 2,360,Pneumonitis,Skin disorders,No,Severe,360,64,65,17.78,No,,13,353,No,Yes,Treatment interruption,15,1
NCT77884538,Adalimumab,Anti-TNF-alpha,Breast Cancer,Phase 3,236,Arthralgia,Musculoskeletal disorders,No,Mild,236,56,61,23.73,No,,1,137,No,No,Dose reduction,27,71
NCT90314156,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,109,Cardiotoxicity,Cardiac disorders,Yes,Severe,109,24,26,22.02,Yes,Lack of efficacy,20,258,No,No,Treatment interruption,5,74
NCT57942592,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,230,Pneumonitis,Hepatobiliary disorders,No,Mild,230,63,64,27.39,No,,2,290,Yes,No,Discontinuation,18,53
NCT33456779,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,258,Anemia,Endocrine disorders,No,Severe,258,22,23,8.53,No,,15,348,Yes,Yes,Discontinuation,24,13
NCT58046234,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,438,Hyperthyroidism,General disorders,No,Severe,438,14,17,3.2,No,,7,218,Yes,No,Dose reduction,13,2
NCT48036692,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 2,314,Hyperthyroidism,General disorders,No,Moderate,314,27,28,8.6,Yes,Competition,12,364,No,No,Discontinuation,1,89
NCT64366797,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 4,418,Diarrhea,Musculoskeletal disorders,No,Severe,418,64,65,15.31,No,,8,355,No,No,Discontinuation,25,2
NCT97763862,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 4,53,Fatigue,Gastrointestinal disorders,Yes,Mild,53,15,20,28.3,No,,9,192,Yes,Yes,Discontinuation,15,40
NCT31802454,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 1,59,Cardiotoxicity,Cardiac disorders,No,Moderate,59,8,10,13.56,No,,10,323,Yes,No,Discontinuation,8,34
NCT41443689,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,48,Hypothyroidism,Skin disorders,No,Mild,48,1,6,2.08,No,,16,362,Yes,No,Supportive care,5,74
NCT59089290,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,107,Diarrhea,Respiratory disorders,Yes,Severe,107,32,34,29.91,No,,20,97,Yes,Yes,Supportive care,17,51
NCT52757731,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,159,Hypothyroidism,Cardiac disorders,No,Severe,159,20,25,12.58,No,,7,342,No,No,Discontinuation,30,88
NCT89800866,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,211,Diarrhea,Cardiac disorders,No,Mild,211,55,56,26.07,No,,7,99,No,No,Dose reduction,26,80
NCT90157847,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 3,475,Pneumonitis,Respiratory disorders,No,Mild,475,119,124,25.05,No,,12,183,Yes,Yes,Discontinuation,12,11
NCT81693130,Adalimumab,Anti-TNF-alpha,Breast Cancer,Phase 4,127,Infusion-related reaction,Blood disorders,No,Moderate,127,7,10,5.51,No,,2,109,No,No,Dose reduction,11,80
NCT97113466,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,343,Hypothyroidism,Skin disorders,No,Mild,343,98,101,28.57,No,,20,259,No,Yes,Treatment interruption,28,36
NCT31302946,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 2,344,Hyperthyroidism,Respiratory disorders,No,Severe,344,21,25,6.1,No,,11,200,No,Yes,Discontinuation,29,72
NCT15737648,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,363,Thrombocytopenia,Blood disorders,No,Severe,363,47,51,12.95,Yes,Lack of efficacy,13,281,Yes,Yes,Dose reduction,10,36
NCT99907711,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,446,Colitis,Hepatobiliary disorders,No,Moderate,446,16,16,3.59,No,,15,123,No,No,Discontinuation,13,81
NCT88311887,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 3,77,Diarrhea,Musculoskeletal disorders,No,Mild,77,9,14,11.69,No,,10,63,Yes,Yes,Supportive care,26,31
NCT75369063,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,364,Anemia,Respiratory disorders,No,Mild,364,23,23,6.32,No,,20,52,No,Yes,Supportive care,11,44
NCT66422724,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 4,473,Pneumonitis,Gastrointestinal disorders,No,Severe,473,46,46,9.73,Yes,Lack of efficacy,4,34,No,No,Supportive care,20,77
NCT16873622,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,186,Diarrhea,Blood disorders,Yes,Mild,186,38,43,20.43,No,,20,276,No,No,Treatment interruption,4,82
NCT50474639,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 1,216,Anemia,Blood disorders,No,Mild,216,24,28,11.11,No,,1,298,Yes,Yes,Treatment interruption,6,31
NCT63953666,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 1,385,Hypothyroidism,Hepatobiliary disorders,No,Mild,385,68,69,17.66,No,,12,279,No,No,Supportive care,15,4
NCT21289814,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 3,396,Rash,Cardiac disorders,No,Moderate,396,34,37,8.59,No,,15,352,Yes,No,Supportive care,2,86
NCT58564033,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 3,409,Cardiotoxicity,Endocrine disorders,No,Mild,409,65,66,15.89,No,,7,156,Yes,No,Discontinuation,7,17
NCT49997145,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 2,296,Diarrhea,Gastrointestinal disorders,No,Moderate,296,37,42,12.5,No,,1,92,Yes,Yes,Discontinuation,3,49
NCT42861789,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,339,Hyperthyroidism,General disorders,No,Moderate,339,29,30,8.55,Yes,Safety concerns,5,141,Yes,Yes,Discontinuation,16,31
NCT42268046,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 2,433,Hypothyroidism,Musculoskeletal disorders,Yes,Moderate,433,121,124,27.94,No,,5,136,Yes,Yes,Treatment interruption,1,5
NCT51435293,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 1,119,Pneumonitis,Respiratory disorders,No,Moderate,119,12,13,10.08,No,,6,170,No,No,Treatment interruption,24,73
NCT92236063,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,434,Nausea,Skin disorders,No,Mild,434,45,49,10.37,No,,3,195,No,Yes,Supportive care,12,62
NCT70693552,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 3,39,Thrombocytopenia,Cardiac disorders,No,Moderate,39,9,9,23.08,No,,8,232,Yes,Yes,Treatment interruption,15,50
NCT97406628,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,49,Pneumonitis,Blood disorders,No,Moderate,49,12,16,24.49,No,,17,283,Yes,Yes,Supportive care,13,45
NCT99487444,Adalimumab,Anti-TNF-alpha,Breast Cancer,Phase 1,234,Diarrhea,Gastrointestinal disorders,No,Moderate,234,64,68,27.35,No,,16,36,Yes,Yes,Treatment interruption,25,74
NCT72890804,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 1,40,Neutropenia,Skin disorders,No,Severe,40,10,11,25.0,No,,15,32,Yes,No,Dose reduction,28,35
NCT81972343,Adalimumab,Anti-TNF-alpha,Breast Cancer,Phase 4,299,Arthralgia,Cardiac disorders,Yes,Moderate,299,59,63,19.73,Yes,Regulatory issues,1,60,No,Yes,Treatment interruption,30,85
NCT61106572,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 2,317,Diarrhea,Cardiac disorders,No,Mild,317,35,39,11.04,No,,1,198,Yes,No,Supportive care,10,56
NCT10496533,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 2,25,Rash,Endocrine disorders,Yes,Mild,25,6,9,24.0,No,,7,303,No,Yes,Discontinuation,1,70
NCT18816276,Adalimumab,Anti-TNF-alpha,Breast Cancer,Phase 3,216,Fatigue,Skin disorders,No,Moderate,216,39,41,18.06,No,,1,259,Yes,No,Supportive care,4,84
NCT78367363,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 4,444,Neutropenia,Respiratory disorders,Yes,Mild,444,52,53,11.71,No,,13,70,No,No,Treatment interruption,28,54
NCT81013932,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,318,Infusion-related reaction,Blood disorders,No,Moderate,318,31,35,9.75,No,,19,195,Yes,No,Treatment interruption,29,2
NCT67844774,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,180,Cardiotoxicity,Skin disorders,No,Moderate,180,19,22,10.56,Yes,Lack of efficacy,2,362,Yes,Yes,Discontinuation,3,15
NCT59473890,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,457,Arthralgia,Hepatobiliary disorders,No,Severe,457,84,85,18.38,No,,19,169,No,Yes,Dose reduction,25,48
NCT67400600,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 3,110,Neutropenia,Gastrointestinal disorders,No,Mild,110,33,38,30.0,No,,19,267,No,No,Discontinuation,10,83
NCT40012602,Adalimumab,Anti-TNF-alpha,Breast Cancer,Phase 2,25,Diarrhea,Respiratory disorders,No,Severe,25,3,8,12.0,Yes,Safety concerns,3,296,Yes,Yes,Supportive care,5,55
NCT69208560,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,148,Hepatotoxicity,Cardiac disorders,Yes,Mild,148,38,39,25.68,No,,10,168,Yes,No,Treatment interruption,17,75
NCT73914304,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,202,Pneumonitis,Musculoskeletal disorders,No,Mild,202,19,24,9.41,No,,16,269,No,Yes,Dose reduction,17,63
NCT52268951,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 1,172,Hepatotoxicity,Gastrointestinal disorders,No,Mild,172,14,15,8.14,No,,17,104,Yes,No,Discontinuation,1,47
NCT13693469,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,488,Infusion-related reaction,General disorders,No,Mild,488,77,78,15.78,No,,10,346,Yes,No,Dose reduction,27,84
NCT42850068,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 1,333,Infusion-related reaction,Endocrine disorders,No,Mild,333,22,24,6.61,No,,2,361,No,No,Treatment interruption,18,15
NCT95758691,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 4,336,Fatigue,Gastrointestinal disorders,No,Mild,336,54,59,16.07,Yes,Safety concerns,13,55,No,No,Supportive care,2,13
NCT45842169,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,157,Hyperthyroidism,Endocrine disorders,No,Mild,157,43,46,27.39,No,,3,354,No,No,Discontinuation,12,63
NCT95363236,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,483,Infusion-related reaction,Respiratory disorders,No,Mild,483,78,79,16.15,No,,9,303,No,No,Discontinuation,17,40
NCT26061629,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 3,409,Arthralgia,Skin disorders,No,Mild,409,73,78,17.85,No,,20,93,No,No,Treatment interruption,25,6
NCT11716091,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,195,Neutropenia,Gastrointestinal disorders,No,Mild,195,7,8,3.59,No,,9,32,No,No,Supportive care,19,51
NCT15823862,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 2,203,Anemia,Musculoskeletal disorders,No,Mild,203,51,55,25.12,No,,7,163,Yes,Yes,Discontinuation,12,54
NCT45668535,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 1,265,Anemia,Respiratory disorders,Yes,Severe,265,46,48,17.36,Yes,Competition,9,284,No,Yes,Dose reduction,5,41
NCT64928886,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 4,360,Neutropenia,Musculoskeletal disorders,No,Severe,360,16,19,4.44,No,,14,361,Yes,Yes,Supportive care,11,11
NCT41263471,Adalimumab,Anti-TNF-alpha,Multiple Myeloma,Phase 2,114,Colitis,Hepatobiliary disorders,Yes,Mild,114,11,12,9.65,No,,3,207,Yes,No,Dose reduction,15,58
NCT77932360,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,453,Rash,General disorders,No,Severe,453,6,6,1.32,Yes,Regulatory issues,5,328,Yes,Yes,Supportive care,29,55
NCT26080870,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,160,Hepatotoxicity,Gastrointestinal disorders,Yes,Mild,160,41,44,25.62,No,,15,179,Yes,Yes,Discontinuation,27,33
NCT89812538,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,304,Anemia,Blood disorders,No,Moderate,304,18,18,5.92,No,,7,230,No,Yes,Dose reduction,22,36
NCT91896102,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,478,Fatigue,Blood disorders,No,Mild,478,86,91,17.99,No,,19,257,Yes,No,Dose reduction,25,9
NCT43924364,Adalimumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,321,Pneumonitis,Endocrine disorders,No,Severe,321,41,42,12.77,No,,7,81,Yes,Yes,Treatment interruption,4,64
NCT72951534,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 1,383,Cardiotoxicity,Skin disorders,Yes,Severe,383,58,58,15.14,Yes,Regulatory issues,20,161,Yes,Yes,Dose reduction,22,25
NCT97841174,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,202,Cardiotoxicity,Cardiac disorders,No,Moderate,202,2,3,0.99,No,,7,157,No,Yes,Dose reduction,2,62
NCT96407769,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 3,495,Hypothyroidism,General disorders,No,Moderate,495,135,136,27.27,No,,10,83,No,Yes,Discontinuation,22,45
NCT34639956,Adalimumab,Anti-TNF-alpha,Melanoma,Phase 4,355,Hypothyroidism,Skin disorders,No,Moderate,355,48,48,13.52,No,,12,277,Yes,Yes,Supportive care,29,18
NCT78642223,Adalimumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,33,Neutropenia,Respiratory disorders,No,Mild,33,8,11,24.24,No,,3,162,No,No,Dose reduction,18,68
NCT45178127,Adalimumab,Anti-TNF-alpha,Lung Cancer,Phase 3,229,Hypothyroidism,Gastrointestinal disorders,No,Mild,229,2,6,0.87,No,,19,86,Yes,Yes,Discontinuation,30,9
NCT89424162,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,94,Fatigue,Skin disorders,Yes,Mild,94,8,13,8.51,No,,15,186,No,No,Treatment interruption,13,28
NCT79635013,Adalimumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,377,Hyperthyroidism,Endocrine disorders,No,Moderate,377,90,93,23.87,No,,17,38,Yes,Yes,Discontinuation,30,30
NCT75348891,Adalimumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 2,74,Thrombocytopenia,General disorders,No,Moderate,74,1,2,1.35,No,,14,356,No,Yes,Dose reduction,2,63
NCT42642467,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,176,Diarrhea,Musculoskeletal disorders,No,Moderate,176,38,38,21.59,No,,7,192,No,No,Discontinuation,21,12
NCT82835984,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 3,418,Thrombocytopenia,Respiratory disorders,Yes,Moderate,418,4,9,0.96,No,,11,245,No,No,Discontinuation,28,52
NCT51058226,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,357,Diarrhea,Respiratory disorders,No,Mild,357,106,110,29.69,No,,4,322,No,Yes,Treatment interruption,13,26
NCT21368080,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,246,Thrombocytopenia,Endocrine disorders,Yes,Severe,246,10,12,4.07,No,,2,54,No,No,Supportive care,3,20
NCT18726596,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 2,368,Thrombocytopenia,Hepatobiliary disorders,No,Mild,368,68,71,18.48,No,,10,191,Yes,No,Treatment interruption,30,22
NCT29676566,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 1,62,Hepatotoxicity,General disorders,No,Mild,62,11,14,17.74,No,,9,220,Yes,No,Discontinuation,6,20
NCT85204171,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,29,Cardiotoxicity,Musculoskeletal disorders,No,Moderate,29,2,4,6.9,Yes,Regulatory issues,20,362,Yes,Yes,Treatment interruption,2,56
NCT93844809,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,463,Rash,General disorders,No,Mild,463,30,34,6.48,No,,3,311,Yes,Yes,Supportive care,27,5
NCT95098188,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 3,249,Colitis,Respiratory disorders,No,Mild,249,33,33,13.25,No,,2,218,Yes,No,Treatment interruption,19,69
NCT60447349,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 2,154,Rash,Musculoskeletal disorders,No,Moderate,154,16,21,10.39,No,,6,186,Yes,No,Supportive care,18,48
NCT73139713,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,440,Rash,Respiratory disorders,No,Mild,440,120,123,27.27,No,,16,337,Yes,No,Discontinuation,28,36
NCT51975701,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 1,425,Cardiotoxicity,Hepatobiliary disorders,No,Moderate,425,92,96,21.65,No,,8,36,Yes,No,Dose reduction,30,20
NCT22266637,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 3,485,Rash,Endocrine disorders,No,Severe,485,93,95,19.18,No,,12,132,Yes,Yes,Discontinuation,13,69
NCT95978029,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,365,Thrombocytopenia,Musculoskeletal disorders,No,Mild,365,84,85,23.01,No,,13,74,No,No,Supportive care,3,59
NCT38889542,Infliximab,Anti-TNF-alpha,Breast Cancer,Phase 4,206,Arthralgia,General disorders,No,Mild,206,52,54,25.24,No,,8,333,Yes,No,Supportive care,3,1
NCT52269815,Infliximab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,298,Thrombocytopenia,Skin disorders,Yes,Moderate,298,5,7,1.68,No,,2,107,No,No,Discontinuation,3,44
NCT64424938,Infliximab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 2,96,Cardiotoxicity,Respiratory disorders,No,Severe,96,19,19,19.79,No,,14,181,Yes,No,Discontinuation,5,90
NCT93439079,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 1,444,Hypothyroidism,Musculoskeletal disorders,No,Moderate,444,41,41,9.23,No,,1,83,Yes,No,Supportive care,10,24
NCT49080566,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 1,183,Hypothyroidism,Musculoskeletal disorders,No,Mild,183,24,28,13.11,No,,2,331,No,Yes,Supportive care,12,19
NCT60331236,Infliximab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,60,Diarrhea,Cardiac disorders,No,Mild,60,17,18,28.33,No,,4,328,Yes,Yes,Supportive care,30,48
NCT98999107,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,185,Cardiotoxicity,Blood disorders,No,Moderate,185,6,9,3.24,Yes,Lack of efficacy,16,236,No,Yes,Discontinuation,3,10
NCT49801027,Infliximab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,137,Hypothyroidism,Blood disorders,No,Mild,137,39,41,28.47,No,,7,159,No,No,Treatment interruption,2,33
NCT95340257,Infliximab,Anti-TNF-alpha,Breast Cancer,Phase 4,52,Rash,Hepatobiliary disorders,No,Moderate,52,3,7,5.77,No,,7,144,Yes,Yes,Dose reduction,13,30
NCT81193085,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 3,150,Hyperthyroidism,Musculoskeletal disorders,No,Mild,150,28,29,18.67,No,,17,346,Yes,Yes,Treatment interruption,6,87
NCT23646933,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,191,Pneumonitis,Skin disorders,Yes,Severe,191,16,18,8.38,Yes,Competition,2,105,No,No,Supportive care,13,62
NCT88050982,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,27,Hepatotoxicity,Cardiac disorders,No,Mild,27,4,4,14.81,No,,7,227,Yes,No,Discontinuation,5,53
NCT94179893,Infliximab,Anti-TNF-alpha,Melanoma,Phase 2,446,Arthralgia,Hepatobiliary disorders,Yes,Moderate,446,48,49,10.76,Yes,Lack of efficacy,16,289,Yes,Yes,Discontinuation,21,43
NCT25623513,Infliximab,Anti-TNF-alpha,Melanoma,Phase 1,465,Colitis,Blood disorders,No,Mild,465,47,47,10.11,No,,9,97,No,No,Supportive care,24,12
NCT30241044,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,33,Infusion-related reaction,Skin disorders,No,Moderate,33,2,3,6.06,No,,9,90,Yes,Yes,Supportive care,18,57
NCT41193365,Infliximab,Anti-TNF-alpha,Breast Cancer,Phase 3,471,Hepatotoxicity,Cardiac disorders,No,Mild,471,23,23,4.88,No,,12,238,No,No,Treatment interruption,11,38
NCT63668642,Infliximab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,306,Arthralgia,Gastrointestinal disorders,No,Moderate,306,86,88,28.1,No,,19,138,Yes,Yes,Discontinuation,10,81
NCT16334533,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,167,Arthralgia,Skin disorders,No,Mild,167,19,21,11.38,No,,14,160,No,Yes,Dose reduction,9,4
NCT36120893,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,191,Diarrhea,Respiratory disorders,No,Mild,191,30,31,15.71,No,,9,251,No,No,Treatment interruption,23,26
NCT41388773,Infliximab,Anti-TNF-alpha,Melanoma,Phase 4,468,Hyperthyroidism,Respiratory disorders,No,Mild,468,76,76,16.24,No,,12,111,Yes,No,Dose reduction,8,80
NCT30498620,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,28,Infusion-related reaction,Endocrine disorders,No,Mild,28,5,6,17.86,No,,16,342,No,Yes,Dose reduction,19,20
NCT67883087,Infliximab,Anti-TNF-alpha,Melanoma,Phase 3,325,Thrombocytopenia,Gastrointestinal disorders,No,Severe,325,22,24,6.77,No,,8,164,No,No,Dose reduction,12,17
NCT45210629,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,101,Diarrhea,Cardiac disorders,No,Mild,101,5,8,4.95,No,,17,216,No,No,Dose reduction,6,46
NCT31119780,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,38,Neutropenia,General disorders,No,Moderate,38,4,9,10.53,No,,20,84,No,Yes,Dose reduction,15,26
NCT34226225,Infliximab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,328,Rash,Cardiac disorders,No,Mild,328,79,83,24.09,No,,15,40,No,No,Dose reduction,25,7
NCT73631751,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 1,381,Thrombocytopenia,Gastrointestinal disorders,No,Mild,381,62,66,16.27,Yes,Competition,8,215,No,Yes,Supportive care,29,82
NCT99282977,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 1,228,Hyperthyroidism,General disorders,No,Severe,228,8,12,3.51,No,,17,42,Yes,No,Discontinuation,4,48
NCT27120077,Infliximab,Anti-TNF-alpha,Breast Cancer,Phase 3,305,Infusion-related reaction,Hepatobiliary disorders,No,Mild,305,38,40,12.46,No,,5,34,Yes,No,Supportive care,9,24
NCT22296271,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 4,260,Rash,Skin disorders,Yes,Mild,260,6,10,2.31,No,,4,268,No,Yes,Supportive care,1,43
NCT18663281,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,433,Nausea,Gastrointestinal disorders,No,Moderate,433,71,76,16.4,Yes,Lack of efficacy,9,160,Yes,Yes,Supportive care,8,29
NCT65687745,Infliximab,Anti-TNF-alpha,Lung Cancer,Phase 3,85,Thrombocytopenia,Hepatobiliary disorders,No,Severe,85,6,6,7.06,No,,13,205,No,Yes,Dose reduction,6,22
NCT64410381,Infliximab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,262,Infusion-related reaction,Respiratory disorders,No,Moderate,262,65,67,24.81,Yes,Safety concerns,12,242,Yes,No,Treatment interruption,23,29
NCT75680684,Infliximab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,212,Hepatotoxicity,Musculoskeletal disorders,No,Moderate,212,21,25,9.91,No,,1,272,Yes,No,Discontinuation,16,63
NCT34520461,Infliximab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 3,77,Rash,Gastrointestinal disorders,No,Mild,77,9,12,11.69,No,,16,104,No,No,Discontinuation,22,62
NCT65720621,Infliximab,Anti-TNF-alpha,Multiple Myeloma,Phase 2,428,Hepatotoxicity,Blood disorders,No,Severe,428,26,26,6.07,No,,5,330,No,Yes,Dose reduction,3,6
NCT36701375,Infliximab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,305,Cardiotoxicity,General disorders,Yes,Moderate,305,9,12,2.95,Yes,Safety concerns,16,346,Yes,No,Discontinuation,21,15
NCT11848614,Infliximab,Anti-TNF-alpha,Breast Cancer,Phase 2,407,Hyperthyroidism,Respiratory disorders,No,Severe,407,8,12,1.97,No,,9,190,Yes,Yes,Discontinuation,10,50
NCT75869143,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 2,481,Pneumonitis,Blood disorders,No,Severe,481,60,65,12.47,No,,19,58,No,No,Discontinuation,16,48
NCT37958707,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 2,309,Infusion-related reaction,Cardiac disorders,No,Mild,309,33,37,10.68,No,,15,358,Yes,No,Dose reduction,7,51
NCT26273898,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,116,Infusion-related reaction,Blood disorders,No,Severe,116,7,10,6.03,Yes,Regulatory issues,8,211,Yes,Yes,Treatment interruption,4,56
NCT32444726,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,440,Fatigue,Skin disorders,No,Severe,440,84,88,19.09,No,,2,290,Yes,Yes,Discontinuation,6,35
NCT44511078,Certolizumab,Anti-TNF-alpha,Melanoma,Phase 4,320,Hypothyroidism,Gastrointestinal disorders,No,Mild,320,16,18,5.0,No,,6,201,Yes,Yes,Treatment interruption,13,45
NCT49319446,Certolizumab,Anti-TNF-alpha,Melanoma,Phase 2,102,Infusion-related reaction,General disorders,No,Severe,102,28,32,27.45,No,,11,171,No,No,Discontinuation,9,60
NCT54163607,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 2,367,Colitis,Hepatobiliary disorders,No,Moderate,367,13,14,3.54,No,,17,106,No,No,Treatment interruption,22,12
NCT82945859,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,407,Pneumonitis,Musculoskeletal disorders,No,Mild,407,64,67,15.72,No,,4,38,Yes,No,Treatment interruption,7,60
NCT59422641,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 4,201,Hepatotoxicity,General disorders,No,Severe,201,55,57,27.36,Yes,Regulatory issues,8,223,Yes,Yes,Supportive care,19,5
NCT61579257,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,373,Nausea,Endocrine disorders,No,Moderate,373,14,16,3.75,No,,9,364,No,Yes,Discontinuation,22,33
NCT60898884,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 2,443,Infusion-related reaction,Endocrine disorders,No,Severe,443,75,77,16.93,No,,11,174,No,Yes,Supportive care,9,63
NCT22304113,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,41,Thrombocytopenia,Cardiac disorders,No,Moderate,41,10,10,24.39,No,,4,95,No,No,Supportive care,6,12
NCT78539140,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 2,53,Neutropenia,General disorders,Yes,Mild,53,11,11,20.75,No,,12,341,No,Yes,Supportive care,1,76
NCT11889689,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,117,Neutropenia,Blood disorders,No,Mild,117,19,20,16.24,No,,9,305,No,Yes,Discontinuation,10,50
NCT34424671,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,436,Colitis,Endocrine disorders,No,Mild,436,71,73,16.28,No,,7,197,No,No,Supportive care,17,83
NCT90211665,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 1,493,Infusion-related reaction,Cardiac disorders,No,Mild,493,17,17,3.45,No,,8,328,Yes,No,Dose reduction,2,75
NCT44285274,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 4,268,Thrombocytopenia,Hepatobiliary disorders,No,Moderate,268,57,58,21.27,Yes,Safety concerns,7,122,Yes,Yes,Discontinuation,7,38
NCT65754929,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 3,176,Infusion-related reaction,Gastrointestinal disorders,No,Severe,176,12,15,6.82,Yes,Regulatory issues,19,178,No,No,Dose reduction,13,51
NCT10069862,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,141,Infusion-related reaction,Musculoskeletal disorders,No,Mild,141,12,15,8.51,No,,2,138,Yes,Yes,Discontinuation,9,62
NCT55098661,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,481,Anemia,Endocrine disorders,No,Severe,481,115,115,23.91,No,,6,184,No,No,Supportive care,18,11
NCT62903304,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 2,351,Hyperthyroidism,Hepatobiliary disorders,No,Severe,351,3,8,0.85,Yes,Regulatory issues,3,198,Yes,No,Supportive care,24,1
NCT76832892,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,341,Hepatotoxicity,Gastrointestinal disorders,No,Moderate,341,12,13,3.52,No,,6,103,Yes,Yes,Treatment interruption,30,51
NCT48978225,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 2,267,Hypothyroidism,Skin disorders,No,Severe,267,67,71,25.09,Yes,Safety concerns,11,35,Yes,No,Supportive care,23,36
NCT75806662,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,461,Cardiotoxicity,Skin disorders,No,Moderate,461,14,17,3.04,No,,9,333,Yes,No,Dose reduction,4,64
NCT53613249,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,262,Cardiotoxicity,Musculoskeletal disorders,No,Moderate,262,54,58,20.61,No,,8,210,Yes,No,Discontinuation,23,3
NCT56450837,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 2,115,Hepatotoxicity,Gastrointestinal disorders,No,Severe,115,25,28,21.74,No,,17,116,Yes,No,Discontinuation,25,14
NCT71414828,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,433,Anemia,Hepatobiliary disorders,Yes,Severe,433,15,17,3.46,Yes,Regulatory issues,14,336,Yes,Yes,Supportive care,5,30
NCT43691742,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,59,Neutropenia,Cardiac disorders,Yes,Moderate,59,3,6,5.08,No,,19,286,Yes,No,Treatment interruption,10,79
NCT50994308,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,365,Thrombocytopenia,Gastrointestinal disorders,No,Mild,365,48,50,13.15,Yes,Competition,2,201,Yes,Yes,Supportive care,18,8
NCT21991542,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 1,105,Anemia,Musculoskeletal disorders,No,Mild,105,29,32,27.62,No,,2,232,No,Yes,Discontinuation,30,41
NCT48681856,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 4,373,Diarrhea,Musculoskeletal disorders,No,Severe,373,33,37,8.85,No,,16,74,No,No,Discontinuation,23,31
NCT51325505,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,177,Hypothyroidism,Musculoskeletal disorders,No,Severe,177,36,38,20.34,No,,18,109,No,No,Discontinuation,26,46
NCT22471895,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,41,Hyperthyroidism,Gastrointestinal disorders,Yes,Severe,41,11,11,26.83,Yes,Safety concerns,12,193,Yes,Yes,Treatment interruption,10,24
NCT24230253,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,68,Pneumonitis,Gastrointestinal disorders,No,Severe,68,16,19,23.53,Yes,Safety concerns,3,195,Yes,Yes,Treatment interruption,22,4
NCT89183206,Certolizumab,Anti-TNF-alpha,Melanoma,Phase 2,113,Hepatotoxicity,Cardiac disorders,No,Mild,113,20,24,17.7,No,,18,53,Yes,No,Discontinuation,17,23
NCT31012902,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,211,Cardiotoxicity,Cardiac disorders,No,Mild,211,26,28,12.32,No,,5,234,Yes,No,Dose reduction,7,6
NCT38065869,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 1,299,Colitis,Gastrointestinal disorders,No,Mild,299,9,14,3.01,No,,5,179,No,Yes,Dose reduction,17,79
NCT70518100,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,490,Pneumonitis,Endocrine disorders,No,Mild,490,80,80,16.33,No,,10,204,Yes,Yes,Treatment interruption,15,80
NCT84164254,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 2,129,Cardiotoxicity,Musculoskeletal disorders,No,Mild,129,24,24,18.6,No,,12,101,Yes,No,Dose reduction,20,32
NCT20600315,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,105,Colitis,Cardiac disorders,No,Severe,105,16,17,15.24,No,,4,140,Yes,Yes,Supportive care,11,6
NCT32749102,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 3,494,Arthralgia,Skin disorders,No,Moderate,494,83,83,16.8,No,,7,204,Yes,Yes,Treatment interruption,6,58
NCT17729747,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,170,Thrombocytopenia,Gastrointestinal disorders,No,Severe,170,40,43,23.53,Yes,Competition,10,38,No,Yes,Treatment interruption,4,57
NCT25623712,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,247,Hepatotoxicity,Skin disorders,No,Mild,247,59,59,23.89,No,,13,88,Yes,Yes,Supportive care,28,49
NCT27102991,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 4,312,Rash,Respiratory disorders,Yes,Moderate,312,8,12,2.56,Yes,Regulatory issues,10,142,Yes,No,Discontinuation,23,84
NCT85198759,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 4,95,Neutropenia,Cardiac disorders,No,Severe,95,3,6,3.16,No,,14,116,Yes,No,Supportive care,21,49
NCT19198388,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 3,323,Diarrhea,General disorders,No,Mild,323,61,65,18.89,No,,1,89,No,No,Treatment interruption,10,55
NCT45915281,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 2,483,Cardiotoxicity,Gastrointestinal disorders,No,Mild,483,50,50,10.35,No,,15,252,No,Yes,Dose reduction,11,15
NCT28701059,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,347,Neutropenia,Gastrointestinal disorders,No,Moderate,347,49,51,14.12,No,,17,129,Yes,No,Supportive care,10,23
NCT46341374,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 4,324,Rash,Respiratory disorders,No,Mild,324,25,25,7.72,No,,13,142,No,Yes,Supportive care,9,19
NCT65758661,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 2,148,Anemia,Respiratory disorders,No,Mild,148,8,11,5.41,No,,18,68,Yes,Yes,Supportive care,2,46
NCT19630401,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 4,360,Fatigue,Musculoskeletal disorders,No,Moderate,360,3,4,0.83,No,,16,110,Yes,Yes,Treatment interruption,11,89
NCT85070968,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,196,Nausea,Hepatobiliary disorders,Yes,Mild,196,23,26,11.73,No,,5,217,Yes,No,Supportive care,25,50
NCT98259755,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 2,128,Pneumonitis,Gastrointestinal disorders,No,Mild,128,14,17,10.94,No,,20,156,Yes,Yes,Supportive care,15,74
NCT70974122,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 3,489,Nausea,Respiratory disorders,No,Moderate,489,120,122,24.54,No,,19,353,Yes,Yes,Dose reduction,26,86
NCT80414183,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,295,Anemia,Blood disorders,No,Moderate,295,36,37,12.2,No,,12,347,Yes,Yes,Supportive care,1,70
NCT31659229,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 3,330,Infusion-related reaction,Blood disorders,No,Severe,330,67,70,20.3,No,,14,39,No,No,Supportive care,22,34
NCT43305553,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 1,435,Rash,General disorders,No,Moderate,435,103,107,23.68,No,,5,351,No,Yes,Treatment interruption,11,3
NCT40725139,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,263,Fatigue,Respiratory disorders,No,Mild,263,4,4,1.52,No,,7,280,Yes,Yes,Treatment interruption,16,60
NCT77590736,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,408,Anemia,Cardiac disorders,No,Severe,408,42,46,10.29,No,,6,96,Yes,Yes,Treatment interruption,2,83
NCT52456764,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,290,Infusion-related reaction,Hepatobiliary disorders,No,Mild,290,46,47,15.86,No,,9,302,Yes,No,Dose reduction,10,89
NCT65399155,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 4,79,Thrombocytopenia,Hepatobiliary disorders,No,Moderate,79,15,17,18.99,No,,4,137,Yes,Yes,Treatment interruption,17,4
NCT30423328,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,428,Pneumonitis,Blood disorders,No,Moderate,428,25,27,5.84,No,,9,66,No,No,Treatment interruption,20,40
NCT40924700,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,172,Anemia,Respiratory disorders,Yes,Mild,172,29,32,16.86,Yes,Regulatory issues,14,87,No,No,Discontinuation,23,27
NCT11539894,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 1,323,Diarrhea,Skin disorders,No,Mild,323,41,44,12.69,No,,7,163,Yes,Yes,Treatment interruption,20,83
NCT88964344,Certolizumab,Anti-TNF-alpha,Melanoma,Phase 1,478,Thrombocytopenia,Respiratory disorders,No,Moderate,478,127,131,26.57,Yes,Competition,8,358,No,No,Discontinuation,20,27
NCT37307195,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 3,279,Hepatotoxicity,Skin disorders,Yes,Moderate,279,10,11,3.58,No,,14,291,Yes,Yes,Dose reduction,26,47
NCT90927113,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,91,Anemia,General disorders,No,Mild,91,3,8,3.3,No,,5,70,Yes,Yes,Discontinuation,13,31
NCT21502265,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,152,Pneumonitis,Musculoskeletal disorders,No,Mild,152,24,29,15.79,No,,17,195,Yes,Yes,Treatment interruption,2,79
NCT35815049,Certolizumab,Anti-TNF-alpha,Colorectal Cancer,Phase 2,196,Colitis,Endocrine disorders,Yes,Moderate,196,7,10,3.57,Yes,Safety concerns,16,151,Yes,No,Discontinuation,24,64
NCT85051282,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,461,Hypothyroidism,Skin disorders,No,Mild,461,134,138,29.07,No,,2,228,No,Yes,Dose reduction,15,49
NCT75462153,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 4,102,Nausea,Endocrine disorders,No,Severe,102,8,8,7.84,Yes,Lack of efficacy,16,276,No,Yes,Treatment interruption,30,12
NCT19263514,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,472,Colitis,Respiratory disorders,Yes,Mild,472,62,65,13.14,No,,9,215,No,Yes,Dose reduction,2,55
NCT96666178,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 1,245,Fatigue,Musculoskeletal disorders,No,Severe,245,56,61,22.86,No,,11,239,No,Yes,Discontinuation,6,43
NCT59410932,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 2,463,Arthralgia,Skin disorders,No,Moderate,463,41,46,8.86,No,,5,232,Yes,No,Supportive care,29,45
NCT36854414,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 1,435,Rash,Hepatobiliary disorders,No,Moderate,435,27,28,6.21,No,,5,353,No,Yes,Treatment interruption,11,36
NCT51006828,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 2,155,Neutropenia,General disorders,No,Moderate,155,46,46,29.68,No,,13,54,Yes,Yes,Treatment interruption,23,28
NCT49547975,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 1,33,Hepatotoxicity,Skin disorders,No,Moderate,33,9,9,27.27,No,,5,85,No,Yes,Supportive care,1,5
NCT56536725,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,402,Fatigue,Cardiac disorders,Yes,Severe,402,16,18,3.98,Yes,Competition,12,164,No,Yes,Treatment interruption,12,21
NCT74490820,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 3,489,Neutropenia,Musculoskeletal disorders,No,Moderate,489,67,68,13.7,No,,12,344,No,Yes,Treatment interruption,8,10
NCT85211641,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,489,Hepatotoxicity,Blood disorders,No,Severe,489,142,147,29.04,Yes,Lack of efficacy,9,200,No,No,Supportive care,10,73
NCT19661357,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 2,225,Arthralgia,Endocrine disorders,No,Severe,225,11,16,4.89,No,,16,127,Yes,No,Dose reduction,30,57
NCT36574354,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 4,323,Cardiotoxicity,Hepatobiliary disorders,No,Moderate,323,4,7,1.24,No,,14,354,No,No,Dose reduction,4,19
NCT95111586,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,84,Rash,Gastrointestinal disorders,Yes,Mild,84,13,15,15.48,No,,3,190,Yes,No,Supportive care,3,17
NCT62643350,Certolizumab,Anti-TNF-alpha,Melanoma,Phase 4,97,Neutropenia,Gastrointestinal disorders,No,Moderate,97,17,20,17.53,No,,1,144,No,No,Discontinuation,18,48
NCT29263128,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 4,498,Colitis,Cardiac disorders,No,Severe,498,63,68,12.65,No,,1,278,No,Yes,Supportive care,8,18
NCT48691700,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 1,93,Colitis,Musculoskeletal disorders,No,Moderate,93,11,12,11.83,Yes,Competition,12,120,Yes,Yes,Discontinuation,30,44
NCT89418209,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,349,Fatigue,General disorders,No,Mild,349,71,72,20.34,No,,4,224,No,No,Dose reduction,23,45
NCT22114551,Certolizumab,Anti-TNF-alpha,Breast Cancer,Phase 3,321,Nausea,Musculoskeletal disorders,No,Moderate,321,38,42,11.84,No,,15,225,No,No,Discontinuation,15,67
NCT89659485,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 3,319,Colitis,General disorders,No,Moderate,319,34,37,10.66,No,,6,324,Yes,Yes,Discontinuation,8,19
NCT65313924,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 4,286,Infusion-related reaction,Cardiac disorders,No,Severe,286,5,6,1.75,No,,18,257,No,No,Supportive care,23,15
NCT54851858,Certolizumab,Anti-TNF-alpha,Lung Cancer,Phase 3,462,Cardiotoxicity,Skin disorders,Yes,Mild,462,130,132,28.14,No,,17,242,No,No,Supportive care,30,34
NCT22413357,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 2,328,Hepatotoxicity,Gastrointestinal disorders,No,Mild,328,32,33,9.76,No,,13,92,Yes,Yes,Supportive care,12,4
NCT80718828,Certolizumab,Anti-TNF-alpha,Multiple Sclerosis,Phase 2,438,Rash,Cardiac disorders,Yes,Moderate,438,43,46,9.82,No,,15,157,No,No,Supportive care,11,90
NCT29129650,Certolizumab,Anti-TNF-alpha,Rheumatoid Arthritis,Phase 3,482,Fatigue,Skin disorders,No,Moderate,482,87,87,18.05,No,,6,186,Yes,No,Discontinuation,15,89
NCT10150718,Certolizumab,Anti-TNF-alpha,Multiple Myeloma,Phase 1,26,Pneumonitis,Blood disorders,Yes,Severe,26,3,6,11.54,No,,20,248,No,No,Dose reduction,18,2
NCT84334582,Certolizumab,Anti-TNF-alpha,Non-Hodgkin Lymphoma,Phase 4,252,Anemia,Musculoskeletal disorders,No,Mild,252,14,17,5.56,No,,3,70,Yes,Yes,Supportive care,18,39
NCT25210598,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 4,51,Neutropenia,Musculoskeletal disorders,No,Moderate,51,1,2,1.96,No,,7,165,No,No,Treatment interruption,2,32
NCT34169753,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 3,474,Nausea,Skin disorders,No,Mild,474,32,32,6.75,No,,7,91,No,No,Dose reduction,2,90
NCT51962243,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 2,169,Fatigue,General disorders,Yes,Moderate,169,25,29,14.79,No,,1,63,No,No,Discontinuation,23,39
NCT31010111,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 2,264,Nausea,Cardiac disorders,No,Severe,264,75,76,28.41,No,,6,322,No,No,Dose reduction,17,53
NCT86389587,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,407,Hyperthyroidism,Cardiac disorders,Yes,Moderate,407,25,30,6.14,Yes,Lack of efficacy,6,267,No,Yes,Dose reduction,13,51
NCT25510588,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,168,Pneumonitis,Respiratory disorders,No,Severe,168,39,43,23.21,No,,20,69,No,No,Treatment interruption,28,48
NCT89168990,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 3,320,Pneumonitis,Endocrine disorders,No,Mild,320,65,70,20.31,No,,20,290,No,Yes,Treatment interruption,10,49
NCT15532415,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 3,438,Diarrhea,Skin disorders,Yes,Moderate,438,44,47,10.05,Yes,Safety concerns,5,153,No,No,Treatment interruption,17,44
NCT38126183,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 3,255,Anemia,Musculoskeletal disorders,No,Moderate,255,42,45,16.47,No,,5,170,No,No,Discontinuation,20,55
NCT81199939,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,493,Rash,Musculoskeletal disorders,No,Moderate,493,121,126,24.54,No,,3,106,Yes,No,Supportive care,25,82
NCT77869059,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,260,Anemia,Cardiac disorders,No,Moderate,260,67,67,25.77,No,,4,98,Yes,No,Discontinuation,9,31
NCT39597652,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,150,Cardiotoxicity,Respiratory disorders,Yes,Mild,150,19,21,12.67,Yes,Safety concerns,12,212,No,Yes,Dose reduction,13,87
NCT51855456,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 1,391,Neutropenia,Gastrointestinal disorders,No,Severe,391,55,59,14.07,Yes,Safety concerns,18,312,No,No,Dose reduction,13,60
NCT98793280,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 4,49,Cardiotoxicity,General disorders,No,Moderate,49,13,17,26.53,No,,7,272,Yes,No,Dose reduction,7,20
NCT36411123,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 3,482,Diarrhea,Blood disorders,No,Severe,482,56,56,11.62,No,,6,234,No,No,Treatment interruption,8,19
NCT13979393,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 4,140,Cardiotoxicity,Musculoskeletal disorders,No,Severe,140,38,42,27.14,No,,1,96,No,No,Discontinuation,30,39
NCT29049298,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 4,305,Colitis,Cardiac disorders,No,Severe,305,80,84,26.23,No,,17,256,Yes,Yes,Supportive care,4,34
NCT76291644,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 1,310,Cardiotoxicity,Blood disorders,No,Severe,310,79,79,25.48,Yes,Competition,11,215,No,No,Dose reduction,13,58
NCT63680231,Tocilizumab,Anti-IL-6,Melanoma,Phase 2,418,Colitis,Hepatobiliary disorders,No,Moderate,418,23,27,5.5,No,,7,138,No,No,Supportive care,8,58
NCT47288295,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 2,229,Thrombocytopenia,Endocrine disorders,No,Severe,229,32,37,13.97,Yes,Lack of efficacy,5,215,Yes,No,Supportive care,10,35
NCT16311343,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 4,348,Pneumonitis,Respiratory disorders,Yes,Mild,348,21,24,6.03,No,,7,52,Yes,Yes,Treatment interruption,26,49
NCT28902213,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 3,293,Pneumonitis,Skin disorders,No,Moderate,293,71,76,24.23,No,,5,167,Yes,Yes,Dose reduction,28,29
NCT89906681,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 2,282,Anemia,Hepatobiliary disorders,No,Moderate,282,64,67,22.7,No,,12,271,Yes,No,Dose reduction,8,70
NCT73666146,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 1,468,Nausea,Respiratory disorders,No,Mild,468,5,6,1.07,No,,16,209,Yes,Yes,Supportive care,13,83
NCT10113025,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 2,265,Colitis,Musculoskeletal disorders,No,Severe,265,10,10,3.77,No,,6,309,Yes,No,Supportive care,4,18
NCT37606866,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 2,78,Hypothyroidism,Cardiac disorders,No,Mild,78,14,16,17.95,Yes,Lack of efficacy,12,35,Yes,No,Discontinuation,29,40
NCT20924302,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 3,499,Colitis,General disorders,No,Mild,499,133,134,26.65,No,,1,220,Yes,No,Treatment interruption,24,73
NCT75343777,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 2,482,Hypothyroidism,Musculoskeletal disorders,No,Severe,482,9,9,1.87,No,,19,290,Yes,Yes,Treatment interruption,10,18
NCT64891842,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 2,280,Cardiotoxicity,Gastrointestinal disorders,No,Severe,280,23,28,8.21,No,,13,32,No,No,Discontinuation,2,8
NCT74186342,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,129,Infusion-related reaction,Blood disorders,No,Severe,129,15,15,11.63,No,,2,280,No,Yes,Treatment interruption,29,39
NCT27750349,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 3,347,Pneumonitis,Musculoskeletal disorders,No,Mild,347,33,38,9.51,No,,9,185,Yes,No,Dose reduction,4,21
NCT84168577,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 2,211,Arthralgia,Endocrine disorders,No,Mild,211,58,59,27.49,No,,5,103,Yes,Yes,Supportive care,22,47
NCT80828375,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 1,331,Hypothyroidism,Musculoskeletal disorders,No,Moderate,331,15,20,4.53,No,,2,247,No,No,Discontinuation,20,56
NCT61878041,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 4,442,Nausea,Hepatobiliary disorders,Yes,Severe,442,53,55,11.99,No,,20,124,Yes,No,Discontinuation,9,53
NCT92992270,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 3,338,Nausea,Respiratory disorders,No,Moderate,338,101,104,29.88,No,,8,343,Yes,No,Dose reduction,26,43
NCT54717171,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,500,Infusion-related reaction,Cardiac disorders,No,Severe,500,2,4,0.4,No,,19,249,No,Yes,Discontinuation,13,64
NCT15830524,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 2,166,Cardiotoxicity,Cardiac disorders,No,Mild,166,22,24,13.25,No,,7,216,Yes,Yes,Treatment interruption,15,24
NCT14408379,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 1,87,Fatigue,Endocrine disorders,No,Mild,87,24,25,27.59,No,,7,306,No,No,Dose reduction,17,86
NCT20836094,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 4,131,Rash,General disorders,Yes,Moderate,131,3,7,2.29,No,,6,52,Yes,Yes,Treatment interruption,28,1
NCT98086940,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 4,313,Neutropenia,Musculoskeletal disorders,No,Mild,313,14,16,4.47,No,,9,218,No,No,Discontinuation,5,85
NCT32933023,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 2,170,Pneumonitis,Hepatobiliary disorders,No,Moderate,170,39,43,22.94,No,,8,213,No,Yes,Treatment interruption,12,71
NCT15703466,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 2,466,Infusion-related reaction,Gastrointestinal disorders,No,Moderate,466,64,64,13.73,Yes,Safety concerns,14,316,Yes,No,Dose reduction,3,61
NCT30426851,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 3,329,Arthralgia,General disorders,No,Severe,329,63,68,19.15,Yes,Safety concerns,7,162,Yes,Yes,Discontinuation,10,43
NCT38613075,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,338,Thrombocytopenia,Musculoskeletal disorders,Yes,Severe,338,70,72,20.71,No,,4,337,Yes,No,Discontinuation,17,39
NCT23081719,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 3,348,Cardiotoxicity,Endocrine disorders,No,Severe,348,103,107,29.6,Yes,Lack of efficacy,18,247,No,No,Dose reduction,8,53
NCT41748920,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 4,72,Hepatotoxicity,Blood disorders,No,Mild,72,7,11,9.72,No,,7,164,No,No,Dose reduction,28,84
NCT25726911,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 2,454,Thrombocytopenia,Cardiac disorders,Yes,Severe,454,1,3,0.22,Yes,Competition,4,46,No,No,Discontinuation,16,6
NCT92158805,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 3,61,Nausea,Respiratory disorders,No,Moderate,61,6,11,9.84,No,,8,248,Yes,Yes,Supportive care,9,65
NCT85548926,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 3,179,Fatigue,Musculoskeletal disorders,No,Mild,179,30,32,16.76,No,,19,72,Yes,Yes,Dose reduction,18,79
NCT97960520,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 3,361,Cardiotoxicity,Skin disorders,No,Severe,361,87,91,24.1,No,,5,223,Yes,Yes,Dose reduction,1,11
NCT20796099,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,160,Anemia,Skin disorders,No,Mild,160,41,42,25.62,No,,10,223,Yes,No,Dose reduction,1,43
NCT68905525,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,394,Colitis,Musculoskeletal disorders,Yes,Severe,394,47,50,11.93,Yes,Safety concerns,10,321,Yes,No,Supportive care,5,77
NCT96982421,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 3,115,Rash,Respiratory disorders,Yes,Mild,115,32,37,27.83,No,,2,301,No,Yes,Treatment interruption,15,41
NCT10229493,Tocilizumab,Anti-IL-6,Melanoma,Phase 2,443,Rash,Respiratory disorders,No,Moderate,443,82,85,18.51,No,,3,198,Yes,Yes,Treatment interruption,11,55
NCT11368996,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,53,Pneumonitis,Skin disorders,No,Moderate,53,5,9,9.43,No,,16,251,No,No,Discontinuation,8,69
NCT16638140,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 1,358,Hyperthyroidism,Endocrine disorders,No,Mild,358,92,95,25.7,No,,19,166,No,No,Discontinuation,6,46
NCT89608755,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,153,Arthralgia,Cardiac disorders,No,Severe,153,32,33,20.92,No,,10,344,No,No,Supportive care,20,3
NCT20254939,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 1,397,Colitis,General disorders,Yes,Moderate,397,43,44,10.83,Yes,Competition,19,201,No,Yes,Dose reduction,2,21
NCT46752813,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 2,27,Pneumonitis,Hepatobiliary disorders,No,Mild,27,3,4,11.11,No,,18,207,No,No,Supportive care,12,59
NCT67669581,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 4,31,Pneumonitis,Blood disorders,No,Mild,31,4,7,12.9,No,,11,166,No,Yes,Treatment interruption,19,45
NCT95152335,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,298,Rash,Cardiac disorders,No,Mild,298,55,58,18.46,No,,14,83,Yes,No,Discontinuation,3,13
NCT28614854,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 4,373,Anemia,Endocrine disorders,No,Mild,373,48,51,12.87,No,,9,247,Yes,Yes,Treatment interruption,24,50
NCT81703343,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 3,497,Diarrhea,Gastrointestinal disorders,No,Mild,497,95,97,19.11,No,,6,305,Yes,Yes,Discontinuation,19,79
NCT54600166,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 3,268,Pneumonitis,Skin disorders,Yes,Mild,268,40,42,14.93,No,,14,314,Yes,No,Discontinuation,21,30
NCT52988536,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 1,427,Rash,Endocrine disorders,No,Severe,427,96,98,22.48,No,,1,227,Yes,Yes,Supportive care,6,31
NCT36273732,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,389,Thrombocytopenia,Musculoskeletal disorders,No,Mild,389,23,24,5.91,No,,9,304,Yes,No,Dose reduction,17,66
NCT96750764,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,120,Fatigue,General disorders,No,Mild,120,28,33,23.33,No,,13,130,No,Yes,Supportive care,29,55
NCT98179891,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 4,131,Colitis,Blood disorders,No,Mild,131,11,14,8.4,No,,16,362,Yes,Yes,Discontinuation,10,51
NCT97530403,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 2,193,Thrombocytopenia,Cardiac disorders,No,Moderate,193,53,54,27.46,No,,3,37,No,Yes,Dose reduction,30,61
NCT73776390,Tocilizumab,Anti-IL-6,Melanoma,Phase 1,409,Diarrhea,Respiratory disorders,No,Mild,409,75,79,18.34,No,,4,72,Yes,Yes,Dose reduction,19,5
NCT85665184,Tocilizumab,Anti-IL-6,Melanoma,Phase 1,98,Hypothyroidism,Hepatobiliary disorders,No,Moderate,98,13,13,13.27,No,,19,335,No,No,Dose reduction,9,44
NCT84792735,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 4,204,Neutropenia,Hepatobiliary disorders,No,Severe,204,50,53,24.51,Yes,Competition,15,221,No,Yes,Discontinuation,11,8
NCT13573621,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 2,351,Pneumonitis,Hepatobiliary disorders,Yes,Moderate,351,27,31,7.69,No,,18,69,Yes,No,Discontinuation,29,46
NCT55724465,Tocilizumab,Anti-IL-6,Melanoma,Phase 2,97,Fatigue,General disorders,No,Moderate,97,8,12,8.25,No,,2,308,Yes,No,Treatment interruption,1,85
NCT33586371,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 2,245,Nausea,Skin disorders,No,Mild,245,56,61,22.86,No,,13,174,Yes,Yes,Discontinuation,13,36
NCT76936337,Tocilizumab,Anti-IL-6,Melanoma,Phase 1,133,Hepatotoxicity,Hepatobiliary disorders,No,Severe,133,5,9,3.76,No,,18,320,No,No,Discontinuation,7,90
NCT21691283,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 2,303,Hypothyroidism,Gastrointestinal disorders,No,Mild,303,39,39,12.87,No,,18,167,No,Yes,Supportive care,5,9
NCT55994580,Tocilizumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 1,61,Thrombocytopenia,Musculoskeletal disorders,No,Mild,61,13,13,21.31,No,,20,177,No,No,Supportive care,26,12
NCT46705587,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 3,52,Arthralgia,General disorders,No,Moderate,52,1,4,1.92,No,,11,310,No,No,Supportive care,28,77
NCT46703581,Tocilizumab,Anti-IL-6,Breast Cancer,Phase 3,466,Thrombocytopenia,Cardiac disorders,No,Moderate,466,93,97,19.96,No,,16,153,Yes,Yes,Discontinuation,29,24
NCT90214945,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 2,302,Hepatotoxicity,Respiratory disorders,No,Moderate,302,48,49,15.89,No,,3,41,No,No,Treatment interruption,9,58
NCT27223216,Tocilizumab,Anti-IL-6,Colorectal Cancer,Phase 1,204,Neutropenia,Hepatobiliary disorders,No,Severe,204,46,49,22.55,No,,12,81,No,No,Discontinuation,30,57
NCT83032986,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 2,20,Thrombocytopenia,Endocrine disorders,No,Moderate,20,3,7,15.0,No,,16,210,Yes,Yes,Treatment interruption,10,81
NCT17735521,Tocilizumab,Anti-IL-6,Melanoma,Phase 4,448,Pneumonitis,General disorders,No,Mild,448,83,88,18.53,No,,6,61,Yes,Yes,Discontinuation,25,80
NCT69018641,Tocilizumab,Anti-IL-6,Lung Cancer,Phase 1,27,Infusion-related reaction,Cardiac disorders,No,Moderate,27,7,11,25.93,No,,2,323,No,Yes,Supportive care,27,48
NCT61440999,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 4,172,Neutropenia,Gastrointestinal disorders,No,Moderate,172,41,42,23.84,No,,4,36,Yes,No,Discontinuation,16,7
NCT16605389,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 2,173,Fatigue,Respiratory disorders,No,Severe,173,12,14,6.94,No,,18,210,No,No,Supportive care,28,80
NCT92437821,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,424,Hyperthyroidism,General disorders,No,Moderate,424,86,91,20.28,No,,18,208,No,Yes,Treatment interruption,27,73
NCT52654571,Tocilizumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,433,Hyperthyroidism,Cardiac disorders,No,Mild,433,113,117,26.1,No,,10,98,No,No,Supportive care,1,59
NCT55202568,Tocilizumab,Anti-IL-6,Multiple Myeloma,Phase 4,457,Neutropenia,General disorders,Yes,Moderate,457,78,81,17.07,Yes,Lack of efficacy,1,350,No,No,Supportive care,6,62
NCT23251602,Tocilizumab,Anti-IL-6,Multiple Sclerosis,Phase 1,73,Infusion-related reaction,Respiratory disorders,No,Mild,73,21,21,28.77,No,,15,208,Yes,Yes,Treatment interruption,8,72
NCT13457252,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 3,338,Arthralgia,Cardiac disorders,No,Mild,338,7,8,2.07,No,,17,118,No,No,Treatment interruption,11,56
NCT70772918,Sarilumab,Anti-IL-6,Breast Cancer,Phase 4,109,Hepatotoxicity,Gastrointestinal disorders,No,Mild,109,27,28,24.77,No,,2,153,Yes,Yes,Discontinuation,14,49
NCT82121287,Sarilumab,Anti-IL-6,Lung Cancer,Phase 2,372,Hyperthyroidism,Gastrointestinal disorders,No,Moderate,372,95,99,25.54,No,,1,170,Yes,No,Treatment interruption,11,25
NCT70254255,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,214,Nausea,Endocrine disorders,No,Moderate,214,62,63,28.97,Yes,Lack of efficacy,4,239,No,Yes,Dose reduction,26,48
NCT67421261,Sarilumab,Anti-IL-6,Breast Cancer,Phase 2,44,Thrombocytopenia,Musculoskeletal disorders,Yes,Moderate,44,11,16,25.0,Yes,Competition,16,191,No,No,Treatment interruption,29,39
NCT16309708,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 1,193,Hyperthyroidism,Musculoskeletal disorders,No,Moderate,193,7,9,3.63,No,,2,304,Yes,No,Treatment interruption,13,24
NCT23896451,Sarilumab,Anti-IL-6,Breast Cancer,Phase 3,293,Hepatotoxicity,Endocrine disorders,No,Severe,293,42,42,14.33,No,,3,168,No,No,Dose reduction,17,66
NCT86029279,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 1,225,Diarrhea,Musculoskeletal disorders,No,Severe,225,17,21,7.56,Yes,Lack of efficacy,3,187,No,No,Supportive care,4,22
NCT66753465,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,66,Anemia,General disorders,No,Moderate,66,5,9,7.58,Yes,Regulatory issues,12,138,Yes,Yes,Discontinuation,10,26
NCT24113290,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 3,95,Diarrhea,Hepatobiliary disorders,No,Severe,95,6,7,6.32,Yes,Safety concerns,7,261,Yes,Yes,Dose reduction,26,13
NCT45303129,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 1,48,Fatigue,Endocrine disorders,No,Moderate,48,13,13,27.08,No,,19,364,Yes,No,Supportive care,3,55
NCT51316315,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 3,90,Cardiotoxicity,Endocrine disorders,No,Mild,90,20,20,22.22,No,,10,243,Yes,Yes,Supportive care,1,4
NCT76199959,Sarilumab,Anti-IL-6,Lung Cancer,Phase 4,408,Fatigue,Gastrointestinal disorders,No,Severe,408,58,61,14.22,No,,3,234,Yes,Yes,Supportive care,19,62
NCT92566866,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 4,237,Diarrhea,Blood disorders,Yes,Severe,237,24,25,10.13,Yes,Lack of efficacy,1,49,Yes,No,Discontinuation,3,9
NCT78627442,Sarilumab,Anti-IL-6,Melanoma,Phase 1,445,Fatigue,Skin disorders,No,Mild,445,28,33,6.29,No,,18,236,Yes,Yes,Supportive care,26,38
NCT51302325,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 3,289,Cardiotoxicity,General disorders,No,Mild,289,65,69,22.49,No,,8,257,Yes,Yes,Dose reduction,21,27
NCT12501354,Sarilumab,Anti-IL-6,Breast Cancer,Phase 2,451,Diarrhea,Musculoskeletal disorders,No,Moderate,451,64,66,14.19,No,,9,109,Yes,Yes,Discontinuation,4,18
NCT47602927,Sarilumab,Anti-IL-6,Melanoma,Phase 3,176,Nausea,Endocrine disorders,No,Mild,176,51,54,28.98,No,,11,189,No,Yes,Supportive care,16,76
NCT92115054,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,351,Neutropenia,Gastrointestinal disorders,Yes,Severe,351,66,66,18.8,No,,15,283,No,Yes,Treatment interruption,7,13
NCT88824864,Sarilumab,Anti-IL-6,Breast Cancer,Phase 3,59,Cardiotoxicity,Cardiac disorders,No,Moderate,59,14,17,23.73,No,,6,236,Yes,No,Treatment interruption,24,33
NCT15672385,Sarilumab,Anti-IL-6,Lung Cancer,Phase 4,226,Thrombocytopenia,Musculoskeletal disorders,Yes,Moderate,226,9,13,3.98,Yes,Competition,20,256,No,No,Discontinuation,24,42
NCT93420517,Sarilumab,Anti-IL-6,Melanoma,Phase 4,181,Nausea,Blood disorders,No,Mild,181,14,15,7.73,No,,18,354,No,No,Supportive care,25,62
NCT95445704,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 3,218,Hyperthyroidism,Skin disorders,No,Severe,218,19,23,8.72,No,,17,139,No,Yes,Discontinuation,14,54
NCT88246770,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 3,450,Cardiotoxicity,General disorders,No,Mild,450,123,127,27.33,No,,9,106,Yes,No,Discontinuation,24,20
NCT62121083,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 2,36,Rash,Blood disorders,No,Moderate,36,1,3,2.78,No,,13,230,Yes,Yes,Discontinuation,14,22
NCT27381381,Sarilumab,Anti-IL-6,Lung Cancer,Phase 1,157,Colitis,Respiratory disorders,No,Moderate,157,9,11,5.73,No,,10,325,Yes,Yes,Dose reduction,26,42
NCT94355547,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 4,339,Cardiotoxicity,Respiratory disorders,No,Moderate,339,42,43,12.39,No,,8,297,Yes,No,Dose reduction,7,55
NCT54397344,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 2,165,Hyperthyroidism,Skin disorders,No,Mild,165,17,21,10.3,Yes,Safety concerns,5,364,Yes,Yes,Discontinuation,22,17
NCT43130464,Sarilumab,Anti-IL-6,Melanoma,Phase 1,41,Thrombocytopenia,Cardiac disorders,No,Mild,41,6,10,14.63,No,,11,338,No,No,Discontinuation,3,68
NCT38609019,Sarilumab,Anti-IL-6,Lung Cancer,Phase 4,472,Anemia,Gastrointestinal disorders,Yes,Severe,472,28,29,5.93,Yes,Safety concerns,13,77,No,No,Supportive care,24,3
NCT43969173,Sarilumab,Anti-IL-6,Melanoma,Phase 1,309,Anemia,Endocrine disorders,No,Moderate,309,25,29,8.09,No,,16,219,Yes,No,Supportive care,11,78
NCT29999996,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 4,143,Thrombocytopenia,Hepatobiliary disorders,Yes,Severe,143,13,18,9.09,No,,10,283,No,No,Discontinuation,3,78
NCT80532310,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 4,444,Pneumonitis,Gastrointestinal disorders,No,Moderate,444,43,44,9.68,Yes,Competition,2,191,No,Yes,Discontinuation,7,28
NCT14511655,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,324,Rash,Blood disorders,No,Moderate,324,75,75,23.15,Yes,Competition,12,194,Yes,No,Treatment interruption,29,3
NCT60652833,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 3,407,Hyperthyroidism,Blood disorders,No,Severe,407,60,65,14.74,No,,15,306,Yes,Yes,Discontinuation,25,83
NCT29398785,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 3,386,Thrombocytopenia,Gastrointestinal disorders,No,Moderate,386,100,105,25.91,No,,9,145,No,Yes,Supportive care,1,28
NCT49731397,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 1,50,Hepatotoxicity,Blood disorders,No,Mild,50,9,10,18.0,No,,10,181,Yes,No,Discontinuation,4,62
NCT82685944,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 3,486,Nausea,Blood disorders,No,Moderate,486,87,92,17.9,Yes,Safety concerns,8,36,No,Yes,Supportive care,6,65
NCT20265243,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 4,328,Colitis,Skin disorders,No,Severe,328,9,10,2.74,Yes,Competition,3,327,Yes,No,Supportive care,9,17
NCT15993389,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 4,344,Diarrhea,Blood disorders,No,Moderate,344,47,47,13.66,No,,5,47,No,No,Treatment interruption,3,9
NCT99645656,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 3,78,Colitis,Endocrine disorders,No,Severe,78,21,25,26.92,No,,15,135,No,Yes,Treatment interruption,4,8
NCT64545373,Sarilumab,Anti-IL-6,Melanoma,Phase 2,119,Arthralgia,Hepatobiliary disorders,No,Moderate,119,35,35,29.41,No,,9,106,No,Yes,Supportive care,20,15
NCT15174755,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 3,171,Nausea,Gastrointestinal disorders,No,Mild,171,17,22,9.94,No,,3,133,Yes,No,Supportive care,21,46
NCT39128142,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,160,Hypothyroidism,Skin disorders,Yes,Mild,160,14,15,8.75,No,,15,37,No,No,Treatment interruption,12,13
NCT84776019,Sarilumab,Anti-IL-6,Breast Cancer,Phase 2,49,Neutropenia,Respiratory disorders,Yes,Moderate,49,4,6,8.16,Yes,Regulatory issues,2,237,Yes,No,Discontinuation,25,73
NCT83728748,Sarilumab,Anti-IL-6,Breast Cancer,Phase 4,272,Arthralgia,Musculoskeletal disorders,Yes,Severe,272,54,54,19.85,Yes,Regulatory issues,19,175,Yes,Yes,Dose reduction,5,82
NCT41885576,Sarilumab,Anti-IL-6,Lung Cancer,Phase 4,475,Thrombocytopenia,Endocrine disorders,No,Moderate,475,81,86,17.05,No,,3,294,No,Yes,Treatment interruption,27,29
NCT11530218,Sarilumab,Anti-IL-6,Breast Cancer,Phase 4,378,Hypothyroidism,Blood disorders,No,Mild,378,72,74,19.05,Yes,Regulatory issues,19,36,No,No,Dose reduction,27,44
NCT93972717,Sarilumab,Anti-IL-6,Melanoma,Phase 3,460,Nausea,Hepatobiliary disorders,Yes,Mild,460,123,128,26.74,No,,11,77,No,No,Treatment interruption,13,40
NCT58320944,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 3,121,Colitis,General disorders,No,Moderate,121,25,29,20.66,No,,6,186,No,No,Discontinuation,14,15
NCT16285629,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 3,99,Rash,Blood disorders,No,Mild,99,2,3,2.02,No,,15,334,No,No,Supportive care,13,36
NCT27726557,Sarilumab,Anti-IL-6,Lung Cancer,Phase 3,321,Infusion-related reaction,General disorders,Yes,Moderate,321,49,54,15.26,No,,20,225,Yes,No,Discontinuation,16,42
NCT46344947,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 1,447,Colitis,Musculoskeletal disorders,Yes,Moderate,447,97,98,21.7,No,,11,201,No,No,Treatment interruption,5,53
NCT23295056,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 2,84,Neutropenia,Hepatobiliary disorders,Yes,Mild,84,3,8,3.57,Yes,Regulatory issues,11,249,No,Yes,Supportive care,7,21
NCT30091723,Sarilumab,Anti-IL-6,Breast Cancer,Phase 4,279,Pneumonitis,Cardiac disorders,Yes,Moderate,279,46,48,16.49,No,,14,327,No,No,Treatment interruption,9,28
NCT65127618,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 2,448,Nausea,Blood disorders,Yes,Moderate,448,116,119,25.89,No,,8,361,No,Yes,Treatment interruption,18,21
NCT85107447,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 1,250,Thrombocytopenia,Musculoskeletal disorders,No,Severe,250,27,28,10.8,No,,17,114,No,No,Supportive care,4,54
NCT41597317,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 3,388,Diarrhea,Cardiac disorders,Yes,Mild,388,36,39,9.28,No,,11,283,No,No,Dose reduction,20,45
NCT75483220,Sarilumab,Anti-IL-6,Melanoma,Phase 2,248,Infusion-related reaction,Musculoskeletal disorders,No,Mild,248,42,44,16.94,No,,12,149,No,Yes,Discontinuation,12,14
NCT83724920,Sarilumab,Anti-IL-6,Melanoma,Phase 1,190,Colitis,Hepatobiliary disorders,No,Mild,190,39,39,20.53,No,,10,139,No,Yes,Supportive care,11,33
NCT99002429,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 4,71,Thrombocytopenia,Hepatobiliary disorders,No,Severe,71,8,11,11.27,No,,17,133,Yes,Yes,Discontinuation,20,62
NCT97012104,Sarilumab,Anti-IL-6,Melanoma,Phase 1,213,Fatigue,Respiratory disorders,No,Severe,213,56,60,26.29,Yes,Safety concerns,18,352,No,Yes,Discontinuation,11,56
NCT47683400,Sarilumab,Anti-IL-6,Melanoma,Phase 3,131,Rash,General disorders,No,Severe,131,28,28,21.37,Yes,Competition,2,253,No,No,Treatment interruption,20,82
NCT17771554,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 1,58,Diarrhea,Musculoskeletal disorders,Yes,Severe,58,6,9,10.34,Yes,Lack of efficacy,15,268,No,No,Supportive care,23,56
NCT36013032,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 2,355,Hyperthyroidism,Hepatobiliary disorders,No,Severe,355,69,72,19.44,No,,17,210,Yes,Yes,Treatment interruption,13,58
NCT88699863,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 4,467,Rash,Skin disorders,No,Moderate,467,6,6,1.28,No,,10,303,No,Yes,Treatment interruption,13,44
NCT45240287,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 1,32,Fatigue,General disorders,No,Moderate,32,2,3,6.25,No,,6,207,Yes,Yes,Discontinuation,27,79
NCT78430349,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 1,106,Fatigue,Hepatobiliary disorders,No,Mild,106,7,7,6.6,No,,20,81,Yes,Yes,Supportive care,8,11
NCT43691303,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 3,421,Rash,Skin disorders,No,Severe,421,3,8,0.71,No,,18,175,Yes,No,Supportive care,21,88
NCT99794218,Sarilumab,Anti-IL-6,Multiple Myeloma,Phase 3,186,Cardiotoxicity,Respiratory disorders,No,Mild,186,52,57,27.96,No,,4,327,No,No,Supportive care,10,53
NCT45659743,Sarilumab,Anti-IL-6,Breast Cancer,Phase 2,67,Pneumonitis,Cardiac disorders,No,Severe,67,12,15,17.91,Yes,Lack of efficacy,10,31,Yes,Yes,Supportive care,30,32
NCT59823823,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,461,Neutropenia,Skin disorders,No,Moderate,461,120,122,26.03,No,,20,53,No,Yes,Dose reduction,28,25
NCT44123353,Sarilumab,Anti-IL-6,Melanoma,Phase 1,394,Infusion-related reaction,Gastrointestinal disorders,No,Severe,394,77,79,19.54,No,,1,288,Yes,Yes,Supportive care,10,54
NCT12231722,Sarilumab,Anti-IL-6,Lung Cancer,Phase 2,244,Rash,General disorders,No,Severe,244,15,17,6.15,Yes,Competition,11,199,Yes,Yes,Supportive care,16,85
NCT25414316,Sarilumab,Anti-IL-6,Colorectal Cancer,Phase 1,78,Hypothyroidism,Hepatobiliary disorders,No,Mild,78,10,12,12.82,No,,17,241,Yes,No,Supportive care,8,74
NCT41606410,Sarilumab,Anti-IL-6,Breast Cancer,Phase 4,31,Thrombocytopenia,Gastrointestinal disorders,No,Severe,31,5,7,16.13,No,,15,286,Yes,No,Treatment interruption,4,66
NCT75499996,Sarilumab,Anti-IL-6,Breast Cancer,Phase 2,498,Diarrhea,Skin disorders,No,Mild,498,4,9,0.8,No,,19,183,No,Yes,Dose reduction,11,44
NCT78683034,Sarilumab,Anti-IL-6,Melanoma,Phase 1,376,Hepatotoxicity,Blood disorders,No,Moderate,376,77,79,20.48,No,,11,331,No,No,Supportive care,3,19
NCT93180402,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 2,420,Infusion-related reaction,Respiratory disorders,Yes,Severe,420,71,73,16.9,Yes,Regulatory issues,8,246,Yes,Yes,Supportive care,10,45
NCT15895644,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 4,370,Arthralgia,Skin disorders,No,Mild,370,13,15,3.51,No,,12,226,Yes,No,Dose reduction,24,36
NCT39816377,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 4,33,Colitis,General disorders,No,Moderate,33,2,3,6.06,No,,4,251,Yes,No,Supportive care,25,72
NCT83823989,Sarilumab,Anti-IL-6,Breast Cancer,Phase 3,410,Colitis,Gastrointestinal disorders,No,Moderate,410,52,53,12.68,Yes,Safety concerns,2,183,No,No,Dose reduction,3,27
NCT21682450,Sarilumab,Anti-IL-6,Rheumatoid Arthritis,Phase 2,196,Anemia,Musculoskeletal disorders,No,Mild,196,6,8,3.06,No,,15,135,Yes,Yes,Supportive care,28,7
NCT98266457,Sarilumab,Anti-IL-6,Breast Cancer,Phase 1,117,Hyperthyroidism,Skin disorders,No,Mild,117,27,32,23.08,No,,1,257,Yes,Yes,Treatment interruption,9,71
NCT71376424,Sarilumab,Anti-IL-6,Multiple Sclerosis,Phase 3,38,Colitis,Hepatobiliary disorders,No,Moderate,38,9,12,23.68,No,,3,316,Yes,No,Dose reduction,11,11
NCT35208074,Sarilumab,Anti-IL-6,Lung Cancer,Phase 2,321,Nausea,Gastrointestinal disorders,No,Moderate,321,63,68,19.63,No,,9,235,No,Yes,Discontinuation,23,88
NCT38156405,Sarilumab,Anti-IL-6,Non-Hodgkin Lymphoma,Phase 1,210,Anemia,Blood disorders,No,Severe,210,32,37,15.24,No,,16,161,Yes,Yes,Supportive care,12,33
NCT83153127,Sarilumab,Anti-IL-6,Lung Cancer,Phase 1,476,Hyperthyroidism,Musculoskeletal disorders,No,Mild,476,1,3,0.21,No,,20,93,Yes,No,Dose reduction,30,38
NCT44552749,Daratumumab,Anti-CD38,Lung Cancer,Phase 1,84,Thrombocytopenia,Musculoskeletal disorders,No,Mild,84,16,17,19.05,No,,11,34,No,Yes,Dose reduction,5,7
NCT22414218,Daratumumab,Anti-CD38,Lung Cancer,Phase 3,342,Hypothyroidism,Respiratory disorders,No,Severe,342,16,19,4.68,No,,8,338,No,Yes,Supportive care,3,72
NCT34138861,Daratumumab,Anti-CD38,Melanoma,Phase 3,96,Thrombocytopenia,Skin disorders,No,Moderate,96,16,16,16.67,No,,13,244,Yes,No,Supportive care,29,73
NCT82160317,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 4,403,Arthralgia,Endocrine disorders,No,Severe,403,21,26,5.21,No,,9,313,No,Yes,Dose reduction,29,61
NCT76233802,Daratumumab,Anti-CD38,Lung Cancer,Phase 1,146,Rash,Blood disorders,No,Moderate,146,3,5,2.05,No,,20,169,Yes,Yes,Dose reduction,28,83
NCT40208190,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 1,279,Fatigue,Musculoskeletal disorders,Yes,Moderate,279,13,14,4.66,Yes,Safety concerns,14,292,Yes,Yes,Treatment interruption,30,30
NCT64647720,Daratumumab,Anti-CD38,Lung Cancer,Phase 2,72,Anemia,Gastrointestinal disorders,No,Mild,72,2,5,2.78,No,,11,54,No,Yes,Discontinuation,29,7
NCT74175230,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 3,232,Anemia,General disorders,Yes,Severe,232,46,47,19.83,No,,4,270,No,No,Treatment interruption,24,16
NCT45192289,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 2,362,Anemia,Blood disorders,No,Moderate,362,72,75,19.89,No,,16,88,Yes,Yes,Discontinuation,27,29
NCT94310933,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 2,433,Colitis,Endocrine disorders,No,Severe,433,89,91,20.55,Yes,Lack of efficacy,2,161,No,Yes,Treatment interruption,14,21
NCT10719032,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 2,353,Neutropenia,Cardiac disorders,No,Moderate,353,75,77,21.25,No,,4,34,No,No,Dose reduction,16,55
NCT26097717,Daratumumab,Anti-CD38,Breast Cancer,Phase 4,451,Rash,Gastrointestinal disorders,No,Mild,451,26,26,5.76,No,,3,35,Yes,Yes,Treatment interruption,27,65
NCT86655843,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 2,123,Infusion-related reaction,Blood disorders,No,Mild,123,7,7,5.69,No,,8,218,No,No,Treatment interruption,30,46
NCT86694103,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,120,Diarrhea,General disorders,No,Mild,120,34,38,28.33,No,,16,262,No,Yes,Dose reduction,4,46
NCT83214129,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 1,312,Cardiotoxicity,Musculoskeletal disorders,No,Moderate,312,57,62,18.27,No,,15,104,Yes,No,Treatment interruption,21,43
NCT78831472,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 1,345,Arthralgia,Musculoskeletal disorders,No,Moderate,345,102,106,29.57,No,,1,120,No,Yes,Discontinuation,17,14
NCT13998629,Daratumumab,Anti-CD38,Breast Cancer,Phase 1,83,Hyperthyroidism,Hepatobiliary disorders,No,Moderate,83,21,23,25.3,No,,3,195,Yes,No,Supportive care,24,42
NCT50333458,Daratumumab,Anti-CD38,Melanoma,Phase 2,175,Colitis,Endocrine disorders,No,Moderate,175,18,20,10.29,No,,11,294,Yes,No,Supportive care,4,1
NCT15516142,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 4,468,Hypothyroidism,Cardiac disorders,Yes,Mild,468,5,7,1.07,No,,6,205,No,Yes,Discontinuation,17,11
NCT76889022,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 1,408,Hyperthyroidism,General disorders,No,Mild,408,102,107,25.0,No,,8,294,No,No,Discontinuation,4,45
NCT21307827,Daratumumab,Anti-CD38,Lung Cancer,Phase 2,149,Cardiotoxicity,Hepatobiliary disorders,No,Mild,149,40,40,26.85,No,,20,50,No,Yes,Supportive care,17,28
NCT11626158,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 4,351,Rash,General disorders,No,Mild,351,69,73,19.66,No,,13,73,No,Yes,Discontinuation,3,29
NCT66707747,Daratumumab,Anti-CD38,Lung Cancer,Phase 2,107,Hypothyroidism,General disorders,Yes,Severe,107,25,30,23.36,No,,11,335,No,Yes,Treatment interruption,26,60
NCT33977672,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 4,422,Arthralgia,Hepatobiliary disorders,No,Mild,422,125,129,29.62,No,,9,329,Yes,Yes,Treatment interruption,25,14
NCT34334992,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 2,486,Rash,Endocrine disorders,No,Mild,486,6,9,1.23,No,,1,267,No,No,Discontinuation,8,53
NCT39014689,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 3,261,Colitis,General disorders,Yes,Moderate,261,30,35,11.49,No,,1,99,No,Yes,Supportive care,8,68
NCT51777402,Daratumumab,Anti-CD38,Melanoma,Phase 4,73,Fatigue,Gastrointestinal disorders,No,Severe,73,21,24,28.77,No,,3,124,Yes,No,Supportive care,19,16
NCT38821023,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 3,390,Arthralgia,General disorders,No,Moderate,390,112,116,28.72,No,,9,72,No,Yes,Treatment interruption,17,55
NCT71348689,Daratumumab,Anti-CD38,Melanoma,Phase 3,107,Neutropenia,Hepatobiliary disorders,No,Mild,107,6,8,5.61,No,,3,325,Yes,Yes,Treatment interruption,26,68
NCT99372822,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 2,188,Cardiotoxicity,Skin disorders,No,Mild,188,45,46,23.94,No,,14,240,Yes,No,Supportive care,26,52
NCT71905226,Daratumumab,Anti-CD38,Melanoma,Phase 4,37,Pneumonitis,Blood disorders,No,Severe,37,9,10,24.32,No,,14,58,Yes,Yes,Treatment interruption,15,85
NCT59816972,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 2,240,Fatigue,Endocrine disorders,No,Mild,240,36,39,15.0,No,,15,325,Yes,Yes,Discontinuation,6,42
NCT49025344,Daratumumab,Anti-CD38,Lung Cancer,Phase 3,208,Colitis,Cardiac disorders,No,Mild,208,53,55,25.48,No,,3,113,Yes,Yes,Dose reduction,28,12
NCT10579297,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 4,449,Pneumonitis,Endocrine disorders,Yes,Moderate,449,129,129,28.73,No,,19,222,Yes,Yes,Discontinuation,14,72
NCT30432652,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,486,Cardiotoxicity,Endocrine disorders,No,Severe,486,122,123,25.1,No,,3,198,Yes,Yes,Discontinuation,12,63
NCT66760716,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 1,374,Thrombocytopenia,Musculoskeletal disorders,No,Mild,374,7,8,1.87,No,,17,51,Yes,Yes,Supportive care,10,3
NCT74299031,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 2,82,Thrombocytopenia,Endocrine disorders,No,Mild,82,4,5,4.88,No,,7,68,No,No,Treatment interruption,12,83
NCT18459614,Daratumumab,Anti-CD38,Melanoma,Phase 3,100,Nausea,Blood disorders,No,Mild,100,4,4,4.0,No,,5,130,No,No,Supportive care,5,59
NCT39179485,Daratumumab,Anti-CD38,Melanoma,Phase 1,103,Cardiotoxicity,General disorders,No,Mild,103,9,13,8.74,No,,16,228,No,Yes,Treatment interruption,24,62
NCT28025209,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 3,210,Hepatotoxicity,Respiratory disorders,Yes,Moderate,210,27,31,12.86,No,,20,134,No,Yes,Treatment interruption,1,60
NCT61501917,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 1,469,Colitis,Blood disorders,No,Severe,469,42,45,8.96,Yes,Safety concerns,8,280,Yes,No,Treatment interruption,24,84
NCT86455632,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 2,411,Anemia,General disorders,No,Mild,411,93,95,22.63,No,,16,316,Yes,No,Supportive care,21,44
NCT66991302,Daratumumab,Anti-CD38,Melanoma,Phase 2,223,Diarrhea,Blood disorders,Yes,Mild,223,53,55,23.77,Yes,Safety concerns,10,115,No,Yes,Discontinuation,25,31
NCT93989135,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 4,169,Hepatotoxicity,Respiratory disorders,Yes,Severe,169,41,42,24.26,Yes,Lack of efficacy,20,205,Yes,Yes,Supportive care,3,81
NCT83024766,Daratumumab,Anti-CD38,Melanoma,Phase 1,382,Pneumonitis,Skin disorders,No,Severe,382,19,23,4.97,No,,3,97,No,No,Discontinuation,25,42
NCT31427622,Daratumumab,Anti-CD38,Breast Cancer,Phase 1,488,Neutropenia,Musculoskeletal disorders,No,Moderate,488,128,130,26.23,No,,19,45,Yes,Yes,Treatment interruption,28,59
NCT65736252,Daratumumab,Anti-CD38,Multiple Myeloma,Phase 4,73,Thrombocytopenia,Endocrine disorders,Yes,Mild,73,5,9,6.85,No,,14,69,Yes,Yes,Discontinuation,30,84
NCT82244475,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 1,309,Hyperthyroidism,Skin disorders,No,Mild,309,64,66,20.71,No,,7,240,No,No,Dose reduction,30,66
NCT53135244,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 4,231,Cardiotoxicity,General disorders,Yes,Severe,231,5,7,2.16,No,,12,286,No,Yes,Dose reduction,8,81
NCT42244162,Daratumumab,Anti-CD38,Multiple Sclerosis,Phase 1,166,Hepatotoxicity,Respiratory disorders,Yes,Severe,166,37,39,22.29,No,,16,193,No,Yes,Treatment interruption,11,75
NCT85202098,Daratumumab,Anti-CD38,Lung Cancer,Phase 2,380,Hepatotoxicity,Skin disorders,No,Severe,380,101,106,26.58,No,,9,52,Yes,No,Treatment interruption,20,73
NCT35469513,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 1,488,Arthralgia,Skin disorders,Yes,Severe,488,2,4,0.41,No,,11,85,Yes,Yes,Discontinuation,26,88
NCT41623294,Daratumumab,Anti-CD38,Breast Cancer,Phase 3,234,Hyperthyroidism,Blood disorders,No,Mild,234,37,39,15.81,No,,14,245,No,Yes,Supportive care,3,48
NCT79664948,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 4,43,Fatigue,Gastrointestinal disorders,Yes,Severe,43,8,10,18.6,Yes,Safety concerns,17,116,No,No,Discontinuation,12,37
NCT73540243,Daratumumab,Anti-CD38,Rheumatoid Arthritis,Phase 1,378,Colitis,Cardiac disorders,No,Mild,378,34,39,8.99,No,,12,237,No,No,Discontinuation,1,49
NCT90170989,Daratumumab,Anti-CD38,Breast Cancer,Phase 2,334,Diarrhea,Hepatobiliary disorders,Yes,Moderate,334,83,84,24.85,Yes,Safety concerns,17,184,No,No,Dose reduction,14,28
NCT14023901,Daratumumab,Anti-CD38,Breast Cancer,Phase 4,448,Diarrhea,Cardiac disorders,No,Moderate,448,57,58,12.72,No,,7,204,No,No,Dose reduction,23,86
NCT63015281,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 3,183,Diarrhea,Cardiac disorders,No,Severe,183,10,15,5.46,Yes,Competition,9,151,Yes,No,Treatment interruption,14,17
NCT66788895,Daratumumab,Anti-CD38,Melanoma,Phase 2,390,Diarrhea,Hepatobiliary disorders,No,Mild,390,103,105,26.41,No,,5,363,Yes,No,Dose reduction,2,19
NCT11475967,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 3,160,Hepatotoxicity,Musculoskeletal disorders,No,Mild,160,47,48,29.38,No,,9,139,No,Yes,Treatment interruption,1,42
NCT94776973,Daratumumab,Anti-CD38,Colorectal Cancer,Phase 3,125,Cardiotoxicity,Hepatobiliary disorders,No,Moderate,125,16,18,12.8,No,,1,365,Yes,Yes,Dose reduction,9,38
NCT84684458,Daratumumab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 3,86,Infusion-related reaction,General disorders,Yes,Mild,86,21,23,24.42,No,,18,268,Yes,Yes,Treatment interruption,5,60
NCT99391660,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,86,Rash,Musculoskeletal disorders,No,Moderate,86,5,9,5.81,No,,8,258,No,No,Treatment interruption,28,68
NCT47595359,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 2,338,Neutropenia,Musculoskeletal disorders,No,Moderate,338,71,74,21.01,No,,20,41,Yes,Yes,Supportive care,6,62
NCT44445183,Isatuximab,Anti-CD38,Melanoma,Phase 3,66,Nausea,General disorders,No,Severe,66,14,19,21.21,Yes,Regulatory issues,10,297,Yes,Yes,Discontinuation,28,39
NCT80465184,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,304,Fatigue,Hepatobiliary disorders,Yes,Moderate,304,75,76,24.67,No,,16,38,No,No,Discontinuation,25,29
NCT76439850,Isatuximab,Anti-CD38,Rheumatoid Arthritis,Phase 2,365,Cardiotoxicity,Hepatobiliary disorders,No,Mild,365,21,25,5.75,No,,10,73,No,No,Discontinuation,12,81
NCT14742062,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,120,Rash,General disorders,Yes,Severe,120,31,34,25.83,No,,16,48,No,No,Dose reduction,9,14
NCT93222239,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 4,333,Colitis,Gastrointestinal disorders,No,Moderate,333,95,100,28.53,No,,17,99,Yes,No,Treatment interruption,13,24
NCT39039450,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,340,Neutropenia,Blood disorders,No,Mild,340,6,7,1.76,No,,5,315,Yes,Yes,Supportive care,2,69
NCT41371937,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 1,199,Thrombocytopenia,Endocrine disorders,No,Moderate,199,52,53,26.13,Yes,Lack of efficacy,16,85,Yes,Yes,Treatment interruption,21,60
NCT69801029,Isatuximab,Anti-CD38,Lung Cancer,Phase 4,191,Arthralgia,Endocrine disorders,No,Moderate,191,37,39,19.37,No,,10,298,Yes,Yes,Discontinuation,2,61
NCT57301311,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 3,145,Neutropenia,Skin disorders,No,Mild,145,21,25,14.48,No,,1,306,No,No,Treatment interruption,24,21
NCT48345266,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 1,236,Hypothyroidism,Musculoskeletal disorders,No,Mild,236,15,18,6.36,No,,14,137,Yes,No,Dose reduction,21,23
NCT85384347,Isatuximab,Anti-CD38,Rheumatoid Arthritis,Phase 4,262,Hyperthyroidism,General disorders,Yes,Severe,262,65,67,24.81,No,,5,333,No,Yes,Dose reduction,11,29
NCT37427467,Isatuximab,Anti-CD38,Rheumatoid Arthritis,Phase 4,83,Infusion-related reaction,Respiratory disorders,No,Moderate,83,5,7,6.02,No,,18,208,No,No,Treatment interruption,13,20
NCT32029790,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 3,408,Nausea,Musculoskeletal disorders,No,Moderate,408,96,99,23.53,Yes,Safety concerns,7,174,Yes,No,Supportive care,16,75
NCT23580415,Isatuximab,Anti-CD38,Breast Cancer,Phase 1,489,Rash,Musculoskeletal disorders,No,Severe,489,97,101,19.84,No,,9,346,No,Yes,Dose reduction,12,13
NCT70082548,Isatuximab,Anti-CD38,Colorectal Cancer,Phase 3,275,Nausea,Gastrointestinal disorders,No,Mild,275,10,14,3.64,No,,8,276,Yes,Yes,Supportive care,13,9
NCT38993341,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 3,322,Arthralgia,Cardiac disorders,No,Mild,322,83,88,25.78,No,,12,279,Yes,No,Treatment interruption,17,24
NCT82245852,Isatuximab,Anti-CD38,Breast Cancer,Phase 4,162,Hypothyroidism,Musculoskeletal disorders,No,Severe,162,41,44,25.31,Yes,Safety concerns,2,279,Yes,Yes,Treatment interruption,18,15
NCT95261187,Isatuximab,Anti-CD38,Rheumatoid Arthritis,Phase 4,453,Hepatotoxicity,Skin disorders,No,Severe,453,130,133,28.7,No,,20,193,Yes,Yes,Dose reduction,30,28
NCT30352120,Isatuximab,Anti-CD38,Colorectal Cancer,Phase 1,344,Nausea,Blood disorders,No,Severe,344,80,82,23.26,No,,6,111,No,No,Treatment interruption,27,90
NCT75184313,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 3,243,Cardiotoxicity,Blood disorders,No,Mild,243,56,59,23.05,No,,3,94,Yes,No,Supportive care,2,27
NCT80465914,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 2,28,Rash,Hepatobiliary disorders,No,Severe,28,3,8,10.71,No,,19,85,No,No,Dose reduction,11,2
NCT49463818,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,373,Hepatotoxicity,Gastrointestinal disorders,Yes,Moderate,373,14,17,3.75,No,,12,71,Yes,Yes,Discontinuation,17,87
NCT74563216,Isatuximab,Anti-CD38,Lung Cancer,Phase 1,35,Nausea,Cardiac disorders,Yes,Mild,35,10,15,28.57,No,,18,349,Yes,Yes,Treatment interruption,21,40
NCT96195986,Isatuximab,Anti-CD38,Rheumatoid Arthritis,Phase 3,438,Hyperthyroidism,Hepatobiliary disorders,No,Severe,438,48,53,10.96,Yes,Safety concerns,4,304,No,Yes,Dose reduction,23,64
NCT13687685,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,365,Infusion-related reaction,Hepatobiliary disorders,No,Moderate,365,44,45,12.05,No,,11,96,No,No,Supportive care,7,12
NCT79691432,Isatuximab,Anti-CD38,Colorectal Cancer,Phase 2,224,Thrombocytopenia,Skin disorders,No,Mild,224,47,47,20.98,No,,1,327,Yes,No,Supportive care,18,23
NCT47250185,Isatuximab,Anti-CD38,Breast Cancer,Phase 4,285,Colitis,Cardiac disorders,Yes,Mild,285,85,89,29.82,Yes,Safety concerns,15,222,Yes,Yes,Discontinuation,6,40
NCT64237390,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 4,231,Thrombocytopenia,Respiratory disorders,Yes,Moderate,231,36,41,15.58,No,,16,345,No,No,Dose reduction,11,73
NCT82942394,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 1,28,Hyperthyroidism,General disorders,No,Mild,28,6,11,21.43,No,,1,276,No,Yes,Treatment interruption,30,69
NCT82609720,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 3,430,Cardiotoxicity,Hepatobiliary disorders,No,Mild,430,69,73,16.05,No,,18,210,Yes,No,Treatment interruption,21,90
NCT21097153,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 2,463,Diarrhea,Blood disorders,No,Severe,463,16,16,3.46,No,,15,164,Yes,No,Discontinuation,25,15
NCT93095130,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 3,59,Nausea,Hepatobiliary disorders,No,Severe,59,9,9,15.25,No,,14,216,No,Yes,Treatment interruption,28,54
NCT99891768,Isatuximab,Anti-CD38,Melanoma,Phase 1,281,Nausea,Skin disorders,Yes,Severe,281,19,21,6.76,No,,18,48,Yes,No,Supportive care,20,90
NCT27236383,Isatuximab,Anti-CD38,Melanoma,Phase 4,383,Hypothyroidism,Gastrointestinal disorders,No,Mild,383,23,28,6.01,No,,4,171,No,Yes,Treatment interruption,9,86
NCT13056632,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 3,402,Hepatotoxicity,General disorders,No,Mild,402,115,119,28.61,No,,3,326,Yes,No,Treatment interruption,19,23
NCT68540635,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 3,278,Infusion-related reaction,Gastrointestinal disorders,No,Mild,278,25,30,8.99,No,,14,194,Yes,No,Dose reduction,28,21
NCT26144580,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,37,Fatigue,Respiratory disorders,No,Moderate,37,4,9,10.81,No,,9,178,No,Yes,Supportive care,29,71
NCT91869800,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 2,313,Hypothyroidism,Blood disorders,No,Severe,313,51,56,16.29,No,,7,179,Yes,No,Supportive care,15,90
NCT91696773,Isatuximab,Anti-CD38,Breast Cancer,Phase 4,457,Arthralgia,Respiratory disorders,No,Moderate,457,115,117,25.16,No,,17,235,No,Yes,Dose reduction,20,70
NCT80457885,Isatuximab,Anti-CD38,Breast Cancer,Phase 4,236,Diarrhea,General disorders,No,Mild,236,4,5,1.69,No,,13,137,Yes,No,Discontinuation,19,83
NCT24459027,Isatuximab,Anti-CD38,Colorectal Cancer,Phase 4,460,Cardiotoxicity,Gastrointestinal disorders,No,Mild,460,20,20,4.35,No,,9,71,Yes,Yes,Supportive care,13,52
NCT45296791,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 2,399,Fatigue,General disorders,Yes,Moderate,399,40,44,10.03,No,,8,278,Yes,Yes,Supportive care,22,4
NCT83822246,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 2,337,Cardiotoxicity,Blood disorders,Yes,Mild,337,23,23,6.82,No,,18,215,Yes,No,Treatment interruption,26,20
NCT91913969,Isatuximab,Anti-CD38,Breast Cancer,Phase 1,390,Cardiotoxicity,Gastrointestinal disorders,No,Moderate,390,78,78,20.0,No,,9,40,No,No,Supportive care,21,72
NCT57597772,Isatuximab,Anti-CD38,Melanoma,Phase 2,256,Nausea,Gastrointestinal disorders,No,Mild,256,21,24,8.2,No,,19,223,No,No,Discontinuation,7,24
NCT22612884,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 4,414,Thrombocytopenia,Respiratory disorders,No,Moderate,414,49,49,11.84,No,,10,54,No,Yes,Dose reduction,29,19
NCT22033490,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 2,23,Infusion-related reaction,General disorders,No,Moderate,23,1,2,4.35,No,,13,146,Yes,No,Supportive care,25,41
NCT50860125,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 1,42,Hepatotoxicity,Skin disorders,No,Moderate,42,6,6,14.29,No,,12,38,Yes,Yes,Dose reduction,19,86
NCT94633844,Isatuximab,Anti-CD38,Melanoma,Phase 2,122,Rash,Cardiac disorders,No,Mild,122,7,9,5.74,No,,15,131,Yes,No,Supportive care,12,59
NCT47861691,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 3,134,Rash,Endocrine disorders,No,Moderate,134,4,5,2.99,No,,8,251,Yes,No,Dose reduction,6,66
NCT65954441,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 4,379,Diarrhea,Musculoskeletal disorders,No,Severe,379,20,23,5.28,No,,5,45,Yes,No,Supportive care,3,7
NCT75920110,Isatuximab,Anti-CD38,Lung Cancer,Phase 1,481,Hypothyroidism,Musculoskeletal disorders,Yes,Mild,481,86,90,17.88,No,,2,216,No,No,Supportive care,12,79
NCT23171857,Isatuximab,Anti-CD38,Colorectal Cancer,Phase 4,418,Nausea,Blood disorders,No,Mild,418,46,48,11.0,No,,2,338,Yes,Yes,Discontinuation,15,58
NCT52577411,Isatuximab,Anti-CD38,Melanoma,Phase 2,76,Colitis,Blood disorders,No,Moderate,76,5,10,6.58,Yes,Safety concerns,7,219,Yes,Yes,Discontinuation,4,36
NCT65885177,Isatuximab,Anti-CD38,Multiple Myeloma,Phase 1,460,Nausea,Respiratory disorders,No,Moderate,460,64,65,13.91,No,,10,126,No,No,Supportive care,24,30
NCT89137535,Isatuximab,Anti-CD38,Melanoma,Phase 3,383,Arthralgia,Blood disorders,No,Severe,383,85,89,22.19,No,,18,247,No,Yes,Treatment interruption,29,15
NCT42513238,Isatuximab,Anti-CD38,Lung Cancer,Phase 3,53,Pneumonitis,Cardiac disorders,Yes,Mild,53,15,15,28.3,No,,19,140,No,No,Supportive care,20,43
NCT66718816,Isatuximab,Anti-CD38,Non-Hodgkin Lymphoma,Phase 3,460,Anemia,Blood disorders,No,Mild,460,54,56,11.74,No,,20,316,Yes,No,Supportive care,10,74
NCT45983891,Isatuximab,Anti-CD38,Multiple Sclerosis,Phase 1,388,Anemia,Endocrine disorders,No,Moderate,388,78,83,20.1,No,,20,213,No,No,Supportive care,7,17
